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 	Chapter 1
	
Chemoenzymatic	peptide	synthesis	
 
Numerous important processes in living organisms are mediated and regulated by 
peptides, which renders them interesting targets for the pharmaceutical, nutritional and 
cosmetic industry. As a result, exploring new ways to synthesise peptides is actively 
pursued. In this chapter both chemical and enzymatic peptide synthesis methods are 
summarised, with their respective advantages and disadvantages. There is a special focus 
on the substrate mimetic strategy: a chemoenzymatic peptide synthesis approach that 
potentially combines the best of two worlds. The definition of the subject and an outline of 
this thesis are included at the end of the chapter. 
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1.1 Introduction 
Peptides are composed of amino acids that are linked to each other by amide bonds. The 
formation of these bonds is accompanied by the loss of water (Figure 1.1). Natural 
peptides consist of L-configured amino acids. When the rather arbitrary length of 50 amino 
acids is exceeded, the compound is usually referred to as a protein instead of a peptide. 
Amino acids can be abbreviated by a one- or three-letter code. Using the one-letter code, it 
is common to indicate the natural amino acids by a capital letter and the D-amino acids by 
a lower case letter. By convention, the amino terminus is taken as the beginning of a 
peptide chain and the carboxylic acid terminus as the end. The variation in size, shape, 
charge, hydrogen bonding capacity, hydrophobic character and chemical reactivity of 
amino acids accounts for the remarkably wide range of functions that are mediated by 
peptides. For example, peptides play a role in cell signalling and immune responses.  
 
 
 
Figure 1.1 Formation of a dipeptide from two amino acids. 
 
The fact that peptides influence many important processes in living organisms renders 
them interesting targets for pharmaceutical companies. However, untill recently they 
could not be applied because of their limited bioavailability. Since these problems are 
currently being addressed, peptides can really be developed and applied as therapeutics.[1] 
Other relevant applications of peptides include the use as nutrients[2] and cosmetic 
ingredients.[3] These recent developments have caused a market growth of 
(pharmaceutical) peptides, which in turn raised the challenge to synthetically take care of 
the increased demand, both in economic and environmental sense.  
 
1.2 Large-scale peptide synthesis 
Due to the fact that every method that exists to manufacture peptides on industrial scale 
has limitations and restrictions, the technologies for peptide production are not 
competitive with each other in most cases, but complementary. Prior to elaborating on 
each method (§ 1.3 and 1.4), an overview is provided of aspects that need to be considered, 
when choosing for a certain method (Table 1.1). 
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Table 1.1  Methods and corresponding characteristics in industrial peptide synthesis 
	 SPPS	 CSPS	 chemoenzymatic	 fermentation	
typical	scale	 mg - ton g - ton g - ton g - ton 
peptide	length	 med - large short - med short - large short - med 
sequence	
limitation	 none none some high 
protection	
required	 total partial - total minimal - partial none 
racemisation	 some some none none 
development	
phase	 mature mature embryonic pacing 
process	R&D	
effort	 very small small large very large 
production	costs	 very high high med med – high 
environmental	
impact	 very high high some some 
more	info	in	
section	 1.3.1 1.3.2 1.4.3 1.4.1 
 
Besides the characteristics of the peptide such as length and sequence, costs, required 
quantity and the time to deliver the product are important parameters, which will differ 
from product to product. Andersson et	 al. focussed on practical aspects of chemical 
methods for the large-scale production of peptides including purification and isolation 
issues of final bulk products and regulatory considerations in an excellent review.[4] 
 
1.3 Chemical peptide synthesis  
Amino acids contain at least two reactive functional groups and can therefore react with 
each other in various ways, resulting in an uncontrolled peptide product. To prevent this 
problem, protecting groups are applied. A distinction is made between ‘temporary’ 
protection of the α-amino function and ‘permanent’ protection of the side chain 
functionalities. In other words, the side-chain protection stays in place during the whole 
synthesis, while the N-terminal protection is removed after every coupling step to enable 
the attachment of a new amino acid. Protecting groups that are not influenced by mutual 
deprotection conditions are called orthogonal. The more complicated the peptide target 
molecule, the more sophisticated protection strategies are required and therefore the 
development of new protecting groups has been deeply tied to peptide synthesis. 
Significant advances have been made in this area and comprehensive analysis of amino 
acid protecting group strategies is provided in the review of Isidro-Llobet.[5] 
Chapter 1 
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The reaction between carboxylic acids and amines does not occur spontaneously at 
ambient temperature. The required elimination of water is generally established by means 
of a coupling reagent, which converts the acid into an activated acylating species with a 
good leaving group, prior to treatment with the amine. Over the past decades, studies to 
identify the most efficient and highest yielding coupling reagent, with lowest epimerisation 
levels and byproduct formation, have resulted in an overwhelming choice. Both Valeur et	
al. and El Faham et	al. reviewed the scope and limitations of recently developed coupling 
reagents.[6]  
 
1.3.1 Solid phase peptide synthesis (SPPS) 
The most commonly used strategy for peptide synthesis is SPPS, which was applied for the 
first time by Merrifield.[7] He attached a growing peptide chain with its C-terminus to a 
completely insoluble but swellable polymeric support and alternated the deprotection of 
the N-terminus of the peptide with the coupling of a new protected amino acid (Figure 
1.2). Extensive washing removed the reagents between each successive coupling. A 
colouring test[8] was applied to check the completeness of each coupling. 
 
 
Figure 1.2 Principle of Solid Phase Peptide Synthesis. The temporary protecting group Y is 
selectively removed, exposing a new reactive site, which is then coupled to the next protected amino 
acid; R1, R2, Rx, Rx=1= amino acid side chains, if necessary, protected with permanent protecting group. 
 
The original Merrifield strategy is based on gradual acid lability and utilises the Boc 
protecting group for temporary protection of the α-amino function. Permanent side-chain 
protection usually involves benzylic or related groups that are cleaved with strong acids. 
The concept was however extended with the development of new protecting groups. In 
 Chemoenzymatic peptide synthesis 
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Fmoc chemistry, the base labile Fmoc group protects the α-amino function.[9] The 
permanent side-chain protection usually relies on the t-Bu group or other acid labile 
groups. Currently, the Fmoc strategy is generally applied, because it involves milder 
reagents and often leads to peptides of higher purity and in higher yields. 
Besides the synthesis strategy, the nature of the solid carrier is a relevant parameter in 
SPPS. Solid support particles should preferably be of conventional and uniform size, 
mechanically robust, easily filterable, chemically inert and stable under the conditions of 
synthesis. They must also be accessible to the solvents allowing the penetration of 
reagents and the enlargement of the peptide chain within its microstructure. Furthermore, 
the solid phase should not physically interact with the growing peptide chain.[10]  
SPPS has important advantages over synthesis in solution (§ 1.3.2), and represented such a 
step forward that Merrifield was awarded the Nobel Prize in chemistry in 1984. These 
advantages include: 
 Reactions can be driven to completion through the use of excess reagents. 
 Excess reagents and soluble by-products can be simply removed by resin washing. 
 Physical losses are minimal since the product remains attached to the polymer 
throughout the synthesis. 
This type of peptide synthesis has one major disadvantage, being the production of more 
than stoichiometric amounts of environmentally aggressive and toxic waste.[10-11] Another 
drawback of the SPPS strategy entails the inability to purify intermediate products; only 
after the final cleavage step purification is possible. 
 
1.3.2 Classical solution phase peptide synthesis (CSPS)  
CSPS was the first general method developed for peptide synthesis. Small peptides, 
consisting of only a few amino acids, were built in solution, usually in EtOAc or DMF. 
Minimal side-chain protection strategies can be applied, because fully protected amino 
acids or peptides are highly insoluble, resulting in various undesired side reactions. Yet, 
the main advantage of this technique is that the intermediate products can be isolated and 
purified after each step of synthesis. 
Besides stepwise elongation, CSPS is nowadays frequently applied to couple fragments, 
often obtained by SPPS. During the synthesis of long or highly polar peptide sequences by 
SPPS, the yield drops drastically after approximately 30 residues. A convergent approach, 
in which multiple peptide segments are condensed in a hierarchical fashion to form the 
full-length polypeptide chain, is generally more efficient than a sequential approach.[12] 
Fragment condensation suffers from two major drawbacks: to avoid racemisation of the C-
terminal amino acid, only glycine or proline can be used in this position. Furthermore, the 
fragment with the free N-terminal amine has to be used in excess compared to the other 
fragment, to afford a high-yielding reaction. 
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1.3.3 Native chemical ligation 
The previously described methods could not completely satisfy the need to obtain 
sufficient peptide or protein material with the potential to site-selectively introduce 
chemical functionalities for chemical biology research. This desire has been the driving 
force for the development of various chemoselective ligation and modification 
strategies,[13] of which native chemical ligation is by far the most advanced technique.[14]  
 
  	
Figure 1.3 The two-step mechanism of native chemical ligation 
 
In native chemical ligation a native peptide bond is formed in aqueous solution at neutral 
pH from unprotected peptides, which are easy to handle because of their high solubility. 
One fragment is C-activated as a thioester, while the other fragment contains an N-terminal 
cysteine (Figure 1.3). These groups selectively react with each other in a two-step fashion, 
thereby preserving the integrity of the unprotected side chains. The first step involves a 
reversible thiol-thioester exchange, followed by rapid intramolecular SN acyl transfer, 
via a favourable five-membered transition state. The reaction rate can be increased by the 
addition of an excess of a more reactive arylthiol. Importantly, additional internal Cys 
residues in the peptide do not interfere with the overall reaction pathway, since the 
rearrangement requires a terminal nucleophilic amine instead of an internal amide. All 
twenty amino acids are allowed at the C-terminus, albeit that the ligation rate is 
significantly affected by the different side chains.  
The high stability and accessibility of the starting materials is key for the success of this 
strategy. The main initial limitation, being the presence of a relatively rare cysteine in the 
sequence, can be overcome by desulfurisation to an alanine residue or the use of an 
auxiliary strategy. A complete overview of the scope and limitations in chemical ligation is 
provided by Kent.[14] 
 
1.4 Enzymatic peptide synthesis 
The current chemical methods generate large amounts of waste because often an excess of 
reagents has to be used to drive the reaction to completion and a copious volume of 
organic solvent is part of the process. An enzymatic approach would offer an attractive 
alternative, since enzymes preferably act in water, require no or minimal side-chain 
protection, and make the use of reactive chemicals superfluous. Obviously, enzymatic 
reactions are associated with drawbacks on a different level, which need to be overcome. 
 Chemoenzymatic peptide synthesis 
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1.4.1 Recombinant expression 
Protein synthesis in living organimsms is an enormously complex process, involving 
numerous components such as an mRNA template, tRNA, amino acyl transferases and 
ribosomes. It is therefore difficult and expensive to use the enzymes involved outside their 
natural context in a reaction flask. It is however possible to use microorganisms for this 
purpose, since they contain the complete synthesis apparatus. By genetic modification, the 
DNA encoding the peptide of interest is introduced into the host cell, for example the 
Escherichia	coli bacterium. Subsequent transcription, translation and expression leads to 
the peptide of interest, which can then be isolated. This technique is particularly suitable 
for large natural peptides and proteins. Disadvantages of this method are the restriction 
that only natural amino acids can be incorporated and the high costs for development and 
production. 
 
1.4.2 Nonribosomal peptide synthesis (NRPS) 
Nonribosomal peptides represent a class of bioactive peptides, displaying antimicrobial, 
antiviral, immunosuppressive, and antitumor activities, containing unique structural 
features such as heterocyclic elements, D-amino acids, and glycosylated as well as N-
methylated residues. They are not produced by ribosomal synthesis, but large multi-
enzyme complexes, which simultaneously represent template and biosynthetic machinery, 
are responsible for their assembly. These complexes are organised in a modular fashion 
and for each specific building block a specific module exists, consisting of catalytically 
independent domains that regulate substrate recognition, activation, binding, modification, 
elongation and release. Due to the increasing knowledge and current techniques, it is now 
possible to rationally redesign the NRPS complex to synthesise a particular peptide target. 
A comprehensive review about NRPS and its potentials has been produced by Sieber.[15]  
 
1.4.3 Isolated proteases 
Besides enzymes dedicated to peptide synthesis, also proteases, which naturally hydrolyse 
peptide bonds, can be employed for the same goal under carefully tuned circumstances. 
They are convenient because proteases (1) are active at mild conditions, with pH optima in 
the range of 6 to 8, (2) are robust and stable, (3) do not require stoichiometric cofactors 
and (4) are also highly stereo- and regioselective. 
 
1.4.3.1 Classifications and mechanisms[16] 
Based on their catalytic mechanism, proteolytic enzymes are divided in six families: serine, 
cysteine and threonine proteases on the one hand, and aspartate, glutamate[17] and 
metalloproteases on the other hand. In the first category, the amino acids after which the 
families are named represent the nucleophile in the active site. As a typical example, the 
catalytic triad of a serine protease is depicted in Figure 1.4. Histidine and aspartate shuttle 
away the proton of the serine residue by hydrogen-bonding interactions, rendering it more 
nucleophilic and capable of attacking the peptide substrate. The negative charge that 
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develops during the formation of the tetrahedral complex is stabilised by the oxyanion 
hole. Upon the collapse of this transition state, part of the peptide is cleaved off and a 
covalent acyl-enzyme intermediate is formed. Subsequent nucleophilic attack by water 
liberates the product and regenerates the enzyme. 
 
 
Figure 1.4 The catalytic mechanism of serine proteases 
 
In the second category, an activated water molecule serves as the nucleophile. In 
metalloproteases activation comes from coordination to a metal ion, mostly zinc, 
sometimes also cobalt (Figure 1.5). In addition, the metal coordinates to the oxygen of the 
carbonyl in the substrate, giving rise to a more electrophilic carbon. Basic or acidic amino 
acid residues from the enzyme fill the remaining available coordination sites.[18]  
 
 
 
Figure 1.5 The catalytic mechanism of metalloproteases 
 
As indicated by the names, in aspartic or glutamic acid proteases the respective amino 
acids are involved in catalysis. The commonly accepted mechanism involves general acid-
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base catalysis, which is aided by another aspartate residue in the first case and a glutamine 
in the latter (Figure 1.6). The carboxylate activates the water by abstracting a proton 
generating a hydroxide. Electrophilic assistance by polarising the carbonyl bond of the 
scissile peptide is provided by the second catalytic amino acid. 
 
Figure 1.6 The catalytic mechanism of aspartic proteases 
 
Another way of categorisation is based on the cleavage site in the protein. Endopeptidases 
hydrolyse amide bonds within a peptide or protein, as opposed to exopeptidases that act 
directly near the termini. Aminopeptidases release a single amino acid from the N-
terminus, whereas carboxypeptidases liberate a single amino acid from the C-terminus. 
Amidases cleave terminal amides, releasing a carboxylate and ammonia. 
The exact site of hydrolysis is determined by the specificity of the protease against amino 
acid residues on either side of the scissile bond. Schechter and Berger[19] introduced 
comprehensive nomenclature (Figure 1.7) to describe the interactions between the 
peptide (P) and the enzyme subsites (S) taking this splitting point as the starting point for 
counting.  
 
 
Figure 1.7 Schechter and Berger nomenclature for the active site of a protease and the peptide 
substrate. The scissile bond is located between P1 and P1’. 
 
Characteristics concerning classification, mechanism and specificity of individual 
proteases (papain, trypsin, α-chymotrypsin and alcalase) will be introduced in the 
corresponding chapters. 
 
1.4.3.2 Thermodynamic vs. kinetic control 
When proteases are used under physiological conditions, they perform hydrolysis and the 
reversed synthesis reaction is negligible. Since proteases, like all catalysts, only alter the 
rate with which the thermodynamic equilibrium of the reaction is reached and do not 
change the equilibrium itself, the reaction conditions need to be manipulated to shift the 
Chapter 1 
 
 
 22 
equilibrium in favour of the synthesis reaction. In practice two synthetically useful 
strategies are applied i.e. the thermodynamically and the kinetically controlled approach. 
 
In the thermodynamically controlled synthesis of peptides, the product is obtained by the 
direct reverse of the hydrolysis reaction. According to the principle of microscopic 
reversibility, both the formation and the hydrolysis of the peptide bond proceed by the 
same mechanism and through the same intermediate (Figure 1.8). This implies that acyl 
donors with a free carboxylate function are used, and all proteases can be applied, 
independent of their individual catalytic mechanism. The rate limiting step is represented 
by the formation of the acyl intermediate from the carboxylic acid.    
 
 
Figure 1.8 Thermodynamically controlled synthesis 
 
In general, the thermodynamic approach gives low yields and requires high enzyme 
concentrations. The unfavourably positioned equilibrium can be shifted in the direction of 
synthesis by the addition of organic solvents, which influences the equilibrium constants of 
both ionisation (Kion) and conversion (Kcon). If the dielectric constant of the medium is 
lowered, the acidity of the carboxyl group of the acyl donor is also reduced, resulting in the 
presence of more protonated, uncharged species. Furthermore, the water activity is 
diminished by the addition of cosolvents, and, as a result, the equilibrium is shifted 
towards synthesis. Conducting the reaction in the absence of water, i.e. in a dry aprotic 
solvent, would be the ultimate situation in this respect. A similar increase of Kcon can be 
achieved when the product is removed from the reaction mixture by precipitation or a 
two-layer system where the product can diffuse to the organic layer, while the enzymatic 
reaction takes place in aqueous environment. A major downside of these manipulations is 
the probable instability and inactivity of the enzyme. 
 
The main issue in kinetically controlled peptide synthesis is the difference in reaction rate 
of the various possible reaction partners. Slightly activated acyl donors (Ac-X), such as 
esters, are normally used. First, a tetrahedral enzyme-substrate complex (E···Ac-X) is 
formed, that collapses into the covalent acyl-enzyme intermediate (Ac-E) (Figure 1.9), thus 
limiting this approach to serine and cysteine proteases. The deacylation of this 
intermediate can be performed by all the nucleophiles (H2O or Nu) present in the reaction 
mixture. Water and the nucleophilic amine will compete with each other for the transfer of 
the acyl group, resulting in hydrolysis (Ac-OH) or synthesis (Ac-Nu), respectively. The 
nucleophilic attack is the rate limiting step. 
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Figure 1.9 Kinetically controlled synthesis 
 
Compared to thermodynamic control, the kinetic approach shows relatively high reaction 
rates and requires a minimal amount of enzyme. The yield of peptide product will depend 
on the apparent ratio of transferase-to-hydrolase rate constants. A drawback of kinetic 
control is the necessity to terminate the reaction after the acyl donor is consumed, because 
the synthesis product will be hydrolysed again. 
There are several ways to affect kinetically controlled reactions, although obviously the 
limits allowed by the enzyme need to be taken into account. The pH can be raised, since the 
amine is only nucleophilic in unprotonated form. Increasing the substrate concentrations 
or the enzyme-to-substrate ratio will also be beneficial. 
 
1.4.4 Improved properties of biocatalysts 
Instability and inactivity of enzymes caused by, for example, the addition of organic 
solvents or by a high operating pH can be dealt with in various ways. Two of them will be 
discussed, i.e. immobilisation and enzyme engineering. Both approaches have the 
additional advantage that they can also influence the S/H ratio of a protease.  
 
1.4.4.1 Immobilisation 
Different types of immobilisation can be distinguished, including the involvement of a solid 
support, the entrapment or encapsulation using polymers and the direct crosslinking of 
enzymes with a bifunctional reagent.[20] A further subdivision for solid carriers is based on 
the type of interaction with the enzyme, which can be non-covalent adsorption by 
hydrophilic, hydrophobic or stronger ionic interactions, or the formation of covalent 
linkages. In what way an enzyme exactly binds, is mainly random, although more 
techniques are developed that are able to direct it. The most distinctive aspect of 
entrapment or encapsulation is the protection it offers by preventing direct contact with 
the environment. With crosslinking the problem of reduced specific and volumetric 
activity of the biocatalyst is circumvented. A practical example is the CLEA method –
crosslinked enzyme aggregates– in which precipitated enzyme is connected with 
glutaraldehyde. Whatever the nature of immobilisation, an important requirement for 
efficient biocatalysis is that substrates and products can freely diffuse inside and outside 
the immobilisation support. Which of the previously mentioned techniques will give the 
best results, is hard to predict. Hanefeld et	al. suggest factors that need to be taken into 
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account when planning the immobilisation of an enzyme and provide some guidelines for 
the selection of a suitable technique.[20a]  
The increased stability of enzymes by immobilisation is, in all probability, caused by the 
restricted freedom of movement and the directly related decreased chance of unfolding. 
The enzyme is trapped in a certain conformation, which likely also is at the basis of the 
changed substrate specificity that is sometimes observed upon immobilisation. An added 
advantage of immobilised catalysts is that they can easily be separated from the reaction 
mixture, which facilitates product purification and is additionally convenient when the 
enzyme must be reused. 
 
1.4.4.2 Enzyme engineering 
Biocatalyst engineering by a genetic approach is a powerful tool to create catalysts with 
tailored properties, such as high stability, but also improved specificity, substrate scope, 
enantioselectivity and diminished product inhibition. Reetz described the most recent 
developments in this field in an excellent review, and, although the focus is on improving 
the enantioselectivity of enzymes, the underlying strategies and added protocols are 
informative and generally applicable.[21] 
In the strategy of directed evolution, natural evolution is imitated by subjecting the gene 
encoding the enzyme of interest to repeated cycles of gene mutagenesis. Both the error-
prone polymerase chain reaction[22] and DNA shuffling[23] can be used for this purpose. The 
generated gene library is then inserted in a bacterial host and expressed. In a screening 
procedure the candidates with the desired features are selected and the process is 
continued until the desired degree of improvement has been achieved. An overwhelming 
amount of enzyme variants can be created this way, requiring an efficient and effective 
screening method.  
The input of knowledge in the mutagenesis process can structurally reduce the number of 
variants that need to be produced and screened. This approach is called site directed 
mutagenesis. Based on structural, mechanistic or bioinformatics data, putative 
randomisation sites are selected, which can reasonably be expected to be involved in a 
certain property. Often these sites will be located around the active site, but distal residues 
that may induce allosteric effects are viable options as well. In iterative site directed 
mutagenesis the putatively important sites are mutated in a systematic way, in order to 
take cooperative effects into account. 
 
1.5 Substrate mimetics approach 
1.5.1 Principle and mechanism 
The basis for the substrate mimetics approach was laid in 1977 by establishing that 
inverse ester substrates containing a cationic centre in the ester leaving group instead of in 
the amino acid side chain, can be hydrolyzed by trypsin.[24] Schellenberger was the first to 
apply this concept in a reversed enzymatic synthesis reaction. Only in 1997, the term 
‘substrate mimetics’ was introduced by Bordusa.[25] 
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According to literature, the substrate mimetics strategy combines the advantages of both 
enzymatic and chemical peptide synthesis, while most of the disadvantages are solved. The 
advantages include freedom in the choice of amino acid to be coupled, high stereo- and 
regioselectivity and the need for only small amounts of reagents and solvents. The latter 
two benefits can be realised by using enzymes for the synthesis reaction. The broad 
recognition of many amino acids, with a single enzyme, can be acquired with a trick. 
Normally, a protease recognises the side chain of a specific amino acid, and cleaves the 
substrate at the C-terminal site of this residue. When this recognition element is, however, 
mimicked as the site-specific ester leaving group, the substrate is still accepted by the 
enzyme, making recognition independent of the side chain of the amino acid.[26] A well-
known example is the guanidinophenyl (OGp) group, a mimic of the arginine side chain, 
which is naturally recognised by the enzyme trypsin. The catalytic mechanism[25] of this 
substrate mimetic (SM; Figure 1.10 B) is analogous to the natural situation (Figure 1.10 A).  
 
 
 
Figure 1.10  Catalytic mechanism of the serine protease trypsin with (A) a natural substrate and 
(B) a substrate mimetic. Recognition takes place in the S1 subsite, with subsequent nucleophilic attack 
of Ser-195 onto the carbonyl. The substrate mimetic is bound in a reversed orientation compared to the 
orientation of the natural substrate. The covalent intermediate can only be liberated by nucleophilic 
attack from the S’ region (double arrow). 
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First the substrate mimetic binds to the S1 pocket, which is followed by nucleophilic attack 
of the catalytic serine residue on the carbonyl of the substrate. Kinetic and computational 
studies have indicated that the substrate mimetic should bind in a reverse orientation to 
enable this attack.[27] In this way, the developing negative charge can still be stabilised by 
the oxyanion hole. Because the deacylation step requires unoccupied S' subsites, the non-
specific acyl residue has to flip from the S' to the S subsites prior to nucleophilic attack, in 
order to liberate both product and enzyme. Water as the nucleophile will result in the 
hydrolysis product, while an amino acid nucleophile will lead to dipeptide synthesis. 
 
1.5.2 Known enzyme – mimetic combinations 
In addition to OGp, several variations of this moiety have been investigated to probe the 
structural requirements of a mimetic for trypsin (Figure 1.11).[24, 28]  
 
 
Figure 1.11 Structures of efficient substrate mimetics and less efficient variations 
 
Besides OGp, pOAp was found to be efficient in enzymatic peptide synthesis. The relocation 
of the guanidino or amidino group to the meta-position (mOGp and mOAp) resulted in 
much less effective esters. The altered bond angle may be an important determinant here, 
as well as the changed direction between the carbonyl group and the cationic substituent. 
The introduction of a methylene between the cationic substituent and the aromatic ring 
(OGmp and OAmp) was highly unfavourable, probably due to the different leaving group 
ability of the phenol as a result of the non-conjugated amidino or guanidino group. From 
the naphthalene derivatives, only O1G4N, in which the two substituents are aligned with 
the shorter axis of the ring, gave a good peptide coupling yield. O1G5N appeared to be 
moderately efficient, whereas both O1G6N and O6G1N reacted very slowly.  
Furthermore, the applicability of the OGp ester was established for the cysteine protease 
clostripain, which specifically recognises arginine residues.[29] This enzyme possesses wide 
acyl acceptor tolerance, since branched amines, amino alcohols and cyclic amines were all 
accepted. 
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A fruitful attempt to extend the substrate mimetic strategy to α-chymotrypsin was 
accompanied by computational docking studies.[30] It was shown that OGp can also be 
employed for this enzyme –which is specific for large aromatic residues– in spite of the 
presence of a charged guanidine group. Rationalisation by a docking approach provided a 
model that allows potential mimetics to be predicted. The binding energies of empirically 
chosen leaving groups derived from benzyl (OBn, OPic), indolyl (OInd) or phenyl (OPh, 
OCp and OCap) esters (Figure 1.12) were calculated and successfully correlated to the 
observed specificity constants in a hydrolysis experiment. The OCap ester of Boc-L-Ala-OH 
was identified as an efficient and slightly higher specific substrate mimetic for α-
chymotrypsin than the OGp ester. 
 
 
Figure 1.12 Structures of potential mimetics used in a computational approach 
 
To demonstrate that the substrate mimetics strategy is not restricted to OGp or arginine-
recognising proteases, novel mimetics were designed for two enzymes, V8 protease from 
Staphylococcus	aureus and Glu-specific endoprotease from Bacillus	 licheniformis, with a 
strong preference for glutamate in their recognition pocket (Figure 1.13).[31]  
 
 
 
Figure 1.13 Structures of potential mimetics for Glu-specific proteases 
 
Both biocatalysts displayed a similar preference pattern for these compounds, but the 
latter enzyme appeared to react more efficiently. The carboxymethyl thioester (SCm) was 
effective in acyl transfer reactions, independent of the acyl moiety connected to it. 
However, compared to classical substrates, the enzyme requirement was high. The 
negative charge was essential for recognition as was demonstrated by the complete 
inactivity of the uncharged carboxyamide (SCam). In an effort to optimise the mimetic, the 
alkyl chain was extended by one carbon (SCe) to make it more similar to a glutamate. In 
addition, the alkyl chain was replaced by a phenyl linker (Cph), analogous to the situation 
that OGp is a good arginine mimetic, the position of the carboxylate was changed (2Cph, 
3Cph, 4Cph) or the thioester bond was replaced by an ester bond (OCph). None of these 
changes significantly affected the properties of the mimetic. 
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1.5.3 Limitations and possible solutions 
Although the substrate mimetics strategy has many advantages, some intrinsic drawbacks 
connected to enzymatic peptide synthesis still remain. The primary specificity of a 
protease continues to be present with the result that product hydrolysis can occur when 
the specific amino acid is part of the peptide, which is most likely the case for long 
peptides. Moreover, the specificity for the acyl donor and the preference for a nucleophile 
are individual characteristics for each enzyme, therefore the efficiency of S/H and thus the 
potential for peptide synthesis will greatly differ from one protease to another. In recent 
years much effort has been devoted to overcome these limitations.  
 
1.5.3.1 Biocatalyst engineering 
As mentioned in § 1.4.4.2, an effective way to change the properties of an enzyme is by 
engineering, either chemically or genetically. Here, examples with respect to substrate 
mimetics are discussed. A chemical method comprises the methylation of the Nε active site 
histidine in trypsin, thereby generating an enzyme variant in which the amidase activity is 
lost, but the esterase activity is retained.[32] Peptide formation with this catalyst using OGp 
esters was successful and the products were not subject to secondary hydrolysis by the 
enzyme. Another way to obtain a universally applicable trypsin variant with decreased 
cleavage activity is site-directed mutagenesis.[33] The known trypsin mutant D189S was 
taken as a starting point, because it exhibits diminished native amidase activity for trypsin 
substrates, whereas its proteolytic activity towards chymotrypsin substrates is improved 
by one order of magnitude. The total hydrolysing capacity of the enzyme was further 
repressed based on a thorough computational analysis of the binding site. With the double 
mutations D189A and S190A, both involved in determining substrate specificity in trypsin, 
a synthetically useful catalyst was acquired for substrate mimetics-mediated peptide 
ligations. In order to find an enzyme with a specificity tailored at the artificial substrate 
mimetic moiety OGp, a variation on the site-directed mutagenesis strategy was applied.[34] 
The rationally designed D189E mutation in trypsin was anticipated to disturb the 
interaction of the carboxylate with arginine or lysine by the presence of an additional 
methyl group, while not hindering the interaction with OGp too much. This manipulation 
indeed led to increased specificity towards OGp esters compared to arginyl- or lysyl-bonds. 
Yet a different approach is the search for enzymes with improved properties from different 
sources. Amongst others, various bacterial and mammalian trypsins have been 
investigated, as well as trypsin enzymes from cold-adapted fish, as they display 
substantially higher catalytic efficiency than their mammalian counterparts.[28c, 35] An 
elegant idea to circumvent the whole problem and to take advantage of the specificity is to 
synthesise all-D-peptides with an L-specific enzyme or apply this concept the other way 
around.[36] 
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1.5.3.2 Freezing strategy or ionic liquids 
Two other approaches to suppress the undesired enzymatic hydrolysis reaction of specific 
peptide bonds have been described, both of which involve lowering the availability of 
water. By freezing the reaction mixture, the amidase activity of a protease for classical 
substrates is severely restricted, while the inherent esterase activity is much less affected. 
Based on experiments with trypsin, chymotrypsin and Bacillus	lichenisformis Glu-specific 
endopeptidase and the appropriate substrate mimetics, it was concluded that the effects 
for substrate mimetics are even more pronounced. Peptides containing specific amino 
acids are generally hydrolysed with higher preference than the respective substrate 
mimetics. At –15 °C, however, such specific fragments could be synthesised without the 
expected proteolytic side reaction, albeit in a much slower rate. Furthermore, the ratio 
between hydrolysis and aminolysis of the substrate mimetics was improved.[37] 
The application of ionic liquids as reaction medium additive in substrate mimetic-
mediated peptide synthesis was positively evaluated. Trypsin, chymotrypsin and V8 
protease and the appropriate substrate mimetics were investigated. Wild-type biocatalysts 
could be used, since any competitive proteolytic side-reactions were suppressed. 
Furthermore, compared to the addition of classical organic solvents, high turnover rates 
were obtained. Due to the exceptional properties of ionic liquids chemically labile 
reactants remained highly stable; moreover the solubility of many reactants is vastly 
improved in this medium.[38] 
 
1.6 Computational modelling[39] 
1.6.1 Molecular docking 
The interaction between an enzyme and its substrate is often a black box for a synthetic 
chemist. Preparing a range of substrate analogues and experimentally determining their 
activity should hopefully result in a relevant structure activity relationship (SAR). A 
computational tool that can help to overcome the lack of insight into the interaction is 
molecular docking. In molecular docking, knowledge about the enzyme is used to predict 
and optimise the binding of small molecules. The primary requirement is a high resolution 
model of the enzyme structure. When the position of the active site in the structure is 
known, it is called direct docking. As in enzymatic models, where more flexibility was 
introduced by switching from the traditional ‘lock and key’ concept to the induced fit 
model, flexibility has been increasingly implemented in molecular docking software. 
Nowadays, both the substrate and to a growing extent also the enzyme are regarded as 
flexible. The main restriction here is the limited computational feasibility. The number of 
degrees of freedom that have to be considered grows exponentially with the number of 
accessible enzyme conformations.[40]  
  
1.6.2 MD simulations 
More insight into the time dependent behaviour of a molecular system can be obtained by 
molecular dynamics (MD) simulations, which provide detailed information on the 
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fluctuations and conformational changes of proteins or protein-ligand complexes. 
Molecular mechanic principles lie at the basis of the calculations, meaning that Newton’s 
equation of motion is applied: F=ma, where F is the force exerted on the particle, m is its 
mass and a is its acceleration. The initial velocities on the atoms are randomly generated at 
the beginning of the dynamics run and force fields are used to describe the interactions 
between the atoms involved. These force fields are an empirical substitution for the 
potential energy function with parameters that are optimised on the basis of reality, with 
consideration of explicit or implicit solvent whatever is desired. Newton’s equation is 
iteratively solved at regular time intervals, resulting in a trajectory that describes the 
positions, velocities and accelerations of the particles as they vary with time. The cycle is 
repeated for a predefined number of steps. Parameterisation of the force field plays a 
crucial role in the accuracy of the molecular model predictions. Furthermore, it is 
important to sample a sufficient amount of phase space and acquire a representative 
conformational sampling. 
 
1.6.3 Ab initio calculations 
When the mechanism of enzyme catalysis is the subject of study, ab	 initio calculations 
should be employed, because this technique is suitable for describing electronic processes 
such as charge transfer, transition states and reaction paths.[41] It is based on quantum 
mechanical calculations instead of empirical parameters. In the Hartree-Fock method, a 
molecular system is regarded as a linear combination of atomic orbitals, which, in turn, can 
be described by a basis set of wave functions. With the density functional theory the 
properties of a many-electron system can be determined by using functionals of the 
spatially dependent electron density. In both cases, the computational requirement is 
large, therefore this method is only feasible for relatively small systems, containing around 
maximally hundred atoms. Therefore quantum mechanical calculations are mostly 
restricted to the active site of an enzyme, while the complementary use of highly efficient 
force field based molecular mechanics methods for the surroundings can provide the 
overall picture.  
 
1.7 Problem definition 
1.7.1 Context provided by IBOS Programme 
IBOS (Integration of Biosynthesis & Organic Synthesis) is a research programme under the 
auspices of NWO (Netherlands Organisation for Scientific Research), in particular the 
division ACTS-CW. The latter focuses on societally relevant chemical issues in which the 
Dutch government, knowledge institutions and the Dutch chemical and life sciences 
industry are involved. A change of strategy in industrial synthetic chemistry by integrating 
state of the art organic chemistry and modern biochemistry and biotechnology is the aim 
of IBOS. This will enable a new and sustainable future for industrial synthesis of complex 
products, such as pharmaceuticals, nutrients or new materials, which contribute 
considerably to the quality of life. In addition, a drastic reduction of waste is envisioned. 
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One of the themes within the IBOS programme is chemoenzymatic peptide synthesis. 
Peptides form the most promising class of bioactive compounds for future biomedical and 
pharmaceutical applications. However, purely chemical synthesis suffers from serious 
disadvantages, such as low yields and high process costs. It is therefore of great value to 
implement solutions offered by nature in this process, as most of the biochemical 
processes that occur in living organisms easily outperform the ‘best practices’ of 
conventional synthetic methods. The aim of the project is to develop low-cost versatile 
chemoenzymatic routes for the synthesis of natural and non-natural peptides of 
importance for pharmaceutical and/or food applications. Key objectives are: 
 Discovery and engineering of peptidases and amidases that can catalyse C-terminal 
activation and coupling of all common amino acids; 
 Defining and optimising suitable bioreactor configurations and process conditions ; 
 Development and validation of the industrial applicability of peptide synthesis based 
on substrate mimetic methods.  
 
These topics were distributed between the collaboration partners of this project. At the 
University of Groningen under the supervision of Prof. dr. D.B. Janssen, Ana Toplak has 
been working on the cloning and expression of new and better endoproteases using two 
approaches. The first approach focused on subtiligase as a starting point, and the second 
on obtaining new subtilisin-like enzymes from extremophiles. The production of a peptide 
amidase and the subsequent characterisation and determination of the biocatalytic 
potential for industrial application has been carried out by Irfan Arif. At Wageningen 
University under the supervision of Prof. dr. ir. J. Tramper, Petra Vossenberg is engaged in 
the development of process conditions for optimal peptide coupling, preferably in one pot, 
investigating the influence of water activity and enzyme incompatibility. The third topic, 
exploration of the substrate mimetics strategy, is the subject of this thesis and the 
objectives and chosen approach are detailed in the next section. 
Industrial partner DSM Innovative Synthesis B.V., represented by dr. P. J. L. M. Quaedflieg, 
contributed ‘in-house’ and ‘in-kind’ research efforts. Part of this research was executed by 
PhD-student Timo Nuijens, who focussed on peptide synthesis in organic media using 
activated esters and immobilised Alcalase. 
 
1.7.2 Objective and approach  
The principle of the substrate mimetics approach seems promising according to literature, 
but since it was only demonstrated on a small scale with expensive mimetic groups, the 
viability for industrial scale needs to be probed. To that end, the scope and limitations of 
the substrate mimetics strategy to enzymatically couple amino acids in aqueous media was 
investigated, paying particular attention to the following aspects: 
 the use of cheap enzymes with a broad substrate range 
 the design of simple mimetics, which are synthetically readily accessible and 
preferably can be synthesised enzymatically 
Chapter 1 
 
 
 32 
In addition, it would be of great value to know which requirements a substrate mimetic 
has to meet in order to function well and to understand their mode of action. Several 
computational modelling techniques will be applied to gain insight into the active site and 
obtain valuable input for the design of new mimetics. 
 
1.7.3 Outline of thesis 
Chapter 1 serves as an introduction into chemoenzymatic peptide synthesis, providing an 
overview of the advantages, potentials, drawbacks and limitations of chemical versus 
enzymatic peptide synthesis. Special attention is given to the substrate mimetics strategy. 
With the intention to widen its scope, this strategy was applied to the cysteine protease 
papain, a cheap enzyme with broad specificity. These results complemented with 
computational studies are described in Chapter 2. In Chapter 3, simplified esters are 
developed, based on the observation that in combination with papain, enzyme-specific 
activation is a more appropriate term than substrate mimetics. Chapter 4 focusses on 
determining what properties are essential for developing a good activating ester or 
mimetic using trypsin as the protease. The influence of different enzymes on enzyme-
specific activation is studied comparing α-chymotrypsin and papain, which is described in 
Chapter 5. In Chapter 6, the effect of nearly anhydrous reaction conditions on enzyme-
specific activation is considered using Alcalase-CLEA. Chapter 7 describes the synthesis of 
all compounds that were required for the previous chapters. By way of overall conclusion, 
the results are put in perspective in Chapter 8. 
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 	Chapter 2
	
Papain‐catalysed	peptide	bond	
formation:	enzyme‐specific	activation	
with	guanidinophenyl	esters	
 
The substrate mimetics approach is a versatile method for small-scale enzymatic peptide- 
bond synthesis in aqueous systems. The protease-recognised amino acid side chain is 
incorporated in an ester leaving group, the substrate mimetic. This shift of the specific 
moiety enables the acceptance of amino acids and peptide sequences that are normally not 
recognised by the enzyme. The guanidinophenyl group (OGp), a known substrate mimetic 
for the serine proteases trypsin and chymotrypsin, has now been applied for the first time 
in combination with papain, a cheap and commercially available cysteine protease. To 
provide insight into the binding mode of various Z-XAA-OGp esters, computational docking 
studies were performed. The results strongly point at enzyme-specific activation of the 
OGp esters in papain through a novel mode of action, rather than their functioning as 
mimetics. Furthermore, the scope of a model dipeptide synthesis reaction was investigated 
with respect to both the amino acid donor and the nucleophile. Molecular dynamics 
simulations were carried out to prioritise 22 natural and unnatural amino acid donors for 
synthesis. Experimental results correlate well with the predicted ranking and show that 
nearly all amino acids are accepted by papain. 
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2.1 Introduction 
The importance of peptides in the fields of healthcare and nutrition renders the amide 
bond probably the most synthesised chemical bond.[1] In light of this, both chemocatalytic 
and enzymatic strategies for amide-bond formation are being developed. The use of 
enzymes is advantageous, particularly on an industrial scale, because they are usually 
selective, prevent racemisation, and require minimal or no side-chain protection. The 
typical enzymes of choice for peptide synthesis are proteases, readily available enzymes 
that normally hydrolyse peptidic amide bonds, but also show the capacity to effect amide 
bond formation. The typical selection criterion for a specific protease is based on the 
specificity for a particular amino acid residue on either side of the scissile bond. However, 
the main drawback of such an approach is the need for a different enzyme for nearly each 
desired peptide bond, as is nicely illustrated by the enzymatic synthesis of octapeptide 
CCK-8 for which three different proteases were required.[2] Secondary hydrolysis of the 
reaction products necessitated a judicious choice in the order of the fragment couplings, 
and prudent fine-tuning of the reaction conditions for each individual step. These 
drawbacks in combination with the limited recognition of many amino acids, both natural 
and unnatural, severely restrict the universal application of enzymes. 
In the so-called substrate mimetics strategy, the problem of limited applicability is 
overcome by incorporating the enzyme-recognised amino acid side chain moiety in the 
ester leaving group, thereby making the enzymatic recognition independent of the side 
chain. A well-known example is the guanidinophenyl (OGp) group, a mimic of the arginine 
side chain, which is naturally recognised by the protease trypsin.[3] Besides fundamental 
studies on the mechanism[4] (see § 1.5.1), much research on substrate mimetics has been 
devoted to method improvement and to solving difficulties related to enzymatic peptide 
synthesis. For example, several variations of the OGp ester have been evaluated as 
alternative substrate mimetics for trypsin,[5] the OGp ester was applied to different 
enzymes such as chymotrypsin[6] and clostripain,[7] but also to trypsin variants with 
diminished hydrolytic activity[8] or purified from different exotic sources.[5c, 5d, 9] The 
undesired enzymatic hydrolysis reaction of specific peptide bonds can be successfully 
suppressed by freezing the reaction mixture[10] or by using ionic liquids as solvents.[11] 
Furthermore, it has been shown that new substrate mimetics could be designed for two 
enzymes that recognise negatively charged amino acids,[12] thus indicating that more- 
general application of the strategy might be feasible. Despite the considerable amount of 
existing research, the substrate mimetics approach has never been applied to the cysteine 
protease papain. This cheap and commercially available enzyme would be a good 
candidate, also for industrial application, because it has been effectively used in enzymatic 
peptide synthesis before and cysteine proteases are known to result in a better synthesis- 
over-hydrolysis (S/H) ratio than serine proteases.[13] The slight preference of papain for 
arginine and lysine residues suggested that the existing OGp ester could be used as a 
mimetic. Furthermore, papain has a broader specificity than trypsin, and this could 
provide relevant information about the applicability of the substrate mimetics approach to 
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less specific enzymes. So far only proteases that bear a narrow specificity towards distinct 
amino acid side chains have been used; hence this research could potentially widen the 
scope of the substrate mimetics approach.  
We used the OGp ester as a potential substrate mimetic for papain-induced dipeptide 
synthesis under aqueous conditions. Subsequent docking studies provided insight into the 
binding mode, and, based on these results, MD simulations served to predict a set of 
suitable amino acid donors. The resulting ranking was experimentally verified, and the 
scope of the amino acid acceptor was determined. 
 
2.2 Results & Discussion 
2.2.1 Initial dipeptide synthesis reaction 
Z-Gly-OGp was prepared as a test substrate in order to study the OGp ester as a mimetic 
applied to papain. Z-Gly-OH was esterified with p-[N’, N’’-Di(Boc)guanidino]phenol[14] by 
using DCC as coupling reagent. Glycine was chosen to be incorporated in the acyl donor 
because it is the simplest amino acid and is not recognised by papain. Next, Z-Gly-OGp was 
subjected to the enzymatic reaction with papain in which H-Phe-NH2 was used as the acyl 
acceptor because of its clear UV-visibility at 254 nm, which simplified the HPLC analyses 
(Scheme 2.1).  
 
 
Scheme 2.1 Enzymatic synthesis with papain 
 
To our delight, the dipeptide product was formed quickly (20 min) and in high yield (92%) 
with hardly any enzymatic hydrolysis (2.4%). This compares favourably to results 
obtained with trypsin.[8a] Concurrently, we observed that chemical hydrolysis of the 
starting material under exactly the same reaction conditions but in the absence of papain 
was substantial (5.6%). This spontaneous hydrolysis is clearly undesirable, because it will 
increase with longer reaction times. 
 
2.2.2 Prediction of the binding mode and validation of Z-XAA-OGp esters  
Having shown that papain can recognise Z-Gly-OGp, we developed an increased molecular 
understanding of the substrate mimetics approach in papain. A molecular modelling study 
was performed by using the flexible docking programme Fleksy.[15] The results were 
visualised and analysed by using the YASARA programme. 
Crystallisation and subsequent structure determination by X-ray methods revealed that 
papain is a single-chain polypeptide containing three disulfide bridges, which is folded into 
two domains with the active site in a groove between them.[16] The most important 
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residues in the active site are Cys25, which provides the nucleophilic thiol, and His159, 
which completes the catalytic diad (Figure 2.1 A). The oxyanion hole is formed by the side 
chain NH2 group of Gln19 and the backbone amide of Cys25. Residues Asp158, Gly66 and 
Trp177 are involved in a conserved hydrogen-bonding network that is required for 
substrate affinity.[17] 
		
Figure 2.1  Molecular modelling of papain substrates. Hydrogen bonding interactions to 
functionally important amino acids in the papain active site are shown for (A) the backbone of a peptide 
substrate and (B) the compound Z-L-Ala-OGp. The overall orientation in the papain peptide binding 
groove is shown for (C) the hexapeptide LLRLSL and (D) the compound Z-L-Ala-OGp. The different 
papain subsites occupied by the hexapeptide are indicated. The white arrows indicate the N- to C-
terminal direction of the scissile bond, thus illustrating the ‘reversed’ binding mode of Z-L-Ala-OGp. 
 
To gain insight into the influence of the configuration of the amino acids and sterically 
demanding substrates, in addition to the achiral glycine ester, the OGp esters of L-alanine, 
D-alanine, -alanine and L-proline were considered in the docking study. Figure 2.1 B 
shows that Z-L-Ala-OGp perfectly fits in the active site, interacting in a similar manner as 
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the natural substrate (Figure 2.1 A). Based on the obtained Z-L-Ala-OGp binding mode, we 
rationalised that the oppositely configured D-alanine ester would be a much poorer 
substrate, as its methyl side chain is predicted to clash with the catalytic His-159. This 
effect is even more profound and disadvantageous for the secondary amino acid L-proline. 
In case of the -alanine ester, the interactions with the oxyanion hole and the hydrogen 
bonding network with the guanidino group could be maintained, but the beneficial 
interaction with Trp177 was disrupted by the introduction of an extra carbon atom in the 
ester backbone. Experimental verification of these modelling-based hypotheses confirmed 
that reaction rates for Z-D-Ala-OGp and Z--Ala-OGp are indeed around 100 times lower 
than those for Z-Gly-OGp and Z-L-Ala-OGp and that Z-Pro-OGp does not react at all. This all 
provides experimental support for the binding mode of Z-L-Ala-OGp proposed in Figure 2.1 
B. 
The different view in Figure 2.1 C shows that the natural substrate is positioned in the 
groove with all the amino acid side chains exposed, including the specificity-determining 
arginine. The substrate mimetic is also located in this cleft, but is oriented reversely as 
compared to the natural substrate (Figure 2.1 D), similar to what Bordusa described for 
the OGp ester in trypsin.[18] It is remarkable though, that the guanidino group present in 
the mimetic is situated in the groove, unlike the natural substrate’s arginine side chain. 
This suggests that, in the case of papain, the OGp ester is not actually mimicking the 
natural substrate in the sense that the guanidino group binds at the same position. 
Nonetheless, the OGp ester is specifically recognised by the enzyme, and therefore we 
propose to call it an enzyme-specific activating ester. 
 
2.2.3 Molecular dynamics simulations of Z-XAA-OGp esters in papain  
To further probe the viability of enzyme-specific activating esters as a more general 
enzymatic method for peptide synthesis, we investigated whether the successful dipeptide 
synthesis with Z-Gly-OGp and H-Phe-NH2 could be extended to a variety of other natural 
and unnatural amino acids. Figure 2.1 D clearly shows that the side chain of Z-L-Ala-OGp 
points up and out of the groove, thereby implying there should be sufficient space to 
accommodate the side chains of other natural amino acids as well. Rather than 
determining the scope of the acyl donor directly, we incorporated a computational 
approach as an intermediate step. A reliable model would be of great use in predicting 
which amino acids will be accepted by the enzyme papain in order to prioritise them for 
synthesis and for reaction planning. All 20 natural and the two previously evaluated 
unnatural amino acids were docked, and the stabilities of the resulting complexes were 
assessed with the help of molecular dynamics simulations. 
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Figure 2.2  Stability of modelled papain-Z-XAA-OGp complexes as assessed by molecular 
dynamics simulations. The presence of a hydrogen bond between Gln19 of the papain oxyanion hole 
and carbonyl of the scissile bond of the substrate throughout the simulation time is shown by bars (left 
axis), and the average distance between the oxyanion hole (Gln19) and carbonyl of the scissile bond of 
the substrate throughout the simulation is shown by a line (right axis). The amino acids that were 
selected for synthesis and testing are indicated with asterisks. All amino acids were considered in the L-
conformation, unless otherwise indicated. 
 
This was done on the assumption that the aforementioned interactions with the oxyanion 
hole are essential to the formation of a productive enzyme-substrate complex. Both the 
distance to oxyanion-hole residue Gln19 and the percentage of simulation time for which 
this residue forms a hydrogen bond with the substrate, were used as measures of complex 
stability. Initially oxyanion hole Cys25 was also taken into account, but including these 
interactions did not affect the results. The ranking is mostly determined by the specific 
interactions that the side chains make with papain during the simulation (Figure 2.2). As a 
result, amino acids with similar characteristics generally show a comparable ranking. For 
instance, asparagine and glutamine are positioned close to each other, as are the β-
branched amino acids isoleucine and valine. The observed discrepancy between 
phenylalanine and tyrosine can be explained by the fact that, although the docking showed 
a nice fit, phenylalanine is drawn into the nearby hydrophobic S1' pocket during the MD 
simulation, an event that is probably prevented for tyrosine due to the presence of the 
additional polar hydroxyl group. Based on the docking studies alone, one would expect a 
higher ranking for serine, but this is presumably prohibited by the formation of an 
intramolecular hydrogen bond during the simulation. 
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2.2.4 Verification of the MD-based predictions 
To verify the MD-based rankings and to determine the scope of the acyl donor 
experimentally, a representative set of amino acids was selected for validation (marked 
with an asterisk in Figure 2.2). The corresponding Z-XAA-OGp esters were synthesised 
starting from amino acids with appropriate side-chain protection. Yields of the coupling 
reactions varied between 63 and 98%. The acidic deprotection appeared to be 
troublesome in some cases, because chemical hydrolysis of the ester occurred as a side 
reaction (<10%). Nevertheless, the crude product obtained after Boc deprotection was 
used directly in the enzymatic reactions, and a correction was performed afterwards. The 
enzymatic reaction was monitored for three hours. The identity of the products formed in 
the enzymatic reaction was confirmed by chemical synthesis of reference compounds and 
LC-MS analysis. Table 1 presents either the time to reach full conversion of the OGp esters, 
or the conversion after three hours. The indicated percentages of enzymatic synthesis and 
hydrolysis remained constant over time, as measured after 24 hours unless stated 
otherwise. The S/H ratio for the various amino acids gives an ambiguous impression. 
While excellent in the case of glycine and threonine (entries 4 and 8), proline (entry 9) 
does not react with papain at all. With the OGp esters of both arginine and asparagine 
(entries 2 and 3) non-enzymatic cyclic side products were formed, a piperidone[19] and 
succinimide[20] respectively; this was facilitated by the guanidinophenyl leaving group. 
Over time the piperidone side product was converted into Z-Arg-OH, while the succinimide 
side product concentration remained constant. 
It is not trivial to assess the correlation between the computational results in Figure 2.2 
and the experimental results in Table 2.1. Given the large variation in the S/H ratios for the 
various amino acids, the analysis should be restricted to conversion rates only. This can be 
rationalised by realising that the simulations address only the effective formation and 
stability of the enzyme-substrate complex, which is merely the first step in a cascade of 
events. The stability of the acyl-enzyme intermediate as well as the velocity of deacylation 
are important factors in defining the S/H ratio, but cannot be predicted from our modelling 
studies. For example, during deacylation, unforeseen steric hindrance might occur 
between the acyl donor residue and the groove of the active centre in papain. Furthermore, 
the type of nucleophile that attacks the enzyme-acyl intermediate is not taken into account 
in our modelling experiments. 
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Table 2.1  Various Z-XAA- OGp esters tested experimentally[a] 
 
 
 
	 	 background enzymatic	
Entry	 Amino	
acid	
Time	
(min)	
Conv.	
(%)	
Z‐XAA‐OH	
(%)	
Z‐XAA‐Phe‐NH2
(%)	
Z‐XAA‐OH	
(%)	
1 L-Ala 2 100 1.9 77.5 20.6 
2 L-Arg 1 100 3.4 45.9[b] 17.2 
3 L-Asn 25 100 1.4 6.1[c] 30.2 
4 Gly 20 100 5.6 92.0 2.4 
5 L-Glu 15 100 3.8 68.5 27.7 
6 L-Ile 90 100 - 24.5[d] 12.2 
7 L-Phe 25 100 3.4 29.8 66.8 
8 L-Thr 20 100 4.3 90.7 5.0 
9 L-Pro 180 5 5.0 - - 
10 D-Ala 180 82 13.5 11.6 5.4 
11 β-Ala 180 39 7.4 31.6 - 
[a] Conditions: 2 mM Z-XAA-OGp, 15 mM H-Phe-NH2, 0.2 M HEPES buffer pH 8.0, 0.2 M NaCl, 
20 mM CaCl2, 10% (v/v) DMF 
[b] Non-enzymatic piperidinone side product formation (33.5%) 
[c] Non-enzymatic succinimide side product formation (62.3%) 
[d] Dipeptide product precipitated during reaction, estimated yield is 87.8% 
 
Despite the aforementioned shortcomings, it is clear that the high-ranking amino acids 
require the shortest reaction times, and that the reaction time generally increases with a 
decreasing predicted stability. However, phenylalanine does not seem to fit the correlation, 
with a much faster experimentally determined reaction time than suggested by its ranking. 
Apparently the hydrophobic pocket that determines the outcome of the MD simulation is 
of less influence on substrate mimetic binding than expected. Threonine also performed 
much better than predicted, based on our simulations. To explain this observation, we 
evaluated the different rotamers accessible to the threonine side chain. In the docking 
experiment, it was positioned in the trans 1 rotamer, which is not the typically preferred 
rotamer for threonine.[21] Therefore, we also assessed the stability of the more preferred 
gauche 1 rotamers and found that the g	rotamer indeed resulted in a more stable complex, 
with an oxyanion hole-substrate hydrogen bond present for 41% of the simulation time. 
This is comparable to what is observed in Figure 2.2 for the other -branched amino acids 
isoleucine and valine, which were both also predicted to bind in their preferred g- and 
trans rotamers.  
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It would not have been possible to decide a	priori what percentage of hydrogen bond 
formation would be sufficient for activity. With the experimental results in hand, we can 
see that only a minor percentage of hydrogen bond formation and proximity is already 
enough to lead to enzymatic activity. Basically every experimentally tested amino acid in 
Table 2.1, except for proline, is accepted by papain. Even the two unnatural amino acids D-
alanine and -alanine, correctly predicted to react considerably slower, do react. The 
difference between predicted and experimentally determined reactivity may be taken as 
an indication that papain is in reality more flexible than modelling suggests. 
 
2.2.5 Probing the influence of the amino acid in the nucleophile – acyl 
acceptor 
Contrary to the acyl donor amino acids, the scope of the nucleophile was not 
computationally studied. As mentioned previously, papain displays broad specificity as a 
result of its wide-open peptide binding groove, which allows for many interactions upon 
substrate binding. The acyl donor can be modelled in this network by utilising known 
interactions with the oxyanion hole, but no such requirement is known for the incoming 
nucleophile. Hence, the influence of the acyl acceptor on the enzyme-specific activation 
was only probed experimentally with a restricted set of amino acid derivatives (Table 2). 
 
Table 2.2  Various nucleophiles esters tested experimentally[a] 
 
 
 
	 background enzymatic	
Entry	 Nucleophile Time	
(min)	
Conv.	
(%)	
Z‐Gly‐OH	
(%)	
Z‐Gly‐Nu‐NH2
(%)	
Z‐Gly‐OH	
(%)	
1 D-Phe-NH2 20 100 2.8 22.9 74.3 
2 L-Phe-OtBu 25 100 3.8 11.8[b] - 
3 L-Tyr-NH2 25 100 6.2 91.3 2.5 
4 L-Tyr-pNA 25 100 5.1 90.6 4.3 
5 L-Ala-NH2 20 100 5.3 87.0 7.7 
6 L-Ala-pNA 20 100 4.0 96.0 - 
7 L-Ser-pNA 30 100 6.0 94.0 - 
8 L-Pro-pNA 30 100 9.7 - 90.3 
9 - 20 100 5.2 - 94.8 
[a] Conditions: 2 mM Z-Gly-OGp, 15 mM Nu, 0.2 M HEPES buffer pH 8.0, 0.2 M NaCl, 20 mM 
CaCl2, 10% (v/v) DMF 
[b] Dipeptide product precipitated 
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Switching the configuration from L-Phe-NH2 to D-Phe-NH2 shifted the enzymatic reaction 
from primarily synthesis to mainly hydrolysis (entry 1). The exchange of an amide for a 
tert-butyl ester did not really affect the reaction time, although the dipeptide product 
precipitated (entry 2). The pNA-amide of phenylalanine did not dissolve under these 
reaction conditions and was therefore excluded from the set. As alternatives, the Tyr-NH2 
and Tyr-pNA pair was tested for the influence of the pNA group, prior to testing the less 
visible amino acids with this chromophore attached. The results were very much 
comparable, with or without pNA, also for the small amino acids alanine and serine. 
Proline, a worse nucleophile, only gave hydrolysis and that at a comparable rate to the one 
seen without an additional nucleophile being present. 
 
2.3 Conclusion 
In this chapter, we have shown that the OGp ester can be successfully applied in papain-
catalysed dipeptide synthesis under aqueous conditions. Our docking studies, which were 
performed to increase our molecular understanding of the system, resulted in an 
unexpected binding mode for the Z-L-Ala-OGp ester, which is supported by experimentally 
observed structure-activity relationships. In contrast to the anticipated function of a 
substrate mimetic, the OGp ester showed an unprecedented enzyme-specific activation in 
papain. Prior to determining the scope of the acyl donor experimentally, we used a 
molecular-dynamics-simulations approach to prioritise 22 natural and unnatural amino 
acids for synthesis. The resulting ranking was in good agreement with the experimental 
data. A representative set of Z-XAA-Phe-NH2 dipeptides was obtained in moderate to 
excellent yields. The scope of the incoming nucleophile was relatively broad, ranging from 
the small Ala-NH2 to the much larger Tyr-pNA. Since the OGp ester exhibits rather 
unexpected enzyme-specific activation, we hypothesise that it is not strictly required to 
have an arginine-like activating ester. Future investigations will be directed towards 
confirming the predicted binding mode of the OGp ester by using X-ray studies and to 
replacing it by a simpler moiety in order to render the described enzymatic approach to 
peptide-bond formation even more accessible. 
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2.5 Experimental Section 
General procedure for the enzymatic reactions:  
Enzymatic acyl transfer reactions were performed at 25 °C in a total volume of 375 L 
containing 0.2 M HEPES buffer (pH 8.0), 0.2 M NaCl, 20 mM CaCl2, 10% DMF and 2 mM pTSA as 
an internal standard. Stock solutions of Z-XAA-OGp esters (50 mM) in DMF and nucleophiles (30 
mM) in buffer were prepared. The final concentrations of acyl donor and acyl acceptor were 2 
mM and 15 mM, respectively. The latter was calculated as free, N-unprotonated nucleophile 
concentration [HN]0 according to the Henderson–Hasselbalch equation [HN]0 = [N]0/(1 + 
10pK−pH). Papain (4 mg) was activated before use by adding DTT (0.6 mg) and 1 mL 0.1 M 
phosphate buffer (pH 6.5) containing 2.5 mM EDTA and shaking for 10 minutes at 25 °C. This 
solution was stored on ice and was freshly prepared daily. Following thermal equilibration of 
assay mixtures, the enzymatic reactions were started by addition of papain at a final 
concentration of 3.5 M. Blanc reactions were run in parallel, but milliQ was added instead of 
papain. From this control experiment the spontaneous ester hydrolysis could be determined, as 
well as non-enzymatic aminolysis of the acyl donor esters of which the latter could be ruled out. 
With regular intervals 20 l aliquots were withdrawn and quenched with 20 l glacial acetic 
acid. The reactions were monitored for 3 hours by HPLC and checked once more for changes in 
reaction mixture composition after 24 hours. The values reported are the average of at least two 
separate experiments. The identity of the formed peptide products was established by chemical 
synthesis of reference compounds and LC-MS.  
HPLC-Analyses:  
Samples were analysed by a Shimadzu LC 2010 analytical HPLC system equipped with a RP C18 
column (Varian, Inertsil ODS-3, 5 m, 150  4.6 mm) and eluted with various mixtures of 
acetonitrile/water containing 0.1% trifluoroacetic acid under isocratic and gradient conditions 
at flow rates of 1.0 mL·min-1. The wavelength of detection was 254 nm. Product yields were 
calculated from peak areas of the substrate esters and the hydrolysis and aminolysis products. 
Molecular modelling of the papain-peptide complex:  
The molecular model of papain bound to the hexapeptide LLRLSL was constructed on the basis 
of the crystal structure of a papain-leupeptin complex (PDB entry 1POP) solved at 2.1 Å 
resolution.[16] This structure contains an LLR peptide bound to only the S-subsites. To gain more 
insight into peptide binding to the S’-subsites, a hybrid model was built using an LSL peptide 
fragment bound to the S’-subsites of another papain crystal structure (PDB entry 2CIO) solved 
at 1.5 Å resolution.[22] First, the two crystal structures were aligned using the MOTIF 
algorithm[23], after which the coordinates of the LSL peptide were transferred to the papain-
leupeptin complex. Subsequently, a peptide bond between the LLR and LSL peptide fragment 
was manually added using the Yasara program[24] and finally the resulting complex was energy 
minimised using the Yasara2 forcefield.[25] 
Molecular docking of papain substrates:  
All molecular docking studies in papain were performed using the flexible docking program 
Fleksy.[15] The crystal structure of a papain-leupeptin complex (PDB entry 1POP) solved at 2.1 Å 
resolution[16] was used as the receptor structure. The structure was prepared for docking by 
removing leupeptin and all water molecules from the complex. Subsequently, hydrogen atoms 
were added to the structure and their positions were optimised using the Yasara program.[24] In 
the applied docking protocol only those docking poses were taken forward in which the scissile 
bond of the docked Z-XAA-OGp compound aligned to the scissile bond of the natural peptide 
substrate. Otherwise, default parameters as described previously[15] were applied.	
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Molecular dynamics simulations:  
The highest ranking docking poses obtained from the docking studies, were used as starting 
complex for molecular dynamics (MD) simulations using the Yasara program.[24] The complex 
was first solvated in a simulation cell two times 10 Å larger than the protein along each axis. 
The cell was neutralised by replacing water molecules with counter ions. The resulting system 
was first minimised with the Amber03 force field[26] using a 7.86 Å force cutoff and the Particle 
Mesh Ewald algorithm to treat long range electrostatic interactions. Simulated annealing was 
used (time step 2 fs, atom velocities scaled down by 0.9 every 10th step) until convergence was 
reached. Subsequently, 3 ns MD simulations were conducted at 298K for each of the 22 
substrates with periodic boundary conditions and 1.25 fs time steps. Intermolecular forces 
were recalculated every two simulation steps and pressure control was employed to maintain a 
water density 0.997 g/cm3. 
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 	Chapter 3
	
Papain‐specific	activating	esters	in	
aqueous	dipeptide	synthesis	
 
Enzymatic peptide synthesis has the potential to be a viable alternative for chemical 
peptide synthesis. Due to the increasing commercial interest in peptides, new and 
improved enzymatic synthesis methods are desirable. In recently developed enzymatic 
strategies such as substrate mimetic approaches and enzyme-specific activation, use of the 
guanidinophenyl ester (OGp) has been shown to suffer from some drawbacks. OGp-esters 
are sensitive to spontaneous chemical hydrolysis, expensive to synthesise and therefore 
not suitable for large-scale application. On the basis of earlier computational studies, we 
hypothesise that OGp might be replaceable by simpler ester groups to make the enzyme-
specific activation approach to peptide bond formation more accessible. To this end a set 
of potentially activating esters (Z-Gly-Act) was designed, synthesised and evaluated. Both 
the benzyl (OBn) and the dimethylaminophenyl (ODmap) esters gave promising results. 
For these esters the scope of a model dipeptide synthesis reaction under aqueous 
conditions was investigated by varying the amino acid donor. The results were compared 
with those obtained from a previous study of Z-XAA-OGp esters. Computational docking 
analysis of the set of esters was performed in order to provide insight into the differences 
in reactivities of all the potentially activating esters. Finally, selected ODmap- and OBn-
activated esters were applied in the synthesis of two biologically active dipeptides on 
preparative scales. 
 
 
 
This chapter has been published: 
R. J. A. C. de Beer, B. Zarzycka, M. Mariman, H. I. V. Amatdjais-Groenen, M. J. Mulders, P. J. L. M. 
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3.1 Introduction 
The market share of peptide-based drugs is steadily increasing and will likely continue to 
do so, because a large number of therapeutic peptides are in clinical trials.[1] Other relevant 
applications of peptides include their use as nutrients[2] and cosmetic ingredients.[3] Large- 
scale peptide synthesis, however, is an expensive and time-consuming procedure, and this 
conflicts with the considerable commercial interest.[4] 
Solid phase peptide synthesis (SPPS) is the most commonly used and versatile strategy for 
the synthesis of peptides in general.[5] The requirement of side-chain protection, the need 
to use excess of reagents, and the risk of racemisation are downsides of this method, but 
are to a large extent compensated by its capability to incorporate virtually any amino acid. 
A strategy commonly used in cases of larger peptides is to produce shorter fragments by 
SPPS and to couple them in solution to make the synthesis more convergent.[6] 
Alternatively, fragments with unprotected side chains can be coupled in aqueous solution 
by the chemoselective native chemical ligation method, which involves a C-terminal 
thioester and an N-terminal cysteine.[7] For large-scale production of long peptides (>50 
amino acid residues) and protein sequences containing only natural amino acids, 
fermentation is currently most feasible, but this requires significant development efforts 
for each individual peptide or protein.[8] A relatively new and rather unexplored area is the 
use of enzymatic hydrolysis of readily available existing proteins to release specific 
peptides.[4a] An alternative use of these proteases, is their potential to create peptide 
bonds.[9] Advantages of such a chemoenzymatic approach include the high selectivity of the 
enzymes, minimal need for side-chain protection and absence of racemisation. On the 
other hand, the generally narrow substrate specificity of enzymes, in particular the 
exclusion of unnatural amino acids, severely restricts their universal application. In 
addition, undesired product hydrolysis when using proteases can be problematic, even 
though strategies have been developed to minimise this side reaction.[9] By employing the 
principle of substrate mimetics,[10] the challenge of inadequate substrate recognition can 
be overcome. In the substrate mimetics approach, the amino acid side chain – crucial for 
enzyme recognition – is transferred to the ester leaving group so that the enzymatic 
process becomes independent of the amino acid to be coupled. The guanidinophenyl (OGp) 
group, a mimetic of the arginine side chain, has been extensively applied in academic 
research with much success.[11] However, the OGp group is unsuitable for industrial 
application because it is expensive and difficult to work with due to the positively charged 
guanidino group. 
We recently reported that the OGp ester can also be used in chemoenzymatic dipeptide 
synthesis under aqueous conditions with the protease papain.[12] In this case, the OGp 
moiety is likely not mimicking the natural substrate, because the guanidine group is 
predicted to bind to papain in a different manner than the arginine side chain. We named 
this phenomenon enzyme-specific activation, because no reaction takes place in the 
absence of the enzyme. From these findings, we hypothesised that it might not be essential 
to have an arginine-like activating ester for papain, as long as sufficient specific 
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interactions with the enzyme can be produced. A set of potentially enzyme-specific 
activating esters was therefore designed, synthesised and evaluated for effectiveness in 
papain-catalysed dipeptide formation. 
 
3.2 Results and Discussion 
3.2.1 Design of potentially enzyme-specific activating esters 
In designing enzyme-specific activating esters for papain, several requirements had to be 
fulfilled. Firstly, sufficient functionalities (e.g,.hydrogen bond donors or acceptors) were 
incorporated to allow for interactions with the binding groove of papain. This is also 
important for gaining insight into the spatial, electronic and chemical requirements for 
papain specific activating esters. Secondly, the stability against spontaneous ester 
hydrolysis needs to be improved. Chemical background hydrolysis for OGp esters is 
substantial (~5% within 30 minutes)[12] and this is undesirable because it will increase 
when longer reaction times are required in more difficult couplings. Compared to phenolic 
esters, aliphatic or benzylic esters are considerably more stable. Thirdly, the new 
activating esters must preferably be cheap and easy to synthesise. A chemoenzymatic 
route – using Alcalase-CLEA,[13] for example – would be particularly attractive in this 
respect. 
 
      
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Structures of potentially activating esters. OGp: p-guanidinophenyl ester; OGb: p-
guanidinobenzyl ester; NGp: p-guanidinobenzyl amide; OAb: p-amidinobenzyl ester; OBn: benzyl ester; 
OCam: carbamoylmethyl ester; O3Cam: carbamoylpropyl ester; O4Cam: carbamoylbutyl ester; O3G: 3-
guanidinopropyl ester; O4G: 4-guanidinobutyl ester; O5G: 5-guanidinopentyl ester; ODmap: p-
(dimethylamino)phenyl ester; OTmap: p-(trimethylammonium)phenyl ester; ODmape: p-
(dimethylamino)phenethyl ester; OTmape: p-(trimethylammonium)phenethyl ester; O4A: 4-aminobutyl 
ester; O5A: 5-aminopentyl ester; OMe: methyl ester; OTfe: 2,2,2-trifluoroethyl ester. 
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N-protected amino acids can be converted into their alkyl or benzyl esters by this enzyme 
in near-anhydrous organic solvents. Furthermore, arylamides can be obtained by ester 
interconversion under the same conditions. The more labile phenyl esters are beyond the 
scope of this method.  
These considerations led to a set of potentially activating moieties, as shown in Figure 3.1. 
These were chemically synthesised as the corresponding Z-Gly-OH esters. In addition, four 
activated esters that have been described in literature in combination with papain, i.e. 
OMe,[14] OCam,[15] OTfe[15] and OBn,[14a, 16] were also included for comparison. The synthesis 
details of all ester substrates can be found in Chapter 7.  
 
3.2.2 Evaluation of potentially enzyme-specific activating esters 
Next, the esters were evaluated for their ability to form the dipeptide Z-Gly-Phe-NH2 with 
papain catalysis. The levels of conversion were determined by a previously described 
assay (Scheme 3.1).[12] 
 
Scheme 3.1 Enzymatic dipeptide synthesis with papain  
 
Table 3.1 shows either the time it takes to reach 100% conversion, or the levels of 
conversion after 3 hours. Background hydrolysis of the esters was determined from blank 
reactions in which no papain was present. The indicated percentages of enzymatic 
synthesis and hydrolysis remained constant over time as measured after 24 hours. 
Ideally, the enzyme-specific activating group should give a fast reaction, a high percentage 
of synthesis and no hydrolysis. In none of the entries all these criteria are met at the same 
time, except for the phenolic ODmap ester (entry 6). However, the liberated 
dimethylaminophenol suffers from decomposition as deduced from the large amount of 
additional peaks in the HPLC chromatogram. The phenolic ester OTmap (entry 5) reacted 
comparably rapidly as OGp, but had a higher spontaneous hydrolysis rate. The 
introduction of two extra carbons (cf. ODmape and OTmape, entries 7 and 8, respectively) 
resulted in a significant increase in reaction time. The benzyl ester (OBn, entry 17) was 
superior to OGp in many respects, except for the time needed to reach full conversion of 
the starting material. The other benzylic esters, OGb and OAb (entries 2 and 4, 
respectively), reacted even more slowly and showed different percentages of enzymatic 
hydrolysis, which is remarkable in view of their similarity. The introduction of an amide 
bond (entry 3) resulted in complete inactivity. Of the set of aliphatic potentially activating 
esters, only the activated OCam and OTfe esters (entries 14 and 18, respectively) reacted 
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reasonably rapidly. As anticipated from their chemical properties, background hydrolysis 
was low for all aliphatic esters.  
 
Table 3.1  Various Z-Gly-Act esters tested experimentally[a] 
 
 
 
	 	 background enzymatic	
Entry	 Act Time	
(min)	
Conv.	
(%)	
Z‐Gly‐OH	
(%)	
Z‐Gly‐Phe‐NH2
(%)	
Z‐Gly‐OH	
(%)	
1 OGp 20 100 5.6 92.0 2.4 
2 OGb 180 97 3.3 92.5 1.2 
3 NGp 180 - - - - 
4 OAb 180 99 2.2 86.5 10.3 
5 OTmap 15 100 8.4 91.6 0 
6 ODmap 10 100 1.2 98.6 0.2 
7 OTmape 180 61 0.4 58.1 2.5 
8 ODmape 180 21 0.1 18.9 2.0 
9 O3G 180 86 1.8 68.6 15.6 
10 O4G 180 83 1.6 66.8 14.6 
11 O5G 180 66 1.2 54.7 10.1 
12 O4A 180 69 2.5 53.9 12.6 
13 O5A 180 70 0.6 56.7 12.7 
14 OCam 15 100 1.8 89.9 8.3 
15 O3Cam 180 80 1.1 67.8 11.1 
16 O4Cam 180 97 0.2 81.9 14.9 
17 OBn 45 100 0 97.5 2.5 
18 OTfe 15 100 1.8 91.5 6.7 
19 OMe 180 70 1.5 58.8 9.7 
[a] Conditions: 2 mM Z-Gly-Act, 15 mM H-Phe-NH2, 3.5 μM papain, 0.2 M HEPES buffer pH 
8.0, 0.2 M NaCl, 20 mM CaCl2, 10% (v/v) DMF 
 
The enzymatic hydrolysis levels, on the other hand, were much higher in all cases. These 
results are in line with earlier studies showing that the Z-Gly esters of OMe,[14b] OBn,[16] 
OCam[14a] and OTfe[15] can be used in combination with papain. Because of the variety in 
documented reaction conditions – in organic solvent, in frozen aqueous solutions, varying 
equivalents, immobilised papain – it was, however, difficult to compare them properly. The 
fact that these reactions could not just be performed in buffer is consistent with the 
relatively high enzymatic hydrolysis values we find for these esters. 
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Although the enzymatic reactions proceed through the the same acyl-enzyme intermediate 
(Z-Gly-papain), differences in S/H ratio are observed. This might be because the first step 
(acylation of the enzyme) is not the rate-determining step for each ester. Another 
explanation might be that the leaving groups have varying affinities for the enzyme and 
therefore influence the attack of the nucleophile (water or H-Phe-NH2) to larger or smaller 
extents. 
    
3.2.3 Docking of activating esters into the active site of papain 
We recently developed a molecular model of the interactions of Z-XAA-OGp esters with the 
active site of papain.[12] A similar molecular modelling study was performed for each of the 
remaining 18 substrates using the flexible docking programme Fleksy.[17] Results were 
visualised and analysed by use of the YASARA programme. Several representative 
examples are shown in Figure 3.2 and discussed below. 
 
 
Figure 3.2 Molecular modelling of a selection of esters in papain. Hydrogen bonding 
interactions to functionally important amino acids in the papain active site are shown for (A) Z-Gly-OGp, 
(B) Z-Gly-OGb, (C) Z-Gly-OBn, (D) Z-Gly-ODmap, (E) Z-Gly-O3G, (F) Z-Gly-OCam and (G) Z-Gly-OTfe. 
 
Z-Gly-OGp (Figure 3.2 A) fits tightly in the papain active site, which is located in a groove 
between two domains.[12, 18] The nucleophilic cysteine is as such positioned to attack the 
carbonyl carbon, whereas the carbonyl oxygen is situated in the oxyanion hole, which is 
made up of the side chain NH2 group of Gln19 and the backbone amide of Cys25. The 
guanidinophenyl group is positioned in the groove, participating in several hydrogen 
bonding interactions.  
In general, all the compounds discussed have the same N- to-C directionality as Z-Gly-OGp 
and fit the oxyanion hole. The most noticeable difference between Z-Gly-OGp and Z-Gly-
OGb (Figure 3.2 B) is that the guanidinobenzyl group is now pointing out of the groove as a 
consequence of the extra carbon atom. As a result, the hydrogen bonding interactions with 
the groove are lost, which might explain the significant change in activity. Similarly, in Z-
Gly-OBn (Figure 3.2 C) the benzyl group is also oriented towards the solvent, but it can 
favourably interact with Gly65 at the edge of the groove. Z-Gly-ODmap (Figure 3.2 D), a 
 Papain-specific activating esters in aqueous dipeptide synthesis 
 
 55 
phenolic ester, is nicely located in the groove and interacts with Tyr67 and Val133. 
Although the aliphatic Z-Gly-O3G (Figure 3.2 E) seems to be reasonably well situated in the 
groove, its reaction time is significantly longer than those of the phenolic esters. The small 
OCam moiety (Figure 3.2 F) participates in additional interactions with Trp26, Asp158 and 
Ala160 and fills the lower part of the peptide groove. High reactivity for OCam esters with 
α-chymotrypsin had already been reported to be attributable to orientation effects of 
hydrogen bonding interactions between the enzyme and the substrate.[19] Similarly, the 
OTfe group (Figure 3.2 G) exactly fills a hydrophobic cavity in the peptide groove, 
interacting with Trp26, Gly65 and Ala160. 
 
 
 
 
 
 
 
Figure 3.3 Product distributions for dipeptide synthesis catalysed by papain for three esters 
(OGp, ODmap and OBn). Results are clustered per amino acid. Conditions: 2 mM Z-XAA-Act, 15 mM H-
Phe-NH2, 3.5 μM papain, 0.2 M HEPES buffer (pH 8.0), 0.2 M NaCl, 10% (v/v) DMF. For reactions with 
Z-XAA-OBn a double quantities of papain were used (7.0 μM). The dipeptide products Z-IF-NH2 and Z-
NF-NH2 precipitated during the reaction, so the yield was estimated, Z-RF-NH2 underwent secondary 
hydrolysis after 1 min and Z-FF-NH2 was converted into Z-FF-OH in the OBn case.[20]    
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These results imply that besides a good fit in the active site with sufficient interactions to 
the peptide groove and proper stabilisation by the oxyanion hole, the leaving group ability 
of the activating ester is also of significant importance. Clearly, the relatively poor leaving 
group ability of the aliphatic esters cannot be compensated for by the enzyme, whereas the 
differences between the much better phenolic leaving groups can be explained on the basis 
of their interactions with papain. The results also show that the good leaving groups OCam 
and OTfe are to some extent even further activated by the enzyme. The outcome with the 
benzyl ester is remarkable in our view, because the inferior leaving group ability is largely 
overcome by enzyme-specific activation.  
 
3.2.4 Scope of the amino acid donor in Z-XAA-OBn and Z-XAA-ODmap 
The high levels of conversion, combined with low hydrolysis rates, observed with the 
readily accessible ODmap and OBn esters led us to select these two for further exploration. 
In particular, in order to probe the more general applicability of the concept of enzyme-
specific activation, we investigated whether the relatively broad range of amino acid 
donors as determined for OGp[12] would be maintained with ODmap and OBn, in order to 
probe. Analogous to the procedure followed for OGp esters, Z-XAA-ODmap and Z-XAA-OBn 
esters were synthesised from a representative set of amino acids with appropriate acid-
labile side-chain protection and evaluated in the enzymatic assay. In the case of OBn esters, 
the amount of papain was doubled to compensate for the slower reaction rate that had 
been observed with Z-Gly-OBn. The identities of the products in the enzymatic reactions 
were confirmed by chemical synthesis of reference compounds and LC-MS analysis. The 
distribution of background hydrolysis, enzymatic synthesis, enzymatic hydrolysis, and in 
some cases side product formation for each of the studied esters is shown in Figure 3.3. 
The background hydrolysis was determined from a blank reaction where no papain was 
present. Above each bar, either the time is indicated that is required to reach 100% 
conversion, or 3 hours, after which regular monitoring was stopped. The indicated product 
distribution remained constant over time, as measured after 24 hours, unless stated 
otherwise. 
For ease of comparison, the results for Z-XAA-OGp[12] are also included in the diagram, and 
the data are clustered per amino acid. Some trends can be distinguished; generally, the 
percentage of enzymatic synthesis (  ) over hydrolysis (  ) is comparable for each 
individual amino acid independent of the ester. This was to be expected because the 
binding pocket for the amino acid did not change. A remarkable exception in this respect is 
the complete inactivity of Z-L-Thr-OBn towards papain, which may be due to steric effects. 
The spontaneous background hydrolysis (  ) decreased on going from the OGp ester to 
the ODmap and OBn esters, which correlates well with the decreasing leaving group ability 
of these esters. The non-enzymatic cyclic side product formation ( ; a piperidone from 
Arg and a succinimide from Asn) dropped drastically in this order for the same reason. All 
of the OBn esters reacted considerably more slowly than the OGp and ODmap esters, 
despite the double quantities of papain. This difference in reactivity became even more 
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apparent for the more challenging amino acids Z-L-Ile-OH, Z-D-Ala-OH and Z-β-Ala-OH. 
Increasing the reaction time for the corresponding OBn esters did not result in 
significantly higher conversions, but dipeptide synthesis occurred when the quantities of 
papain were simultaneously increased by a further factor of ten, (Table 3.2). 
 
Table 3.2  Various Z-XAA-OBn esters tested experimentally with a high papain concentration[a] 
	 	 background enzymatic	
Entry	 Amino	
acid	
Time	
(h)	
Conv.	
(%)	
Z‐XAA‐OH	
(%)	
Z‐XAA‐Phe‐NH2
(%)	
Z‐XAA‐OH	
(%)	
1 L-Ile 6 100 - 30.9 (85.5)[b] 14.5 
2 D-Ala 10 100 0.8 51.7 47.5 
3 β-Ala 24 26 - 25.4 0.6 
[a] Conditions: 2 mM Z-XAA-OBn, 15 mM H-Phe-NH2, 70 μM papain, 0.2 M HEPES buffer pH 
8.0, 0.2 M NaCl, 20 mM CaCl2, 10% (v/v) DMF 
[b] Dipeptide product precipitates during reaction, estimated yield is given in parentheses 
 
The scope of the amino acid donor is comparably broad for ODmap and OGp esters. The 
OBn ester also enables the papain catalysed synthesis of various dipeptides, provided that 
the amount of enzyme is increased. This seems an acceptable trade-off given the fact that 
OBn esters are readily accessible, even with an enzymatic approach. 
 
3.2.5 Synthesis of a selected dipeptide on preparative scale 
The applicability of the enzyme-specific activation strategy was illustrated by means of 
preparative scale syntheses of two biologically active peptides: Z-Gly-Phe-NH2 with Z-Gly-
ODmap as activating ester, and H-Glu-Trp-OH starting from enzymatically synthesised Z-L-
Glu-OBn. The first dipeptide is a substrate for metalloendoproteases blocking the 
exocytotic release of histamine and catecholamines from mast cells and adrenal chromaffin 
cells.[21] Furthermore, it interferes with insulin processing and inhibits glucose transport in 
adipocytes.[22] The second is also known as thymogen, oglufanide, or IM862, a naturally 
occuring immunomodulator, which is a potent anti-angiogenic agent and normallises the 
immune system function of immunocompromised individuals.[1a, 23] 
Firstly, the small-scale experiment (Table 3.3, entry 1) was repeated with 100 mg acyl 
donor instead of 0.25 mg, resulting in a longer reaction time and a slightly increased 
amount of hydrolysis as determined by HPLC analysis of a sample from the reaction 
mixture (entry 2). The desired dipeptide was isolated in 74% yield after column 
chromatography. Next, the excess of H-Phe-NH2 was decreased to arrive at equimolar 
amounts of acyl donor and acceptor (entry 3). At this point, additional DMF was required 
to keep all compounds in solution, and the papain concentration was increased tenfold to 
compensate for the anticipated loss of activity. These conditions resulted in a faster 
reaction, a somewhat better S/H ratio and an isolated yield of 79%. Finally, this reaction 
was performed again on gram scale (entry 4). Despite the ten times higher papain 
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concentration, the reaction was not completed after 75 minutes, but the product was 
purified nevertheless. The isolated yield of 74% was equal to the yield calculated from the 
level of conversion indicated by HPLC. 
 
Table 3.3  Reaction conditions and yields preparative scale synthesis of Z-Gly-Phe-NH2 
 
 
 
Entry	 Scale	 D/A[a]	 DMF Papain	 Time Conv.[b]	 S/H	ratio[c]	 Yield[d]	
	 (mg)	 (mM) %	(v/v) (μM) (min) (%) (%) (%)	
1 0.25 2:15 10 3.5 10 100 98:2 n.a. 
2 100 2:15 10 3.5 120 97 85:12 74 
3 100 15:15 20 35 60 99 90:9 79 
4 1000 15:15 20 350 75 89 74:15 74 
[a] Donor to acceptor ratio Z-Gly-ODmap : H-Phe-NH2 
[b] According to HPLC 
[c] Synthesis over hydrolysis ratio Z-Gly-Phe-NH2 : Z-Gly-OH 
[d] Isolated yield of dipeptide after purification by flash chromatography 
 
The synthesis of the second dipeptide was envisioned as depicted in Scheme 3.2. The 
chemoenzymatic method developed by Nuijens was employed to benzylate Z-Glu-OH 
selectively at the α-position and the activating ester was obtained in 96% yield.[13a] This 
synthesis clearly emphasises the advantage of OBn as activating ester over phenolic esters, 
which cannot be enzymatically prepared.. H-Trp-OBn was selected as the nucleophile to 
enable the simultaneous removal of both protecting groups, but with the risk of repeated 
coupling due to the continued presence of the OBn group, which is recognised by papain. 
Test experiments on preparative scale indicated that multiple addition of H-Trp-OBn did 
indeed occur, but that it could be minimised by stopping the reaction in time. These 
experiments also showed that the reaction proceeds much more rapidly but with a worse 
S/H ratio than in the case of the previous dipeptide. This led us to conduct a 500 mg scale 
experiment with a 1:1 donor/acceptor ratio and a papain concentration of 8.8 µM. Under 
these conditions, HPLC analysis showed full conversion within 45 min and an S/H ratio of 
66:27; additionally, a 7% yield of tripeptide was formed. The desired dipeptide was 
isolated in pure form in 60% yield after column chromatography. Subjection of the 
protected dipeptide to hydrogenolysis conditions provided biologically active H-Glu-Trp-
OH in 87% yield.  
 
 Papain-specific activating esters in aqueous dipeptide synthesis 
 
 59 
 
Scheme 3.2.  Synthesis of bioactive dipeptide H-Glu-Trp-OH. Reaction conditions step 1: Z-Glu-
OH, BnOH, Alcalase-CLEA, THF, mol sieves (3 Å), 150 rpm, 37 °C; step 2: 5 mM Z-Glu-OBn, 5 mM H-
Trp-OBn, 8.8 μM papain, 0.2 M Hepes buffer pH 8.0, 0.2 M NaCl, 20 mM CaCl2, 15% (v/v) DMF, 25 °C; 
step 3: H-Cube, 10% Pd/C, 10 bar H2, 1 mL/min, rt. 
 
3.3 Conclusion 
In this chapter, we have shown that papain-catalysed dipeptide synthesis can also be 
performed successfully with activating esters that do not resemble arginine. Out of  a set of 
potentially activating esters, both the ODmap and OBn esters appeared to be suitable 
replacements for OGp, with the added benefits of (1) being simpler in structure and 
therefore cheaper and easy to synthesise, and (2) giving smaller amounts of undesired 
hydrolysis product. The scopes of the ODmap and OBn acyl donors were compared with 
that of the OGp esters and it was found that the S/H ratios are variable for the different 
amino acids, but rather independent of the ester involved. The reactions with OBn esters 
required increased quantities of papain to afford similar reaction rates. The applicability of 
the ODmap ester was validated in preparative-scale syntheses of two biologically active 
dipeptides.  
The computational model of papain, which was originally built for OGp, was effectively 
applied in a docking study to get insight into the differences in reactivity of all the 
potentially activating esters. This exercise showed that besides a proper fit in the active 
site, the leaving group ability is also important. To shed light on this intricate relationship, 
further studies, both computational and experimental, are currently underway. The 
balance between a good leaving group ability to enable the enzymatic reaction, a stable 
ester that does not undergo rapid spontaneous hydrolysis and the extent to which the 
ester is activated by the enzyme seems to be delicate.  
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3.5 Experimental section 
Synthesis: see Chapter 7 for a detailed description of the synthetic procedures and product 
characterisation. 
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Computational studies: a detailed description of the computational analyses can be found in a 
previous article on this subject.[12] 
 
Enzymatic acyl transfer reaction: see experimental § 2.5. 
 
Enzymatic synthesis on preparative scale: 
To a round-bottomed flask was added the acyl donor, the acyl acceptor and pTSA as an internal 
standard. This was disolved in a small amount of DMF to which was added HEPES buffer with a 
final concentration of 0.2 M, pH 8 and containing 0.2 M NaCl and 20 mM CaCl2. Finally, papain, 
activated with DTT in phosphate buffer (0.1 M, pH 6.5) containing EDTA (2.5 mM), was added to 
start the reaction. The mixture was stirred at 25 °C until total conversion of the starting 
material was observed, which was determined by HPLC. Then, the reaction mixture was 
extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over 
sodium sulfate and evaporated to dryness.  
 
   pTSA DMF buffer milliQ papain 
Acyl donor (mg) Acyl acceptor (mg) (mg) (mL) (mL) (mL) (mg) 
Z-Gly-
ODmap 99 H-Phe-NH2 443 57 15 75 60 12 
Z-Gly-
ODmap 99 H-Phe-NH2 59 7.6 4 10 6 16 
Z-Gly-
ODmap 985 H-Phe-NH2 59 76 40 100 60 160 
Z-Glu-OBn 557 H-Trp-OBn 496 114 45 150 105 60 
 
Nα‐Cbz‐Glycine‐phenylalanine	amide		(Z‐Gly‐Phe‐NH2)	
The product was obtained as a white solid after purification by column 
chromatography (MeOH in CH2Cl2, 25%). Rf 0.45 (10% MeOH in 
CH2Cl2). Mp 143.0 °C. []20D +7.1 (c 2.60, MeOH). IR (film) 3460, 3299, 
3062, 3032, 1712, 1681, 1644, 1563, 1529, 1284, 1250, 1219, 1172, 
1045, 992, 728, 697 cm−1. 1H NMR (CD3CN, 400 MHz): δ 7.42-7.18 (m, 
10H), 6.88 (d, J = 7.7 Hz, NH), 6.44 (br s, NH), 5.98 (br t, NH), 5.83 (br s, NH), 5.07 (s, 2H), 4.52 
(ddd,  J = 5.2, 8.3, 8.3 Hz, 1H), 3.67 (dd, 	J = 6.1. 17.0 Hz, 1H), 3.62 (dd, J = 6.0. 16.9 Hz, 1H), 3.13 
(dd, J = 5.1, 14.0 Hz, 1H), 2.89 (dd, J = 8.5, 14.0 Hz, 1H). 13C NMR (CD3CN, 75 MHz): δ 173.8, 
170.1, 157.7, 138.4, 137.9, 130.2, 129.4, 129.2, 128.9, 128.7, 127.5, 67.3, 54.9, 44.9, 38.2. HRMS 
(ESI) m/z calcd for C19H21N3NaO4 (M+Na)+: 378.1430, found: 378.1443. 
 
Nα‐Cbz‐Glutamate‐Tryptophan	benzyl	ester	(Z‐Glu‐Trp‐OBn)	
The product was obtained as a white solid after purification by 
column chromatography (AcOH/MeOH/ EtOAc 1:5:94) and 
lyophilisation from dioxane. Rf 0.50 (AcOH/MeOH/EtOAc 1:25:474). 
Mp 48.7 °C. []20D 13.8 (c 1.00, MeOH). IR (film) 3312, 3058, 3031, 
2963, 2918, 1714, 1664, 1528, 1455, 1342, 1213, 743, 698 cm−1. 1H 
NMR (CD3CN, 400 MHz): δ 9.17 (s, NH), 7.51 (d, J = 7.9 Hz, NH), 7.41-
7.19 (m, 11H), 7.15-7.10 (m, 1H), 7.08-7.01 (m, 3H), 5.99 (d, J = 7.4 Hz, 
NH), 5.09-4.99 (m, 4H), 4.75-4.69 (m, 1H), 4.13-4.05 (m, 1H), 3.29-
3.15 (m, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.82-1.71 (m, 2H). 13C NMR (CD3CN, 75 MHz): δ 174.7, 
172.4, 172.3, 157.1, 137.3, 136.8, 129.4, 129.1, 129.0, 128.8, 128.6, 128.3, 124.7, 122.5, 120.0, 
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119.2, 118.2, 112.2, 110.3, 67.6, 67.2, 55.1, 54.2, 30.4, 28.2, 28.1. HRMS (ESI) m/z calcd for 
C31H31N3O7 (M+H)+: 558.2240, found: 558.2240.  
Chemoenzymatic synthesis of Z-Glu-OBn: 
Before use, Alcalase-CLEA (3 g, Type OM, CLEA-Technologies, 580 U/g) was suspended in 
tBuOH (100 mL ) and crushed with a spatula. After filtration, the enzyme was resuspended in 
MTBE (50 mL) followed by filtration. Large enzyme particles were removed by a sieve (0.5 mm 
pore size). 3 Å Molecular sieves (Acros, 8 to 12 mesh) were activated (200°C under vacuum 
overnight), crushed and sieved (0.5 mm pore size) to remove large particles.  
Alcalase-CLEA (509 mg) was added to a solution of Z- L-Glu-OH (977 mg, 3.48 mmol, 1 equiv) in 
THF (9 mL) and benzylalcohol (1 mL, 9.66 mmol, 2.8 equiv). The mixture was shaken at 37 °C at 
150 rpm for 16 h in the presence of 3 Å molecular sieves. After filtration, the enzyme was 
washed by resuspension in THF (3 × 20 mL) followed by filtration. The combined organic layers 
were concentrated in	vacuo and the resulting oil was purified by column chromatography using 
aminomethyl resin (TFA in CH2Cl2, 02.5%). The solution was concentrated, TFA was removed 
by co-evaporation with toluene (2 × 20 mL) and CHCl3 (2 × 20 mL) and the product was 
lyophilised from MeCN/H2O 3:1 to give Z-Glu-OBn(1.24 g, 96%) as a white solid. Spectral data 
were in accordance with those reported in the supporting information for the chemically 
synthesized compound. 
 
Glutamate‐tryptophan	(H‐Glu‐Trp‐OH)	
Z-Glu-Trp-OBn (121 mg, 0.22 mmol, 1 equiv) was dissolved in 20% H2O 
in MeOH (12 mL) and hydrogenated with 10% Pd/C in the H-Cube 
(ThalesNano) at room temperature, 1 mL/min and 10 bar H2 pressure. 
The product was obtained as a slightly pink solid after evaporation of 
the solvent in	 vacuo (63 mg, 87%). Rf 0.27 (CHCl3/MeOH/NH4OH 
65:45:20). Mp 159.2 °C. []20D +22.4 (c 0.31, DMSO). IR (film) 3213, 3067, 
1693, 1665, 1597, 1548, 1483, 1455, 1414, 1339, 740 cm−1. 1H NMR 
(CD3OD/D2O, 400 MHz): δ 7.64 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.1 Hz, 
1H), 7.18 (s, 1H), 7.11 (ddd, J = 1.1, 7.1, 8.1 Hz, 1H), 7.04 (ddd, J = 1.1, 
7.1, 8.0 Hz, 1H), 4.61 (dd, J = 4.8, 8.7 Hz, 1H), 3.82 (dd, J = 5.2, 7.4 Hz, 1H), 3.39 (dd, J = 4.8, 14.7 
Hz, 1H), 3.18 (dd, J = 8.8, 14.7 Hz, 1H), 2.52-2.36 (m, 2H), 2.16-1.95 (m, 2H). 13C NMR 
(CD3OD/D2O, 75 MHz): δ 179.5, 177.5, 169.8,  137.7, 128.7, 124.7, 122.4, 119.8, 119.4, 112.4, 
111.5, 56.9, 54.3, 33.3, 28.6, 28.4. HRMS (ESI) m/z calcd for C16H20N3O5 (M+H)+: 334.1403, 
found: 334.1391.  
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 	Chapter 4
	
Enzyme‐specific	activation	versus	
leaving	group	ability	
 
Enzyme-specific activation and the substrate mimetics strategy are effective ways to 
circumvent the limited substrate recognition often encountered in protease-catalysed 
peptide synthesis. A key structural element in both approaches is the guanidinophenyl 
(OGp) ester, which enables important interactions for affinity and recognition by the 
enzyme. At least, this is usually the explanation given for its successful application. In this 
study we show that leaving group ability is of equal or even greater importance utilising 
experimental and computational methods, comprising (1) the synthesis of close analogues 
of OGp and their evaluation in a dipeptide synthesis assay with trypsin, (2) molecular 
docking studies that provided insight into the binding mode and (3) ab	initio calculations 
to evaluate their electronic properties.  
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4.1 Introduction 
These days enzymes are commonly used in organic synthesis.[1] The benefits of enzymatic 
reactions, including their generally excellent regio- and enantioselectivity, are widely 
recognised. Because of the usually mild reaction conditions, enzymatic conversions are 
often regarded as a green alternative to classic organic reactions. However, the limited 
substrate scope of many enzymes remains a big disadvantage.    
One of the areas of application of enzymes is peptide synthesis. In this field, proteases are 
employed to form the peptide bonds (which they would natively hydrolyse) by exploiting 
the reversibility of each chemical reaction. A prerequisite for this enzymatic activity, 
irrespective of whether aqueous media or organic solvents are used, is that the amino acid 
in question is specifically recognised.[2] The latter problem of recognition can be 
circumvented by applying the substrate mimetics strategy as previously described for 
trypsin and other proteases.[3] The guanidinophenyl (OGp) ester, which in essence 
resembles the naturally recognised side chain of arginine, is claimed to serve as a 
recognition moiety for trypsin, thereby making recognition independent of the side chain 
of the amino acid and thus broadening the substrate scope. This approach is typically 
applied under aqueous conditions, but because OGp also functions as a leaving group, the 
commonly occurring issue of secondary hydrolysis is prevented, as the product formed 
becomes unrecognisable for the enzyme.  
A similar solution to limited substrate acceptance was found for papain, i.e. enzyme-
specific activation.[4] Based on docking studies, the OGp group is predicted to bind to the 
enzyme in a different orientation than its natural substrate arginine. Nevertheless, due to 
alternative recognition papain is able to catalyse dipeptide formation with unspecific 
amino acid residues. We noticed these versatile applications of the OGp moiety and 
wondered what the reason would be for these remarkable properties. Additional research 
into the replacement of OGp for simpler esters indicated that besides recognition and 
affinity for the enzyme, the leaving group ability may be an important factor.[5] In this 
study, the contribution of these components is investigated, using both experimental and 
computational methods. Several analogues of OGp were designed, synthesised and docked 
in trypsin to provide insight into the binding mode. Subsequently, their effectiveness in 
dipeptide formation was experimentally determined and an attempt was made to increase 
the activity by further variation of one of the analogues. An ab	initio study provided insight 
into the electronic properties of the analogues under investigation. 
 
4.2 Results & Discussion 
4.2.1 Prediction of the binding mode of OGp analogues in trypsin 
To distinguish between the effects of affinity for the enzyme and leaving group ability, we 
evaluated a set of close analogues of OGp that differed slightly in both properties. We opted 
for trypsin as the model system, because this enzyme is highly specific for arginine, in 
contrast to the aforementioned protease papain, which exhibits broad substrate specificity 
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with only a slight preference for arginine. Moreover, the catalytic mechanism of the serine 
protease trypsin,[6] also with respect to substrate mimetics,[7] is well known. 
The analogues were designed in such a way that they closely resemble OGp in structure, 
while the leaving group character was varied considerably (Figure 4.1).  
 
 
 
Figure 4.1 Structures of OGp analogues 
 
Two benzylic variants (OAb and OGb) were synthesised as the corresponding Z-Gly-OH 
esters,[5] as well as an aliphatic analogue (O3G) and an OGp equivalent where the ester 
bond was replaced by an amide bond (NGp). The substrates were restricted to glycine 
esters in order to rule out any influence of the side chain in the coupling reactions. The 
anticipated analogy of these four compounds was evaluated using a computational docking 
study, with the flexible docking programme Fleksy.[8] The results were visualised and 
analysed by using the YASARA programme.[9]  
The three dimensional structure of trypsin has been previously solved by crystallographic 
studies.[10] The secondary structure of this globular enzyme consists of β-structures 
organised into two densely packed hydrophobic barrels. Five subpockets (S3 through 
S2’)[11] are important for specific binding of the substrate. A crucial interaction occurs with 
the carboxylate moiety of Asp189 at the bottom of subpocket S1, which primarily 
determines the specificity of trypsin for positively charged side chains. The catalytic triad 
comprises Ser195, His57 and Asp102. The joint backbone amides of Gly193 and Ser195 
create the oxyanion hole (Figure 4.2 A). 
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Figure 4.2 Molecular modelling of OGp analogues in trypsin 
 
The Z-Gly-OGp ester (Figure 4.2 B) could be easily docked in the active site of trypsin, 
positioned in a similar way as the arginine side chain (Figure 4.2 A), which was in 
agreement with previous results from literature.[7] The guanidino group made the 
aforementioned crucial interaction with Asp189 in the S1 pocket and, additionally formed 
hydrogen-bonds with Ser190 and Trp215. Furthermore, the substrate carbonyl was nicely 
located in the oxyanion hole. The docking poses of the benzylic esters Z-Gly-OGb and Z-Gly-
OAb were both suboptimal, even though the carbonyl groups were located in the oxyanion 
hole. Figure 4.2 C shows that OGb slightly extended beyond the volume occupied by the 
arginine side chain as a result of the additional carbon atom, whereas OAb (Figure 4.2 E) 
has to adopt a somewhat distorted conformation to be located in the oxyanion hole while 
simultaneously retaining interaction between the amidinium group and Asp189. The 
aliphatic Z-Gly-O3G analogue (Figure 4.2 D) perfectly mimicked the side chain of arginine, 
thus achieving hydrogen bond interactions with Asp189, Ser190 and Tyr217. The 
oxyanion hole residues Gly193 and Ser195 were in the correct position to stabilise the 
carbonyl of the ester. Z-Gly-NGp showed a binding mode similar to Z-Gly-OGp. 
 
4.2.2 Experimental activity of OGp analogues 
Subsequently, the OGp analogues were evaluated experimentally in an enzymatic assay 
with trypsin. H-Phe-NH2 was used as the acyl acceptor because of its distinctive UV 
properties at 254 nm, which simplifies HPLC analyses. The enzymatic reaction was 
monitored for three hours. The identity of the products was confirmed by chemical 
synthesis of reference compounds and LC-MS analysis. Table 4.1 presents either the time 
to reach full conversion, or the extent of conversion after three hours. The background 
hydrolysis of the analogues was determined from a blank reaction where no trypsin was 
present. The indicated percentages of enzymatic synthesis and hydrolysis remained 
constant over time, as measured after 24 hours, unless stated otherwise. 
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Table 4.1  Various Z-Gly-Act compounds tested experimentally[a] 
 
 
 
	 	 background enzymatic	
Entry	 Act	 Time	
(min)	
Conv.	
(%)	
Z‐Gly‐OH	
(%)	
Z‐Gly‐Phe‐NH2
(%)	
Z‐Gly‐OH	
(%)	
1 OGp 15 100 2.7 22.5 74.8 
2 OAb 180 43 2.0 23.4 17.6 
3 OGb 120 99 3.3 72.5 23.2 
4 NGp 180 - - - - 
5 O3G 180 38 0.9 29.6 7.5 
   6[b] O3G 180 73 5.0 54.0 14.0 
7 O3G= 180 100 2.4 76.3 21.3 
8 OTfe 90 100 5.7 73.6 20.7 
[a] Conditions: 2 mM Z-Gly-Act, 15 mM H-Phe-NH2, 0.2 M HEPES buffer pH 8.0, 0.2 M NaCl, 20 
mM CaCl2, 10% (v/v) DMF 
[b] The entries below the line will be discussed in § 4.2.3 
 
Z-Gly-OGp is readily converted by trypsin, although the synthesis over hydrolysis ratio is 
not too favourable (entry 1). The remaining analogues do not show any activity at the 
same enzyme concentration, except for Z-Gly-OGb, which was slightly active. A hundred-
fold increase in trypsin concentration gave some differentiation: Z-Gly-OGb (entry 4) is 
almost completely consumed in two hours, whereas Z-Gly-OAb (entry 3) and Z-Gly-O3G 
(entry 6) are converted for 43 and 38%, respectively, in three hours. The lower activity of 
Z-Gly-OAb may be explained by its somewhat distorted fit in the active site of trypsin. The 
low activity of Z-Gly-O3G, however, is absolutely unexpected, as this analogue appeared to 
be a perfect mimetic. Z-Gly-NGp is the only analogue that remained completely inactive 
under these conditions. In all cases, the leaving group character of the analogues is 
reduced compared to OGp. Hence, we conclude that although all the analogues are 
expected to be fairly similar in terms of affinity for the enzyme, this contribution to activity 
is rather small. Inversely, these results imply a large influence of the leaving group ability 
of the ester. 
 
4.2.3 O3G variants with increased activity 
If electronic properties indeed play an important role, it should be possible to increase the 
activity of the analogues by transforming them into better leaving groups. For this purpose 
O3G was selected, as it appears to be a perfect mimic of the natural substrate and its 
activity is surprisingly low compared to OGp.  
Inspection of the molecular model of trypsin with Z-Gly-O3G revealed that there is some 
space in the binding pocket for the introduction of a small substituent (Figure 4.3), such as 
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a methylene (O3G=) or two fluorides (O3GF2), which are weak and strong inductively 
electron-withdrawing groups, respectively. However, these modifications also create 
additional Van der Waals interactions with the pocket, which by itself can be a reason for 
increased affinity of the ester for the enzyme. To assess this effect, the cyclopropyl (O3G) 
group was included, which was shown to fit in the binding pocket to make these additional 
interactions, without altering the electronic properties. 
 
O N
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O N
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Figure 4.3 Structures of O3G variants and their docking poses 
 
Enzyme-specific activation versus leaving group ability 
 69 
After the synthesis of the O3G variants, they were experimentally evaluated in the 
enzymatic assay with trypsin (Table 4.1). As the synthesis of Z-Gly-O3GF2 failed (synthesis 
details are provided in Chapter 7), the trifluoroethyl ester (OTfe) was taken as an 
alternative, as it also nicely fits in the active site of trypsin (Figure 4.3 D) and it is known to 
act as a good leaving group. Both 03G variants showed considerable superior activity over 
O3G. As anticipated, the addition of the steric cyclopropyl group (entry 7) increased the 
activity (from 38 to 73% conversion in 180 min), whereas the introduction of the slightly 
inductively electron withdrawing methylene (entry 8) improved the activity even further 
(100% conversion in 180 min). Surprisingly, of all the analogues tested, Z-Gly-OTfe (entry 
9), yielded the fastest reaction (100% conversion in 90 min), despite the fact that no 
cationic recognition element was present in the molecule. This again supports the idea that 
the leaving group ability is the main contributor to the suitability of the ester for enzymatic 
peptide synthesis. 
 
4.2.4 Ab initio calculations 
An appropriate computational technique to study electronic events within or between 
molecules is ab	initio calculations. As the computational requirements are large for these 
calculations, only four compounds were selected, i.e. Z-Gly-OGp, Z-Gly-O3G, Z-Gly-NGp and 
Z-Gly-OTfe. Furthermore, the system was drastically simplified, in that the enzyme was 
represented by only the hydroxyl connected to a carbon of the active site serine. In 
addition, part of the protecting group of the ester was not taken into consideration. This 
situation is displayed in the white spot of Figure 4.4 A. The first step of the reaction 
comprises the formation of a tetrahedral intermediate, which is stabilised by the oxyanion 
hole (Figure 4.4 B). The subsequent collapse of the intermediate will liberate the alcohol, 
or amine in the case of NGp, from the complex (Figure 4.4 C). This is the endpoint of our 
calculations, as we are interested in differences in leaving group ability. Obviously, the 
enzyme still needs to be deacylated by a nucleophile to complete the catalytic cycle, which 
will also proceed through a tetrahedral intermediate. 
 
 
Figure 4.4 Reaction path of Z-Gly-Act in trypsin 
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We started out to locate the tetrahedral intermediate for the OGp compound. After 
exhaustive partial optimisations, in which the C-O bond connecting OGp to the central 
carbon of the tetrahedral intermediate was kept fixed, we came to the conclusion that 
nowhere along this internal coordinate did a stationary point exist. No optimum or saddle 
point could be found. Removing the restraint of the fixed C-O bond always resulted in 
dissociation upon optimisation. A stable intermediate was found, however, when a 
hydrogen atom was added to the oxygen carrying the negative charge. This is in line with 
the commonly accepted hypothesis[12] that, in the natural protein environment, hydrogen 
bonding in the oxyanion hole stabilises the tetrahedral intermediates. As an equivalent 
amount of atoms and charge is required throughout the calculations, a hydrogen atom was 
added to the leaving group too. This corresponds with the accepted mechanism that the 
leaving group is protonated upon formation of the first tetrahedral intermediate.[13] With 
the stable intermediates identified, the energy diagram as shown in Figure 4.5 and the 
accompanying Table 4.2 were produced. 
 
 
Figure 4.5 Energy diagram derived from ab initio calculations. A, B and C correspond with the 
structures depicted in Table 4.2. 
	
 
 
Enzyme-specific activation versus leaving group ability 
 71 
Table 4.2  Ab initio computed energies 
 
 
 
Compound	
(XR)	
Reaction	
coordinate	
E‐B3LYP	
(Hartree)	
ZPVE
(Hartree)	
E‐relative	
(Kcal/mol)	
OGp A -1023.822519 0.318313 0 
 TS (AB) -1023.768428 0.317477 33.5 
 B -1023.827721 0.323082 -0.2 
 TS(BC) -1023.796406 0.318871 16.8 
 C -1023.836929 0.319910 -8.0 
O3G A -910.799298 0.326420 0 
 TS (AB) -910.745545 0.324387 32.5 
 B -910.793383 0.330697 6.4 
 TS(BC) -910.744129 0.323695 32.9 
 C -910.770669 0.325304 17.3 
NGp A -1003.978561 0.333122 0 
 TS (AB) -1003.923725 0.330513 32.8 
 B -1003.970149 0.337313 7.9 
 TS(BC) -1003.913334 0.330891 39.5 
 C -1003.981686 0.332390 -2.4 
OTfe A -964.639842 0.194069 0 
 TS (AB) -964.582210 0.193946 34.2 
 B -964.638998 0.200064 2.4 
 TS(BC) -964.588930 0.193792 29.9 
 C -964.639257 0.195890 -0.4 
 
In the diagram, the relative energies are compared, so for convenience the position of the 
starting point for each of the reaction paths is arbitrarily set to zero. The activation energy 
(TS1) of the formation of tetrahedral intermediate (B) is quite similar for all compounds 
under investigation, although the energy level of B differs for each analogue. The next 
transition state (TS2), which is most indicative for the leaving group ability of the various 
alcohols and amine, shows more variation but with a similar trend. The enzyme is 
cooperative in stabilising the negative charge that develops on the leaving group during 
the collapse of the tetrahedral intermediate, which was simulated by a proton. However, 
the differences between the leaving groups are mainly determined by the extent to which 
they can stabilise the developing negative charge. The low activation energy (TS2) of OGp 
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reflects its ability to mesomerically stabilise the negative charge, whereas the high 
activation energy of NGp, also capable of mesomeric stabilisation, can be explained by the 
lower electronegativity of nitrogen compared to oxygen. Similarly, but to a lesser extent, 
the inductively electron-withdrawing effect of the OTfe group is helpful in stabilising the 
negative charge. In the case of O3G, the negative charge is isolated on the oxygen, without 
possibilities for further stabilisation, which may also account for the high energy level of 
situation C.  
Upon linking these computational results to the experimental outcomes, one should bear 
in mind that only the acylation step was computationally studied. The experiments with 
trypsin provide insight in the efficiency of the complete catalytic cycle, including 
deacylation of the enzyme. In spite of this, the ranking OGp > OTfe > O3G > NGp from the 
ab	initio calculations is in agreement with the experimentally determined activities of Z-
Gly-OGp and its analogues. In addition, the marked contrast between the highly energetic 
tetrahedral intermediate and TS2 of NGp and the favourable energies for OGp, seem to be 
consistent with the observation that acylation is the rate determining step in amide 
hydrolysis[14] as opposed to deacylation being rate limiting in OGp ester hydrolysis.[15] 
However, according to Menger et	al. the reaction kinetics of proteases towards esters are 
highly dependent of the nature of the ester, as was demonstrated by comparing the p-
nitrophenyl ester with the ethyl ester.[16] These authors argue that the ‘p-nitrophenyl ester 
syndrome’ can be attributed to excellent electrophilic assistance to the departing entity. 
When reasoning by this analogy, it follows that the O3G ester does not stand a chance 
against OGp. 
 
4.3 Conclusion 
Various methods were employed to determine the properties to which the success of the 
OGp ester as substrate mimetic and enzyme-specific activating ester can be attributed. 
Although a direct experimental approach to determine solely the affinity of a substrate is 
not available, a computational docking study of closely related OGp analogues was 
insightful.  
Z-Gly-OGb and Z-Gly-OAb showed that a worse fit in the active site, could be directly linked 
to a decrease in activity in the enzymatic assay. This was anticipated, as a good fit in the 
active site can be considered as an indication for affinity. To our complete surprise, 
however, it was also demonstrated that Z-Gly-O3G, although being a perfect analogue of 
the natural substrate arginine according to docking studies, is barely active compared to Z-
Gly-OGp. Apparently, recognition of the ester by the enzyme is alone insufficient for 
activity, in contrast to what has been suggested for substrate mimetics in literature.  
We hypothesised that a major contribution was provided by the leaving group ability of 
the ester, which was supported by ab	initio calculations showing that OGp is a good leaving 
group whereas NGp and O3G are not. Furthermore, we were able to design improved O3G 
variants based on this hypothesis. Increasing activity was observed in the order O3G < 
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O3G < O3G= < OTfe, the latter being the most convincing one because, although no 
cationic recognition element is present in this molecule, it is a good leaving group. 
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4.5 Experimental Section 
Molecular modelling of trypsin – OGp analogue complexes:  
All described molecular docking studies were performed using the flexible docking programme 
Fleksy.[8, 17] The crystal structure of trypsin in complex with bovine pancreatic trypsin inhibitor 
(BPTI)[18], solved at 1.5 Å resolution, was used as the receptor structure (PDB entry 3FP6). The 
structure was prepared for docking by removing BPTI and all water molecules from the 
complex. Subsequently, hydrogen atoms were added to the structure and their positions were 
optimised using the Yasara program[9]. In the applied docking protocol only those docking poses 
were taken forward in which the scissile bond of the docked substrate mimetic aligned to the 
scissile bond of the natural peptide substrate. Otherwise, default parameters as described 
previously[8] were applied. 
General procedure for the enzymatic reactions:  
Enzymatic acyl transfer reactions were performed at 25 °C in a total volume of 375 L 
containing 0.2 M HEPES buffer (pH 8.0), 0.2 M NaCl, 20 mM CaCl2, 10% DMF and 2 mM pTSA as 
an internal standard. Stock solutions of Z-Gly-Act compounds (50 mM) in DMF and H-Phe-NH2 
(30 mM) in buffer were prepared. The final concentrations of acyl donor and acyl acceptor were 
2 mM and 15 mM, respectively. The latter was calculated as free, N-unprotonated nucleophile 
concentration [HN]0 according to the Henderson–Hasselbalch equation [HN]0 = [N]0/(1 + 
10pK−pH). To trypsin (9.6 mg) was added milliQ (1 mL), the solution was stirred and stored for 
maximally one month in aliquots at –20 °C. Following thermal equilibration of assay mixtures, 
the enzymatic reactions were started by addition of trypsin at a final concentration of 1.6 or 160 
M. Blanc reactions were run in parallel, but milliQ was added instead of trypsin. From this 
control experiment the spontaneous ester hydrolysis could be determined, as well as non-
enzymatic aminolysis of the acyl donor esters of which the latter could be ruled out. With 
regular intervals 20 l aliquots were withdrawn and quenched with 20 l glacial acetic acid. 
The reactions were monitored for 3 hours by HPLC and checked once more for changes in 
reaction mixture composition after 24 hours. The values reported are the average of at least two 
separate experiments. The identity of the formed peptide products was established by chemical 
synthesis of reference compounds and LC-MS.  
HPLC-Analyses:  
Samples were analyzed by a Shimadzu LC 2010 analytical HPLC system equipped with a RP C18 
column (Varian, Inertsil ODS-3, 5 m, 150  4.6 mm) and eluted with various mixtures of 
acetonitrile/water containing 0.1% trifluoroacetic acid under isocratic and gradient conditions 
at flow rates of 1.0 mL·min-1. The wavelength of detection was 254 nm. Product yields were 
calculated from peak areas of the substrate esters and the hydrolysis and aminolysis products. 
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Ab initio calculations:  
Standard LCAO-MO-SCF calculations were performed with the programme Gamess-US[19]  
employing restricted Hartree-Fock (RHF) procedures and Density Functional Theory DFT). All 
DFT calculations were done using B3LYP exchange-correlation functional.[20] The geometries of 
the isomers were determined using analytical gradient and numerical second-derivative 
optimisation procedures with the 6-31G** basis set. The relative energies were corrected for 
the contribution of zero-point vibrational energies (ZPVE). The ZPVEs were calculated for the 6-
31G** optimised geometries employing RHF and 6-31G** basis set. 
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 	Chapter 5
	
α‐Chymotrypsin‐catalysed	peptide	
bond	formation	
 
The concept of enzyme-specific activation has so far only been investigated in combination 
with the cysteine protease papain. To study the somewhat broader scope of this 
phenomenon, our set of potentially activating esters was applied to the serine protease α-
chymotrypsin and a comparison between both enzymes was made. The benzyl (OBn) and 
dimethylaminophenyl (ODmap) esters appeared to be papain-specific, whereas the 
guanidinobenzyl ester (OGb) gave the best results with α-chymotrypsin. For the latter 
ester the scope of a model dipeptide synthesis reaction under aqueous conditions was 
investigated by varying the amino acid donor. Computational docking analysis of the set of 
esters was performed to provide insight into the difference in reactivity of all the 
potentially activating esters. 
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5.1 Introduction 
The protease papain was able to effect dipeptide synthesis in aqueous environment in 
moderate to excellent S/H ratios with the OGp ester as a recognition group. Instead of 
functioning as a substrate mimetic as we had anticipated, we showed by analysing a large 
set of esters and conducting computational docking studies that the reaction proceeds 
through an unprecedented phenomenon which we called enzyme-specific activation.[1] 
Based on this insight, we developed the simplified alternative activating esters ODmap and 
OBn.[2] These scientifically interesting and unexpected results made us wonder whether 
the concept of specific activation would be applicable to other enzymes besides papain.  
A preliminary screening with cheap and commercially available enzymes such as a 
protease from Aspergillus	oryzae, bromelaine, pronase E and α-chymotrypsin, showed that 
results with the latter protease were most promising to pursue. 
Chymotrypsin is a digestive enzyme produced in the pancreas as the inactive precursor 
chymotrypsinogen. Processing occurs with the help of trypsin and autolysis, resulting in 
varying amounts of α, π, δ and  forms, of which the first is predominantly present.[3] This 
serine protease consists of 241 amino acid residues divided over three separate 
polypeptide chains (A, B and C) linked by disulfide bridges. α-Chymotrypsin selectively 
catalyses the hydrolysis of peptide bonds on the C-terminal side of tyrosine, phenylalanine, 
tryptophan and leucine. 
 
5.2 Results and Discussion 
5.2.1 Evaluation of potentially enzyme-specific activating esters 
The set of potentially activating esters that was originally designed for papain (Figure 3.1) 
was not adapted to better match the specificity of α-chymotrypsin, since several esters 
already contained an aromatic part. It is described in literature that the OGp ester 
functions as a substrate mimetic for α-chymotrypsin,[4] although the terminology in this 
case is questionable, since the natural substrates of this protease do not contain a 
positively charged guanidino moiety. In addition, OTfe[5] and OCam[6] esters are known to 
broaden the substrate scope of α-chymotrypsin considerably.  
The esters were evaluated for their ability to form the dipeptide Z-Gly-Phe-NH2. The 
conversions were determined using a previously described assay, but now using α-
chymotrypsin instead of papain (Scheme 5.1).[1] The amount of α-chymotrypsin was 
adjusted such, that the activity of both enzymes with the Z-Gly-OGp ester was comparable. 
 
 
Scheme 5.1 Enzymatic dipeptide synthesis with α-chymotrypsin  
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Table 5.1 shows either the time to reach 100% conversion, or the conversion after 3 hours. 
The background hydrolysis of the esters was determined from a blank reaction where no 
α-chymotrypsin was present. The indicated percentages of enzymatic synthesis and 
hydrolysis remained constant over time as measured after 24 hours. 
 
Table 5.1  Various Z-Gly-Act esters tested experimentally[a] 
 
 
 
	 	 background enzymatic	
Entry	 Act[b]	 Time	
(min)	
Conv.	
(%)	
Z‐Gly‐OH	
(%)	
Z‐Gly‐Phe‐NH2
(%)	
Z‐Gly‐OH	
(%)	
1 OGp 25 100 6.5 78.4 15.1 
2 OGb 180 97 0.7 86.0 10.3 
3 NGp 180 - - - - 
4 OAb 120 100 3.0 76.0 21.0 
5 OTmap 15 100 13.1 74.4 12.5 
6 ODmap 120 100 3.1 80.2 16.7 
7 OTmape 180 50 1.9 35.5 12.6 
8 ODmape 180 <1 0.6 0.2 0.2 
9 O3G 180 32 2.3 22.4 7.3 
10 O4G 180 51 2.0 36.1 12.9 
11 O5G 180 89 2.4 63.8 22.8 
12 O4A 180 13 0.3 9.4 3.3 
13 O5A 180 32 1.5 23.6 6.9 
14 OCam 120 100 9.2 73.9 16.9 
15 O3Cam 180 9 0.7 7.4 0.9 
16 O4Cam 180 20 1.0 14.6 4.4 
17 OBn 180 80 0.3 57.3 22.4 
18 ONb 180 31 [c] 10.4 20.6[c] 
19 OTfe 45 100 3.5 74.5 22.0 
20 OMe 180 7 0.6 4.9 1.5 
[a] Conditions: 2 mM Z-Gly-Act, 15 mM H-Phe-NH2, 0.2 M HEPES buffer pH 8.0, 0.2 M NaCl, 20 
mM CaCl2, 10% (v/v) DMF 
[b] Structures can be found on the inside of the back cover flap 
[c] Because the HOBn peak showed overlap with the Z-Gly-OH peak in the HPLC 
chromatogram, it was not possible to distinguish between spontaneous and enzymatic 
hydrolysis.  
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The fastest esters are OTmap (entry 5), OGp (entry 1) and OTfe (entry 19), which show an 
increasing amount of enzymatic hydrolysis in this order and a decreasing, but relatively 
high amount of background hydrolysis. The fact that OGp and OTfe are both active is in 
agreement with the literature.[4-5] The next fastest cluster of esters consists of OAb (entry 
4), ODmap (entry 6) and OCam (entry 14). The S/H ratios are mutually comparable and in 
the same range as OTfe. The background hydrolysis of OCam is significantly higher than 
that of the other two. Miyazawa reported that the OCam ester is superior to the OTfe ester, 
which is not confirmed by our data. This deviation may be due to the different nature of 
the solvents, aqueous in our case, but nearly anhydrous for the case reported.[5-6]  
Although the previously mentioned esters gave faster reactions, the best properties are 
actually found for the OGb ester (entry 2). The background hydrolysis is low, and it shows 
the best S/H ratio, which are both desirable properties. At this point, it is noteworthy to 
pay some attention to the differences in performance of the various benzylic esters. The 
benzyl ester with no substituents (OBn, entry 17) reacts more slowly and in a worse S/H 
ratio than both OAb and OGb (entries 4 and 2, respectively). The addition of a nitro group 
on the para position (ONb, entry 18), which improves the leaving group ability, only 
deteriorates the situation. Apparently, a positively charged substituent is most favourable. 
As could be expected from their electronic properties, OTmape, ODmape (entries 7 and 8, 
respectively) and most of the aliphatic esters are hardly active, with the exception of O5G 
(entry 11). Upon closer inspection, a trend becomes visible that comprises an increasing 
activity with increasing length of the aliphatic chain. This holds true for the sequence 
O5G>O4G>O3G as well as for O5A>O4A and O4Cam>O3Cam. Remarkable in this respect is 
that the largest effect is again accomplished by the positively charged guanidino group. 
 
5.2.2 Activity in α-chymotrypsin versus papain 
To properly estimate the enzyme-dependence in our set of potentially activating esters, 
the results from papain and α-chymotrypsin were compiled in one diagram for 
convenience of comparison (Figure 5.1). 
The most noticeable difference between the two enzymes is that the percentage of 
enzymatic hydrolysis is structurally higher for all esters in the case of α-chymotrypsin. 
Moreover, the reactions generally proceed more slowly. The background hydrolysis is very 
well comparable, as it should be, since the blanc experiments are actually exact copies of 
each other. Only OCam shows a higher amount of background hydrolysis with α-
chymotrypsin, which can be explained by the eight times longer reaction time that was 
required for complete conversion (15 versus 120 minutes). 
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Figure 5.1 Visual comparison of activating esters in papain and α-chymotrypsin. The diagram 
is composed of data from Tables 3.1 and 5.1  
 
The trend that was observed of higher reactivity with increasing aliphatic chain length in 
α-chymotrypsin, is less obvious in papain. The correlation seems to be reversed for the 
guanidino containing compounds (03G, O4G and O5G), absent for the amino containing 
compounds (O4A and O5A) and less profound in the case of the compounds with a 
carbamoyl moiety present (O3Cam and O4Cam). Important to notice is that the OBn and 
ODmap esters indeed are specifically activating esters for papain, as they are not 
particularly activating with α-chymotrypsin. 
 
5.2.3 Docking of activating esters into the active site of α-chymotrypsin 
Molecular docking studies have been valuable before, so that this technique was also 
applied to α-chymotrypsin. The three dimensional structure of α-chymotrypsin has been 
previously solved by crystallographic studies.[7] The three interlinked peptide chains form 
an enzyme structure that is relatively similar to trypsin. Five subpockets (S3 through S2’) 
are involved in the specific binding of the substrate, of which S1 is the most important. 
Contrary to trypsin, where interactions with Asp189 are most determining for substrate 
specificity, the S1 pocket of α-chymotrypsin does not contain one such crucial residue. In 
this protease, the pocket is characterised as a rather large, highly hydrophobic cavity with 
the ability to fit in moieties as big as an indole ring. Multiple contacts, especially involving 
Ser190, Cys191-220, Val213, Trp215 and Tyr228, contribute to the preference for large 
hydrophobic amino acids. Furthermore, α-chymotrypsin contains the same catalytic 
residues as trypsin, namely Ser195, His57 and Asp102. Likewise, the oxyanion hole is 
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created by the backbone amides of Gly193 and Ser195.[8] These important residues are all 
indicated in Figure 5.2. 
 
 
 
 
Figure 5.2 Model of Z-Gly-OGp in α-chymotrypsin  
 
The Z-Gly-OGp ester (Figure 5.2) showed a comparable binding mode as predicted by 
Günther et	 al.[9] The guanidino group is part of a hydrogen bonding network, which 
probably accounts for the good results that were obtained with esters containing a 
positively charged substituent. Instead of discussing the docking studies in detail, a 
summary is given in the sequel. The S1 pocket of α-chymotrypsin is so large, that all our 
esters fit in, with the exception of ODmape and OTmape (Table 5.1, entries 7 and 8), which 
are too large. Several amino acid residues present in the cavity are available for hydrogen 
bonding. The differences in activity of the various esters can mostly be attributed to 
differences in their ability to actually make these hydrogen bonding interactions.  
 
5.2.4 Scope of the amino acid donor of Z-XAA-OGb 
As OGb appeared to be the best alternative for OGp, with respect to the decreased 
background hydrolysis and increased S/H ratio, the scope of the acyl donor was 
experimentally determined using this ester. A representative set of amino acids was 
selected and the corresponding OGb esters were synthesised (see § 7.2.2). The amount of 
α-chymotrypsin in the enzymatic synthesis assay was increased five-fold to compensate 
for the slower reaction rate. The identity of the products in the enzymatic reaction was 
confirmed by chemical synthesis of reference compounds and LC-MS analysis. Table 5.2 
presents either the time to reach full conversion of the OGb esters, or the conversion after 
three hours. 
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Table 5.2  Various Z-XAA-OGb esters tested experimentally[a] 
 
 
 
	 	 background enzymatic	
Entry	 Amino	
acid	
Time	
(min)	
Conv.	
(%)	
Z‐XAA‐OH	
(%)	
Z‐XAA‐Phe‐NH2
(%)	
Z‐XAA‐OH	
(%)	
1 L-Ala 45 100 2.6 54.4 43.0 
2 Gly 45 100 2.4 86.0 11.6 
3 L-Gln[b] 5 100 0.7 42.3 57.0 
4 L-Ile 180 100 - 51.5[c] 49.5 
5 L-Lys[b] 15 100 [d] 32.6 67.4[d] 
6 L-Phe 0.5 100 - 70.1 29.9 
7 D-Phe 90 100 - 70.8 29.2 
8 L-Pro 180 - - - - 
9 D-Ala 180 36 - 11.3 24.7 
10 β-Ala 180 37 - 6.7 30.3 
[a] Conditions: 2 mM Z-XAA-OGp, 15 mM H-Phe-NH2, 0.2 M HEPES buffer pH 8.0, 0.2 M NaCl, 
20 mM CaCl2, 10% (v/v) DMF 
[b] Measured once, molar extinction coefficients estimated based on similar compounds 
[c] Dipeptide product precipitated during reaction, this is the estimated yield 
[d] Because the Z-L-Lys-OGb peak showed overlap with the Z-L-Lys-OH peak in the HPLC 
chromatogram, it was not possible to distinguish between spontaneous and enzymatic 
hydrolysis. 
 
The reaction times as well as the S/H ratios vary considerably for the different amino 
acids. Glycine (entry 2) reacts fast with the most synthesis and β-alanine (entry 10) 
reacting slowly with the worst ratio. Z-L-Phe-OGb (entry 6) reacts really fast, which can be 
explained by the fact that phenylalanine is also naturally recognised by α-chymotrypsin. 
Interestingly, mainly dipeptide product is formed instead of hydrolysis taking place. It is 
noticeable that Z-D-Phe-OGb (entry 7), its enantiomer, results in the same S/H ratio, albeit 
at a much slower rate. The composition of the reaction mixtures was checked after 24 
hours, showing that over time, all the Z-XAA-Phe-NH2 products were partially enzymatically 
converted into Z-XAA-Phe-OH. Non-enzymatic side product formation as found for some Z-
XAA-OGp esters, was not observed for any of the OGb esters, probably because OGb is a 
worse leaving group.  
 
5.2.5 Future plans 
Another important reason to select OGb for further evaluation was the expectation that 
this moiety is accepted by Alcalase-CLEA in organic solvent, so that the ester can be 
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synthesised enzymatically. However, a preliminary study in which diBoc protected HOGb 
was subjected to Alcalase-CLEA in organic solvent in the presence of an acyl donor, 
showed only a minor amount of the desired product. From the HPLC chromatogram was 
deduced that the alcohol was not stable and rapidly decomposed. 
 
As became clear from a comparison of the results of papain and α-chymotrypsin, the latter 
shows more enzymatic hydrolysis. In spite of this, we hypothesise that the advantage of a 
large S1 pocket can be exploited by converting the enzyme from a serine into a cysteine 
protease. This strategy to improve the S/H ratio has been successfully applied before to 
subtilisin.[10] Due to the complexity of the post-translational processing of 
chymotrypsinogen to a mature protease, chymotrypsin has not been obtained as a 
recombinant protein produced by microorganisms. This excludes the genetic introduction 
of a point mutation. However, a chemical way to modify the active site is available.[11] 
To specifically target the serine in the active site, the serine protease inhibitor 
phenylmethanesulfonyl fluoride (PMSF) is employed (Figure 5.3). Because of its increased 
nucleophilic character, only this serine is assumed to react. The hydroxyl is in this way 
converted into a good leaving group, which can then be substituted by addition of 
thioacetate. Subsequent spontaneous hydrolysis will result in the desired cysteine 
protease.  
 
 
 
 
Figure 5.3 Procedure for the chemical conversion of an active site serine into a cysteine 
 
A possible bottleneck in the application of this procedure to α-chymotrypsin is the 
presence of several disulfide bridges that hold together the three polypeptide chains. The 
excess of thioacetate used for the substitution reaction might cause denaturation and 
inactivity of the enzyme. However, preliminary treatment of α-chymotrypsin with an 
excess of thioacetate for 24 hours revealed that the activity with a test substrate was 
completely retained, which is an encouraging finding to start with. Further experiments on 
this procedure, however, were no further pursued. 
 
5.3 Conclusion 
Several esters of our set were successfully used in peptide synthesis catalysed by α-
chymotrypsin, among which the OGp, OTmap, OCam and OTfe esters. The best result with 
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respect to S/H ratio was, however, obtained with the OGb ester. Subsequent docking 
studies showed that the S1 pocket of α-chymotrypsin is rather large and hydrophobic, but 
in addition offers various possibilities for hydrogen bonding interactions, which may be an 
explanation for the apparent preference for guanidinium containing esters. It is notable 
that OBn and ODmap, which are activating esters for papain, do not specifically activate α-
chymotrypsin. Thus, the activating properties of esters are indeed enzyme dependent. 
Compared to papain, α-chymotrypsin displays a relatively high amount of enzymatic 
hydrolysis, even in the case of OGb. On the other hand, a pocket with ample space to 
accommodate many substrates might be worthwhile to further explore, provided that the 
S/H ratio can be improved. 
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5.5 Experimental section 
General procedure for the enzymatic reactions:  
Enzymatic acyl transfer reactions were performed at 25 °C in a total volume of 375 L 
containing 0.2 M HEPES buffer (pH 8.0), 0.2 M NaCl, 20 mM CaCl2, 10% DMF and 2 mM pTSA as 
an internal standard. Stock solutions of Z-Gly-Act or Z-XAA-OGb compounds (50 mM) in DMF and 
H-Phe-NH2 (30 mM) in buffer were prepared. The final concentrations of acyl donor and acyl 
acceptor were 2 mM and 15 mM, respectively. The latter was calculated as free, N-
unprotonated nucleophile concentration [HN]0 according to the Henderson–Hasselbalch 
equation [HN]0 = [N]0/(1 + 10pK−pH). To chymotrypsin (18.75 mg) was added milliQ (1 mL), the 
solution was stirred and stored for maximally one month in aliquots at –20 °C. Following 
thermal equilibration of assay mixtures, the enzymatic reactions were started by addition of α-
chymotrypsin at a final concentration of 3.0 or 15 M. Blanc reactions were run in parallel, but 
milliQ was added instead of trypsin. From this control experiment the spontaneous ester 
hydrolysis could be determined, as well as non-enzymatic aminolysis of the acyl donor esters of 
which the latter could be ruled out. With regular intervals 20 l aliquots were withdrawn and 
quenched with 20 l glacial acetic acid. The reactions were monitored for 3 hours by HPLC and 
checked once more for changes in reaction mixture composition after 24 hours. The values 
reported are the average of at least two separate experiments. The identity of the formed 
peptide products was established by chemical synthesis of reference compounds and LC-MS.  
HPLC-Analyses:  
Samples were analyzed by a Shimadzu LC 2010 analytical HPLC system equipped with a RP C18 
column (Varian, Inertsil ODS-3, 5 m, 150  4.6 mm) and eluted with various mixtures of 
acetonitrile/water containing 0.1% trifluoroacetic acid under isocratic and gradient conditions 
at flow rates of 1.0 mL·min-1. The wavelength of detection was 254 nm. Product yields were 
calculated from peak areas of the substrate esters and the hydrolysis and aminolysis products. 
Molecular modelling of α-chymotrypsin – Z-Gly-Act complexes:  
All described molecular docking studies were performed using the flexible docking programme 
Fleksy.[12] The crystal structure of α-chymotrypsin in complex with bovine pancreatic trypsin 
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inhibitor (BPTI)[13], solved at 1.7 Å resolution, was used as the receptor structure (PDB entry 
1T8O). The structure was prepared for docking by removing BPTI and all water molecules from 
the complex. Subsequently, hydrogen atoms were added to the structure and their positions 
were optimised using the Yasara program[14]. In the applied docking protocol only those 
docking poses were taken forward in which the scissile bond of the docked substrate mimetic 
aligned to the scissile bond of the natural peptide substrate. Otherwise, default parameters as 
described previously[12a] were applied. 
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 	Chapter 6
	
Alcalase‐catalysed	peptide	bond	
formation	
 
Chemoenzymatic dipeptide synthesis was investigated using the previously described set 
of esters in organic solvent with Alcalase-CLEA. The goal of this exercise was twofold: (1) 
study the performance of our activated esters in a chemoenzymatic system that was 
recently developed by DSM, and (2) investigate whether our set of esters could 
successfully be applied in dipeptide synthesis under anhydrous conditions. 
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6.1 Introduction 
Alcalase is the brand name for subtilisin A (Subtilisin Carlsberg), a serine endoprotease 
from Bacillus	 licheniformis.[1]	 Because this enzyme possesses broad substrate tolerance, 
with a preference for large hydrophobic residues in P1, it is applied in the synthesis of 
numerous peptides.[2] Moreover, it is an inexpensive industrial protease (from Novozymes, 
10 wt% solution, 6.75 €/kg). 
In contrast to the dipeptide formation that was observed for papain, trypsin and α-
chymotrypsin with our set of esters (Chapters III, IV and V, respectively), Alcalase only 
gave fast and complete hydrolysis of the starting material in all cases. Hence it was 
concluded that in order to explore the potential of this relatively unspecific enzyme for 
dipeptide formation, a system devoid of water was required. 
Recently, Nuijens et	al. noticed that Alcalase is capable of catalysing an esterification in 
tert-butanol at low water content to give tert-butyl esters from N-protected amino acids.[3] 
Normally, the water produced during this reaction and the water required for enzyme 
activity prohibits a favourable position for the esterification equilibrium resulting in low to 
moderate yields. However, upon the addition of molecular sieves, high yields were 
obtained since the continuous removal of water shifted the equilibrium towards product 
formation. Moreover, the enzyme apparently remained active under these conditions. 
Azeotropic distillation, which is much more efficient for large-scale reactions than 
molecular sieves, also efficiently removed the water. Further improvement of the system 
included the immobilisation of Alcalase as a CLEA,[4] so that the enzyme could easily be 
recovered by filtration and recycled with minimal loss of activity.  
In addition to ester synthesis, the Alcalase system proved to be suitable for peptide 
synthesis as well. C-Terminal deprotection and activation was achieved in one single step 
by interconverting tert-butyl esters into primary alkyl esters, in particular methyl esters, 
which could then be coupled to the next amino acid (Scheme 6.1).[5] Besides tert-butyl 
esters α-carboxamides could be converted into primary alkyl esters in a similar process.[6] 
 
  
Scheme 6.1 Chemoenzymatic peptide synthesis in the NC direction using C-terminal t-Bu 
ester or carboxamide to ester interconversion. 
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To broaden the scope of Alcalase-catalysed peptide synthesis even further, OCam and OTfe 
esters were introduced as acyl donors.[7] These moieties are known to be specifically 
recognised by some enzymes,[8] thereby overcoming their primary specificity. The coupling 
of challenging substrates such as sterically demanding amino acids as acyl donors (valine, 
isoleucine, threonine), notoriously weak nucleophiles (proline), or D- and other non-
proteinogenic amino acid residues, became well feasible in high yields without any 
hydrolytic side reactions. However, coupling reactions sometimes remained rather slow 
and a relatively large amount of enzyme was required, especially when longer peptide 
fragments were to be coupled. Clearly, there is room for improvement of the acyl donor 
ester in Alcalase catalysed peptide synthesis.  
 
6.2 Results & Discussion 
The available library of Z-Gly-Act esters was employed to test the coupling efficiencies in 
Alcalase-catalysed dipeptide synthesis, with H-Phe-NH2 functioning as the nucleophile. A 
solvent mixture of DMF/THF (1:9 (v/v)) ensured good solubility of all starting materials. 
Molecular sieves were added to remove water from the reaction mixture, preventing any 
hydrolytic side reactions and Alcalase-CLEA facilitated convenient handling and workup. 
The results of the screening are given in Table 6.1. 
	
Table 6.1  Relative activity of various Z-Gly-Act esters[a] 
 
 
 
Entry	 Act	 Structure	 Relative	activity	(%)	
1 OGp 
 
100 
2 OTmap 
 
95 
3 ODmap 
 
70 
4 OTfe  68 
5 OCam  60 
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6 ONb 
 
34 
7 OGb 
 
31 
8 OTmape 
 
30 
9 OAb 
 
28 
10 O4G 
 
23 
11 O4Cam  11 
12 O3Cam  9 
13 O4A  8 
14 OBn  8 
15 O3G 
 
7 
16 O5G 
 
4 
17 O5A  4 
[a] Conditions: 2 mM Z-Gly-Act, 0.33 M H-Phe-NH2, DMF/THF, crushed 3Å mol sieves, 50 °C, 
      60 min  
 
Clearly, the substituted phenyl esters (entries 1-3) are the most active species for the 
Alcalase-CLEA catalysed peptide coupling. Especially for entries 1 and 2 this is remarkable, 
since Alcalase has a preference for large uncharged hydrophobic residues in both the P1 
and the P1’ positions.[9] The OTfe and OCam ester derivatives follow closely (entries 4 and 
5). It is believed that the amide group of the OCam ester moiety (Figure 6.1 B) binds to the 
enzyme via a hydrogen bond in the same fashion as an amide of a peptide backbone 
(Figure 6.1 A) binds when it is recognised and cleaved by an endoprotease.  
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Figure 6.1 Similarity of the natural peptide at the cleavage site of an endoprotease and the 
OCam and OCam-XAA-NH2 ester. 
 
The relative activities of the substituted benzyl (entries 6, 7 and 9) and phenethyl (entry 8) 
esters are mutually comparable, yet significantly decreased compared to entries 1-5. An 
exception is the benzyl ester (entry 14), which clusters with the aliphatic esters (entries 
11-13 and 15-17) in the low activity range. This contrasts with the high activity of the 
benzyl ester in combination with the enzyme papain.[10] Apparently, the length of the 
carbon linker is important, as demonstrated by the O4G ester (entry 10), which clearly 
outperformed both the O3G and O5G ester (entries 15 and 16, respectively). Generally, it is 
noticeable that high activity seems to coincide with strong electron-withdrawing 
properties of the esters, which render the carbonyl more susceptible to nucleophilic attack 
by the active site serine of the protease and the corresponding alcohol a better leaving 
group.  
An important drawback of phenyl esters is that, due to their high activation level, they are 
relatively difficult to synthesise, while both the chemical[11] and enzymatic[7] synthesis of 
the OCam ester (entry 5) is well feasible. Analogous to the strategy followed by Wells et	al., 
the OCam ester can presumably be improved by elongating it with an amino acid amide, 
thereby creating additional binding interactions with the enzyme (Figure 6.1 C).[12] To this 
end, a library of Fmoc-Val-Ala-OGlyc-XAA-NH2 esters was evaluated, where XAA stands for 
all 20 proteinogenic amino acids, with either a protected or an unprotected side chain 
functionality. The best results were obtained with the OGlyc-Phe-NH2 ester, resulting in a 
two-fold enhancement.[13] 
This optimal OGlyc-Phe-NH2 ester was compared to the most active substituted phenol 
esters from the first Z-Gly-Act screening (Table 6.1, entries 1, 2). To clearly discern the 
intrinsic reactivities, the challenging substrate Z-D-Phe-OH was chosen as the acyl donor 
with H-Phe-NH2 as the nucleophile (Table 6.2). D-Amino acids are notoriously difficult 
substrates for Alcalase, in fact, Chen et	al.	reported that no peptide product was obtained 
at all using Alcalase and Z-D-Phe as acyl donor.[2]	
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Table 6.2  Relative activity of various Z-D-Phe-Act esters[a] 
 
  
 
Entry	 Act	 Structure	 Relative	activity	(%)	
1 OTmap 
 
100 
2 OGp 
 
98 
3 OGlyc-Phe-NH2 
 
90 
4 OCam  54 
[a] Conditions: 2 mM Z-Gly-Act, 0.33 M H-Phe-NH2, DMF/THF, crushed 3Å mol sieves, 50 °C, 
      60 min  
 
As is evident from Table 6.2, the elongated OCam ester (entry 3) shows a comparable 
reactivity as the substituted phenyl esters (entry 1, 2). An equally active but more 
conveniently accessible ester was thus developed for Alcalase-CLEA catalysed peptide 
synthesis. Another advantage is that no racemisation occurred on the activated amino acid 
ester, i.e. D-Phe, using the Z-D-Phe-OGlyc-Phe-NH2 ester (entry 3, e.e. of D-Phe >99.5), this is 
in contrast with the Cbz-D-Phe-OTmap ester (entry 1, e.e. of D-Phe 85.8%). 
 
6.3 Conclusion 
Summarising, our set of activated esters was subjected to the enzyme Alcalase in 
anhydrous organic solvents. With this system developed by DSM, it became possible to 
shift the Alcalase activity entirely from hydrolysis in aqueous buffers to synthesis in the 
absence of water. To our surprise, it appeared that positively charged phenolic esters were 
most active. It was also demonstrated that the activity of OCam esters can be increased to 
the level of the most active phenolic esters by elongation with (apolar) amino acids and 
amino acid amides.  
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6.5 Experimental Section 
General remarks:  
Before use, 3 g Alcalase-CLEA (Type OM, CLEA-Technologies, 580 U/g) was suspended in 100 
mL tBuOH and crushed with a spatula. After filtration, the enzyme was resuspended in 50 mL 
MTBE followed by filtration. Large enzyme particles were removed by a sieve (0.5 mm pore 
size). Analytical HPLC chromatograms were recorded on an HP1090 Liquid Chromatograph, 
using a reversed-phase column (Phenomenex, C18, 5 m particle size, 150 × 4.6 mm) at 40°C. 
The gradient program was: 0-25 min linear gradient ramp from 5% to 98% eluent B and from 
25.1-30 min with 5% eluent B (eluent A: 0.5 mL/L methane sulfonic acid (MSA) in H2O, eluent B 
0.5 mL/L MSA in acetonitrile). The flow was 1 mL/min from 0-25.1 min and 2 mL/min from 
25.2-29.8 min, then back to 1 mL/min until stop at 30 min. Injection volumes were 20 μL. The 3 
Å molecular sieves (Acros, 8 to 12 mesh) were activated (200°C under vacuum overnight), 
crushed and sieved (0.5 mm pore size) to remove large particles. To determine the e.e. of Phe 
the samples concentrated in	vacuo and the residue suspended in excess 6 N HCl and refluxed 
overnight. Chiral HPLC was performed on a crownether (+) column (150 mm length, 4.0 mm 
internal diameter, 5 μm particle size) at 25 °C with 30 mM aqueous HClO4 (pH = 2.0) as the 
eluent. UV detection was performed at 210 nm using a UV-VIS linear spectrometer. The flow 
was 1 mL/min. Injection volumes were 5 μL. Rt (D-Phe) = 6.90 min, Rt (L-Phe) = 8.82 min. 
General procedure for the relative activity determination of Alcalase-CLEA catalysed peptide 
coupling in organic media:  
To a suspension of Alcalase-CLEA (4.5 mg), H-Phe-NH2 (0.54 mg) and crushed 3 Å molecular 
sieves (4.5 mL) in THF (900 μL), was added amino acid or peptide ester stock solution in DMF 
(20 mM, 100 μL). The reaction mixture was shaken at 50 °C with 200 rpm for 60 min. 
Afterwards, the reaction mixtures were filtrated and analysed by analytical HPLC by integrating 
the peptide coupling product peak. Integration areas of different reactions were compared to 
determine the relative activity (ester which gave the highest peptide product intergration area 
= 100%). 
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 	Chapter 7
	
Synthesis	
 
The synthesis of all previously encountered mimetics and activating esters is described in 
this chapter. The reaction sequences primarily consisted of synthesis of the required 
alcohol, DCC-mediated esterification of this alcohol with an amino acid and subsequent 
deprotection. 
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7.1 Introduction 
A variety of mimetics and activating esters were introduced and discussed in the previous 
chapters. The synthesis of these compounds was deliberately not described in the 
corresponding chapters as not to divert the attention from the experiments carried out 
with them. However, now the synthesis is considered, which can be regarded as a matrix 
that had to be filled, with the various alcohols on one axis and the various amino acids on 
the other. Initially, only the Z-Gly-OH esters were prepared from the various alcohols and, 
in a later stage, a range of amino acids were coupled to a selected set of alcohols. The 
syntheses are grouped based on similarity of the esters. To prevent overlap in the 
discussion, the typical issues encountered when working with amino acids with a 
functional side chain are described in § 7.2.2.   
 
7.2 Aromatic guanidino- and amidino-based mimetics 
7.2.1 Z-Gly-OGp, Z-Gly-OGb and Z-Gly-NGp 
The synthesis of the aromatic guanidino group containing mimetics started from the 
corresponding amino alcohol (1,4), or aminoaniline (7) in the case of NGp (Table 7.1). First 
the diBoc protected guanidino group was installed (2,	5, 8), then a DCC-coupling with Z-
Gly-OH was carried out to form the ester (3,6), or amide (9) in the case of NGp, followed by 
deprotection of the acid labile protecting groups. 
 
Table 7.1  Synthesis of aromatic guanidino-based mimetics 
 
 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 2	 65 3G 82 Z‐Gly‐OGp quant 
2 5	 65 6G 97 Z‐Gly‐OGb quant 
3 8	 55 9G quant Z‐Gly‐NGp quant 
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In some cases spontaneous hydrolysis of the ester occurred under acidic conditions, 
resulting in a mixture that could not be separated because of the high polarity of the 
guanidine-containing compounds. Since hydrolysis was always less than 10 percent, and 
the uncoupled amino acid would not interfere in the enzymatic reactions, the crude 
product was used as such. 
 
7.2.2 Z-XAA-OGp and Z-XAA-OGb 
Both alcohols HOGp and HOGb were selected for coupling to a range of amino acids (Tables 
7.2 and 7.3, respectively). The same scheme as depicted in Table 7.1 was followed for the 
synthesis, provided that functional amino acid side chains were properly protected. Acid 
labile protecting groups were preferred, as they could be simultaneously removed with the 
Boc groups, and are orthogonal to Cbz. Another aspect that was taken into account was the 
difficulty of purification after deprotection so that traceless protecting groups such as tBu, 
Boc and TBS were chosen. 
 
Table 7.2  Synthesis of various Z-XAA-OGp esters 
Entry	 Product	 Yield	(%)	 	Product	 Yield	(%)	
1 3A 63 Z‐L‐Ala‐OGp quant 
2 3a 80 Z‐D‐Ala‐OGp quant 
3 3βA 88 Z‐β‐Ala‐OGp quant 
4 3R(diBoc) 85 Z‐L‐Arg‐OGp quant 
5 3N(Trt) 81 Z‐L‐Asn‐OGp quant 
6 3E(OtBu) 91 Z‐L‐Glu‐OGp quant 
7 3I 97 Z‐L‐Ile‐OGp quant 
8 3F 89 Z‐L‐Phe‐OGp quant 
9 3P 82 Z‐L‐Pro‐OGp quant 
10 3T(OTBS) 98 Z‐L‐Thr‐OGp quant 
 
Table 7.3  Synthesis of various Z-XAA-OGb esters 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 6A 99 Z‐L‐Ala‐OGb quant 
2 6a 92 Z‐D‐Ala‐OGb quant 
3 6βA 93 Z‐β‐Ala‐OGb quant 
4 6D(OtBu) 89 Z‐L‐Asp‐OGb quant 
5 6Q(Trt) 99 Z‐L‐Gln‐OGb 82 
6 6I 94 Z‐L‐Ile‐OGb quant 
7 6K(Boc) 90 Z‐L‐Lys‐OGb 65 
8 6F 54 Z‐L‐Phe‐OGb quant 
9 6f 88 Z‐D‐Phe‐OGb quant 
10 6P 83 Z‐L‐Pro‐OGb quant 
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Our initial presumption was that Z-Arg-OH, when positively charged, could be used in 
unprotected form (entry 4 in Table 7.2, 7.7 and 7.10). However, attempts to form the ester 
under DCC coupling conditions mainly resulted in the cyclised δ-lactam form of Z-Arg-OH 
(Scheme 7.1).[1] Even diBoc protection could not completely prevent this side reaction, 
since approximately 15% of δ-lactam was observed.[2] 
 
 
Scheme 7.1 δ-lactam formation from Arg 
 
We neither anticipated that the amide-containing side chain of Z-Asn-OH would interfere 
with ester formation (entry 5 in Table 7.2, 7.7 and 7.10). Nevertheless, the major product 
appeared to be the dehydrated nitrile (Scheme 7.2).[3] After trityl protection, the desired 
product was obtained in good yield. The remainder of this protecting group was readily 
removed by washing the aqueous layer with Et2O and subsequent lyophilisation. 
 
 
Scheme 7.2 Dehydration of Z-Asn-OH  
 
7.2.3 Z-Gly-OAb 
The desired ester Z-Gly-OAb was accessed by the transformation of p-
(hydroxymethyl)benzonitrile (10) into its so-called Pinner salt by subjection to a dry 
solution of HCl in ethanol (Scheme 7.3). Exclusion of water was essential to prevent 
unwanted hydrolysis of ethyl imidate 11 to the corresponding ester. Therefore, imidate 11 
was obtained in	situ and directly converted into amidine 12 by nucleophilic displacement 
of the ethoxide with ammonia dissolved in ethanol. Amidine 12	could not be coupled to Z-
Gly-OH directly without side reactions, so that first the amidino group was mono Boc 
protected. After DCC coupling, the Boc group was removed again with TFA to obtain Z‐Gly‐
OAb in an overall yield of 36% over five steps. 
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Scheme 7.3 Synthesis of Z-Gly-OAb 
 
7.3 Aliphatic amino- and guanidino-based esters 
7.3.1 Z-Gly-O3G, Z-Gly-O4G and Z-Gly-O5G 
The synthesis of the aliphatic guanidino group-containing esters proceeded analogous to 
their aromatic counterparts (Table 7.4). Amino alcohols 15, 18 and 21 were converted 
into the corresponding diBoc protected guanidino alcohols 16, 19 and 22, respectively, in 
good yields. Subsequent coupling with Z-Gly-OH and deprotection with TFA led to the 
targeted esters.  
 
Table 7.4  Synthesis of aliphatic guanidino-based esters 
 
 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 16	 95 17 70 Z‐Gly‐O3G quant 
2 19	 78 20 96 Z‐Gly‐O4G quant 
3 22	 99 23 quant Z‐Gly‐O5G 96 
Chapter 7 
 
 98 
7.3.2 Z-Gly-O4A and Z-Gly-O5A 
Aminobutanol and aminopentanol (24 and 27) were Boc-protected prior to coupling with 
Cbz-Gly-OH under the influence of DCC. Deprotection was performed with TFA in CH2Cl2 
providing the amino esters Z‐Gly‐O4A and Z‐Gly‐O5A	in excellent yields (Table 7.5). 
 
Table 7.5  Synthesis of aliphatic amino-based esters 
 
 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 25	 quant 26 83 Z‐Gly‐O4A 97 
2 28	 99 27 64 Z‐Gly‐O5A quant 
 
7.4 Dimethylamino- and trimethyl ammonium-containing esters  
7.4.1 Z-Gly-ODmap, Z-Gly-OTmap, Z-Gly-ODmape and Z-Gly-OTmape 
Dimethylamino phenol 31 was obtained via an Eschweiler-Clarke-like reaction of 
aminophenol 30 with paraformaldehyde and sodium cyanoborohydride in acetic acid 
(Table 7.6). The homologous phenethyl alcohol 33 was commercially available. DCC-
coupling with Z-Gly-OH resulted in the desired esters Z‐Gly‐ODmap and Z‐Gly‐ODmape, 
which could then be converted into the corresponding trimethylammonium-containing 
esters with methyl iodide in MeCN providing Z‐Gly‐OTmap and Z‐Gly‐OTmape, 
respectively. In order to obtain a satisfactory yield, it is essential not to methylate prior to 
the DCC- coupling. 
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Table 7.6  Synthesis of dimethylamino- and trimethyl ammonium-containing mimetics 
 
 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 Z‐Gly‐ODmap 15 Z‐Gly‐OTmap 59 
2 Z‐Gly‐ODmape 75 Z‐Gly‐OTmape quant 
 
7.4.2 Towards Z-Gly-ODmab 
An attempt was also made to synthesise Z‐Gly‐ODmab (Scheme 7.4). 4-
(Dimethylamino)benzyl alcohol 35 was prepared by the reduction of the corresponding 
aldehyde 34. Subsequent DCC-mediated esterification with Z-Gly-OH seemed to work, but 
the purification was troublesome. Presumably, the formed product is an unstable ester 
that decomposed during work-up.  
 
Scheme 7.4 Synthesis towards Z-Gly-ODmab 
 
7.4.3 Z-XAA-ODmap 
Alcohol HODmap was selected to be coupled to a range of amino acids too (Table 7.7), 
which was done in the same way as depicted in the scheme that is part of Table 7.6. For 
amino acids with a functional side chain an additional deprotection step was required. 
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Table 7.7  Synthesis of various Z-XAA-ODmap esters 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 Z‐L‐Ala‐ODmap 29[a] n.a. n.a. 
2 Z‐D‐Ala‐ODmap 81[b] n.a. n.a. 
3 Z‐β‐Ala‐ODmap 92 n.a. n.a. 
4 32R(diBoc) 86 Z‐L‐Arg‐ODmap quant 
5 32N(Trt) 40[b] Z‐L‐Asn‐ODmap 50 
6 32E(OtBu) 97 Z‐L‐Glu‐ODmap quant 
7 Z‐L‐Ile‐ODmap 98 n.a. n.a. 
8 Z‐L‐Phe‐ODmap 90 n.a. n.a. 
9 Z‐L‐Pro‐ODmap 88 n.a. n.a. 
10 32T(OtBu) 86 Z‐L‐Thr‐ODmap quant 
[a] Pure fraction from first column, no second column purification of remainder 
[b] T3P[4] was used as coupling reagent 
 
7.5 Miscellaneous esters  
7.5.1 Z-Gly-O3Cam and Z-Gly-O4Cam 
These two OCam esters were synthesised by ring-opening of γ-butyrolactone (36) and δ-
valerolactone (38) with liquid ammonia in a sealed tube at 40 °C and the resulting 
hydroxyl amides (37 and 39) were coupled with Z-Gly-OH using EDC·HCl or DCC.  
 
Table 7.8  Synthesis of carbamoyl-based esters 
 
NH2
O
HO N
H
O
NH2
Cbz
O
O
n
O
O DCC, DMAP
EtOAc
N
H
Cbz OH
O
NH3 (l)
36: n = 1
38: n = 2
37: n = 1
39: n = 2
Z-Gly-O3Cam: n = 1
Z-Gly-O4Cam: n = 2
n n
 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 35 97 Z‐Gly‐O3Cam 46 
2 37 62 Z‐Gly‐O4Cam 94 
 
7.5.2 Z-Gly-OCam, Z-Gly-OTfe, Z-Gly-OMe, Z-Gly-ONb and Z-Gly-OBn 
The esters in this section were all obtained in a single reaction step (Table 7.9). To prepare 
Z‐Gly‐OCam, Z-Gly-OH was converted into its potassium salt and reacted with 
chloroacetamide in DMF.[5] Z-Gly-OH was coupled to trifluoroethanol with EDC to afford Z‐
Gly‐OTfe. Z‐Gly‐OMe was obtained after a reaction of Z-Gly-OH with methyl 
chloroformate. Z-Gly-OH was coupled to p-nitrobenzyl alcohol with DDC to obtain Z‐Gly‐
 Synthesis 
 101 
ONb. Benzyl bromide in DMF under basic conditions was used to prepare Z‐Gly‐OBn from 
Z-Gly-OH. 
 
Table 7.9  Synthesis of miscellaneous esters  
Entry	 Structure	 Product	 Yield	(%)	
1 
 
Z‐Gly‐OCam	 49 
2  Z‐Gly‐OTfe	 64 
3  Z‐Gly‐OMe	 96 
4 
 
Z‐Gly‐ONb	 83 
5 
 
Z‐Gly‐OBn	 84 
 
7.5.3 Z-XAA-OBn 
Besides Z-Gly-OH, a range of other amino acids was treated with benzyl bromide to obtain 
the corresponding Z‐XAA‐OBn esters (Table 7.10). In case amino acids with a protected 
functional side chain were applied (40), acidic deprotection was necessary to afford the 
final products. 
 
Table 7.10  Synthesis of various Z-XAA-OBn esters 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 Z‐L‐Ala‐OBn 89 n.a. n.a. 
2 Z‐D‐Ala‐OBn 97 n.a. n.a. 
3 Z‐β‐Ala‐OBn 93 n.a. n.a. 
4 40R(diBoc) 92 Z‐L‐Arg‐OBn 95 
5 40N(Trt) 82 Z‐L‐Asn‐OBn 61 
6 40E(OtBu) 85 Z‐L‐Glu‐OBn 78 
7 Z‐L‐Ile‐OBn 91 n.a. n.a. 
8 Z‐L‐Phe‐OBn n.a.[a] n.a. n.a. 
9 Z‐L‐Pro‐OBn 98 n.a. n.a. 
10 Z‐L‐Thr‐OBn n.a.[a] n.a. n.a. 
[a] Commercially available 
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7.6 O3G variants 
7.6.1 Z-Gly-O3G 
The synthesis of Z‐Gly‐O3G commenced with LiAlH4 reduction of acid amide 41	 to 
provide amino alcohol 42 in 55% yield (Scheme 7.5).[6] This low value is mainly due to the 
difficult work-up. Subsequent guanylation of the amine (43) and esterification of the 
alcohol resulted in Boc-protected precursor 44 in excellent yield. Acidic deprotection 
afforded Z‐Gly‐O3Gquantitatively as the TFA salt. 
 
 
Scheme 7.5 Synthesis of Z-Gly-O3GΔ 
 
7.6.2 Z-Gly-O3G= 
Diol 45, with the desired methylene group already present, was taken as the starting 
compound for the synthesis of Z‐Gly‐O3G= (Scheme 7.6). In order to convert only one of 
the alcohols into an amine in a more than statistical distribution, it was first turned into 
cyclic sulfite 46, followed by ring-opening with sodium azide to acquire azido alcohol 47.[7] 
Staudinger reduction with trimethylphosphine followed by acidic work-up yielded amino 
alcohol 48, which was directly guanylated (49). Subsequent coupling with Z-Gly-OH (50) 
and deprotection with TFA gave rise to Z‐Gly‐O3G= in 46% overall yield. 
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Scheme 7.6 Synthesis of Z-Gly-O3G= 
 
7.6.3 Towards Z-Gly-O3G=O and Z-Gly-O3GF2 
Starting from 50, the corresponding ketone was obtained via ozonolysis (Scheme 7.7). 
Besides the major product 51, many byproducts were formed. In addition, the subsequent 
deprotection step appeared troublesome; treatment with both TFA in CH2Cl2 or HCl in 
dioxane led to complete decomposition of ketone 51. Hence, it was concluded that Z‐Gly‐
O3G=O is an unstable compound. 
 

Scheme 7.7 Synthesis towards Z-Gly-O3G=O and Z-Gly-O3GF2 
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The synthesis of Z‐Gly‐O3GF2 was attempted by utilising DAST as nucleophilic fluoride 
donor on ketone 50 (Scheme 7.8). Unfortunately, no reaction occurred. Alternative 
approaches, involving the synthesis of fluorinated amino alcohol 53 by various methods, 
failed to succeed.  
 
7.7 Nucleophiles 
Some of the nucleophiles used in the enzymatic experiments, were not commercially 
available and thus had to be synthesised. A convenient method for the synthesis of amino 
acid p-nitroanilides has been described by Rijkers et	al.[8] Table 7.11 shows the results of 
this coupling strategy using POCl3 and acidic deprotection. 
 
Table 7.11  Synthesis of pNA-containing nucleophiles 
Entry	 Product	 Yield	(%)	 Product	 Yield	(%)	
1 Boc‐Pro‐pNA 65 Pro‐pNA 94 
2 Boc‐Ser(OtBu)‐pNA 46 Ser‐pNA 85 
 
7.8 Conclusions 
The synthesis of most mimetics and activating esters appeared relatively straightforward. 
Exceptions were the Z-Gly-O3G variants, which however, were mainly synthesised to 
fundamentally analyse a principle and not with a large-scale application in mind. In 
general, no attempts were made to improve the yields, since small amounts of product 
were sufficient to carry out the enzymatic experiments. 
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7.10 Experimental section 
General remarks:  
All chemicals were obtained from commercial sources and used without further purification, 
unless stated otherwise. If appropriate, reactions were carried out under an inert atmosphere of 
dry nitrogen or argon. Standard syringe techniques were applied for the transfer of dry solvents 
and air- or moisture-sensitive reagents. Reactions were followed and Rf values were obtained 
using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the 
 Synthesis 
 105 
indicated solvent mixture. Detection was performed with UV-light, and/or by charring at 
~150 °C after dipping into aqueous basic permanganate. Melting points were analysed with a 
Büchi melting point B-545. IR spectra were recorded on an ATI Mattson Genesis Series FTIR 
spectrometer, or a Bruker Tensor 27 FTIR spectrometer. NMR spectra were recorded on a 
Bruker DMX 300 (300 MHz and 75 MHz for 1H and 13C, respectively). 1H-NMR chemical shifts 
are reported in parts per million (ppm) relative to tetramethylsilane (TMS) as internal 
standard, or a residual proton peak of the solvent: δ = 7.26 ppm for CDCl3, δ = 3.31 ppm for 
CD3OD, δ = 2.94 ppm for CD3CN and δ = 2.50 ppm for DMSO-d6. Multiplicities are reported as: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), dq 
(double quartet), ddd (double, double doublet), ddt (double, double triplet) or m (multiplet). 
Broad peaks are indicated by br. Coupling constants are reported as J-values in Hz. The number 
of protons (n) for a given resonance is indicated as nH, and is based on spectral integration 
values. 13C-NMR chemical shifts (δ) are reported in ppm relative to CDCl3 (δ = 77.0), CD3OD (δ = 
49.0), CD3CN (δ = 1.24) or DMSO-d6 (δ = 39.5). Column or flash chromatography was carried out 
using ACROS silica gel (0.035-0.070 mm, and ca 6 nm pore diameter). Optical rotations were 
determined with a Perkin Elmer 241 polarimeter. High resolution mass spectra were recorded 
on a JEOL AccuTOF (ESI), or a MAT900 (EI, CI, and ESI). Elemental analyses were carried out 
using a Carlo Erba Instruments CHNS-O EA 1108 element analyser. 
General procedure A1: DCC-coupling of Cbz-protected amino acids with an alcohol 
To a cooled solution (0 °C) of Z-XAA-OH (1.4 equiv), alcohol (1 equiv) and DMAP (0.2 equiv) in 
EtOAc (10 mL), DCC (1.4 equiv) was added slowly. The reaction mixture was stirred at 0 °C for 1 
h and an additional 2 h at room temperature. The solid DCU was filtered off and in some 
experiments a washing step was performed (general procedure A2) before the solvent was 
evaporated in	vacuo. In that case the reaction mixture was poured in citric acid (5%, 5 mL) and 
extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with saturated 
NaHCO3 (5 mL) and brine (10 mL), dried over sodium sulfate and then evaporated to dryness. 
The crude reaction mixture was purified with column chromatography. 
General procedure A3: EDC coupling of Cbz-protected amino acid with an alcohol or amino 
amide 
EDC (1.2 equiv) was added to a cooled solution (0 °C) of alcohol or amino amide (1 equiv), Z-
XAA-OH (1 equiv) and DMAP or DIPEA (1 equiv) in CH2Cl2. The solution was stirred at room 
temperature for at least 3 hours. The mixture was concentrated and the residue was dissolved 
in EtOAc, and washed with water (3 × 10 mL). The organic layer was dried over Na2SO4, 
concentrated and purified by column chromatography if the 1H NMR showed impurities. 
General procedure B1: Boc-deprotection with TFA 
The Boc-protected compound (100 mg) was dissolved in CH2Cl2 (2 mL) to which TFA was added 
(0.5 mL). The reaction mixture was stirred at room temperature overnight. The solvents were 
removed under reduced pressure and co-evaporated with tBuOH (3 × 10 mL). The obtained oil 
was lyophilized from a H2O/dioxane mixture (10 mL) in the presence of 2M HCl (0.5 mL), to 
give the product. In several experiments co-evaporation took place with CH2Cl2 and the 
remaining oily TFA salt was directly used (general procedure B2). 
General procedure B3: Boc-deprotection with HCl in dioxane 
The Boc-protected compound (100 mg) was treated with a commercially available solution of ~ 
4 M HCl in dioxane (2 mL) and stirred at room temperature overnight. The solvents were 
removed under reduced pressure and co-evaporated with tBuOH (3 × 10 mL). The obtained oil 
was lyophilized from a H2O/dioxane mixture (10 mL) to give the product. 
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General procedure C: benzyl ester synthesis of Cbz-protected amino acids 
To a solution of Z-XAA-OH (1 equiv) in DMF (1.5 mL) was added K2CO3 (1 equiv) and benzyl 
bromide (1.1 equiv). After being stirred for 6 hours the reaction mixture was quenched with 
water (10 mL) and extracted with EtOAc/heptane 1:1 (3 × 25 mL). The combined organic layers 
were washed with water (3 × 50 mL) and brine (1 × 50 mL), dried over Na2SO4 and then 
evaporated to dryness. The crude reaction mixture was purified with column chromatography. 
General procedure D: p-nitroanilide synthesis with POCl3[8] 
A protected amino acid (1 equiv) and recrystallized p-nitroaniline (1 equiv) were dissolved in 
dry pyridine. The clear yellowish solution was cooled to -15 °C and phosphorus oxychloride (1.1 
equiv) was added dropwise with vigorous stirring. During the addition, the reaction mixture 
coloured deeply red and became turbid in the course of 5 to 20 minutes. The colour of the 
suspension slowly changed to orange, the reaction being complete after a total of 10 to 30 min 
(monitored by TLC). The reaction mixture was then quenched with crushed ice/water (100 mL) 
and the nitroanilide was extracted into EtOAc (1 × 50 mL and 3 × 30 mL). The combined EtOAc 
layers were washed with saturated NaHCO3 and brine (3 × 30 mL each). After drying on Na2SO4, 
the EtOAc layer was filtered and evaporated in	 vacuo. The residue was co-evaporated 
successively with toluene, EtOAc and MeOH. 
 
p‐[N’,	N’’‐di(Boc)guanidino]phenol	(2)	
N,N′-di(Boc)-S-methylisothiourea (2.90 g, 10.0 mmol, 1 equiv) and p-
aminophenol (1.64 g, 15.0 mmol, 1.5 equiv) were dissolved in dry THF 
(60 mL) and this mixture was cooled to 0 °C before HgCl2 (2.99 g, 11.0 
mmol, 1.1 equiv) was added. After stirring for 20 min under argon, the 
temperature was raised to room temperature and the mixture was 
stirred for 20 h. The white precipitate that was formed during the reaction was filtered off and 
the filtrate was concentrated under reduced pressure. Recrystallisation from methanol yielded 
1.53 g (43%) of the pure product. The mother liquor was then evaporated to dryness and the 
remaining solid was purified by column chromatography (EtOAc/heptane 1:91:2) to afford 3 
(753 mg, 65%) as an off-white solid. Rf	0.37 (EtOAc/heptane 1:2). Mp dec at >240 °C. IR (film) 
3264, 2979, 2737, 1720, 1647, 1517, 1409, 1227, 1152, 1112, 1059 cm−1. 1H NMR (CDCl3, 300 
MHz): δ 11.61 (s, NH), 10.04 (s, NH), 7.14 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.3 Hz, 2H), 6.22 (br s, 
OH), 1.54 (s, 9H), 1.46 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 163.2, 155.9, 155.3, 153.2, 127.0, 
126.3, 116.1, 83.7, 79.8, 28.1. HRMS (ESI) m/z calcd for C17H26N3O5 (M+H)+: 352.1873, found: 
352.1875. Spectral data were in accordance with those reported in literature.[9] 
 
Nα‐Cbz‐Glycine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3G)	
General procedure A1 using Z-Gly-OH (879 mg, 4.2 mmol), 2 
(1.05 g, 3.00 mmol), DMAP (73 mg, 0.6 mmol) and DCC (867 
mg, 4.21 mmol). The product was obtained as a white solid 
after purification by column chromatography (MeOH in 
CH2Cl2, 14%) (1.33 g, 82%). Rf 0.67 (4% MeOH in CH2Cl2). 
Mp 111 °C. IR (film) 2978, 2928, 1779, 1720, 1640, 1508, 1412, 1240, 1154, 1114, 1057 cm−1. 
1H NMR (CDCl3, 300 MHz): δ 11.62 (s, NH), 10.35 (s, NH), 7.62 (d, J = 8.5 Hz, 2H), 7.41-7.28 (m, 
5H), 7.07 (d, J = 8.3 Hz, 2H), 5.34 (m, NH), 5.15 (s, 2H), 4.22 (d, J	= 5.3 Hz, 2H), 1.53 (s, 9H), 1.50 
(s, 9H). 13C NMR (CDCl3, 75 MHz): δ 168.6, 163.4, 156.2, 153.5, 153.3, 146.8, 136.1, 134.8, 128.6, 
128.2, 128.1, 123.2, 121.6, 83.9, 79.8, 67.3, 42.9, 28.2, 28.1. HRMS (ESI) m/z calcd for 
C27H34N4NaO8 (M+Na)+: 565.2274, found: 565.2274. 
 
 
 
 
N
H O
OCbz
N
H
N
N
H
Boc
Boc
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Nα‐Cbz‐Glycine	p‐guanidinophenyl	ester	(Z‐Gly‐OGp)	
General procedure B1 using 3G (100 mg, 0.184 mmol). The 
product was obtained as a sticky oil (69.8 mg, quant). Rf 0.50 
(CHCl3/MeOH/NH4OH, 65:45:20). IR (film) 3309, 3166, 
2950, 1770, 1706, 1671, 1629, 1588, 1507, 1455, 1280, 
1201, 1166, 1053 cm−1. 1H NMR (DMSO-d6, 300 MHz): δ 
10.03 (s, NH), 7.89 (t, J = 5.9 Hz, NH), 7.56 (br s, 4NH), 7.40-7.25 (m, 7H), 7.21-7.15 (m, 2H), 5.08 
(s, 2H), 4.07 (d, J = 6.1 Hz, 2H). 13C NMR (DMSO-d6, 75 MHz): δ 169.0, 156.5, 156.0, 148.2, 136.8, 
132.9, 128.3, 127.8, 127.7, 125.7, 122.7, 65.6, 42.4. HRMS (ESI) m/z calcd for C17H18N4NaO4 
(M+Na)+: 365.1226, found: 365.1231. 
 
Nα‐Cbz‐L‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3A)	
General procedure A1 using Z-L-Ala-OH (625 mg, 2.8 mmol), 2 
(703 mg, 2.00 mmol), DMAP (49 mg, 0.41 mmol) and DCC 
(578 mg, 2.81 mmol). The product was obtained as a white 
solid after purification by column chromatography (MeOH in 
CH2Cl2, 12%) (702 mg, 63%). Rf 0.63 (2% MeOH in CH2Cl2). 
Mp 60 °C. []20D 14.7 (c 0.30, CH2Cl2). IR (film) 2976, 2933, 1761, 1717, 1634, 1507, 1410, 1238, 
1150, 1113, 1058 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.63 (s, NH), 10.33 (s, NH), 7.60 (d, J	= 8.5 
Hz, 2H), 7.39-7.29 (m, 5H), 7.03 (d, J = 8.1 Hz, 2H), 5.53 (d, J = 7.0 Hz, NH), 5.12 (s, 2H), 4.67-4.52 
(m, 1H), 1.57-1.46 (m, 21H). 13C NMR (CDCl3, 75 MHz): δ 171.5, 163.3, 155.6, 153.4, 153.1, 
146.9, 136.1, 134.5, 128.4, 128.1, 128.0, 123.1, 121.4, 83.7, 79.6, 66.8, 49.7, 28.0, 27.9, 18.2. 
HRMS (ESI) m/z calcd for C28H37N4O8 (M+H)+: 557.2611, found: 557.2605. 
	
Nα‐Cbz‐L‐Alanine	p‐guanidinophenyl	ester	(Z‐L‐Ala‐OGp)	
General procedure B1 using 3A (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.50 
(CHCl3/MeOH/NH4OH, 65:45:20). [] 20D 34.5 (c 0.24, 
MeOH). IR (film) 3313, 3175, 2941, 1757, 1704, 1671, 1630, 
1589, 1507, 1452, 1257, 1195, 1169, 1067 cm−1. 1H NMR 
(CD3CN, 300 MHz): δ 9.87 (s, NH), 7.40-7.25 (m, 7H), 7.18-7.10 (m, 2H), 7.02 (br s, 3NH), 6.31 
(d, J = 6.6 Hz, NH), 5.09 (s, 2H), 4.43 (dq, J = 7.3, 7.3 Hz, 1H), 1.50 (d, J = 7.3 Hz, 3H). 13C NMR 
(CD3CN, 75 MHz): δ 172.7, 158.1, 157.0, 150.7, 133.0, 129.4, 128.9, 128.7, 128.0, 124.0, 67.2, 
51.0, 17.4. HRMS (ESI) m/z calcd for C18H20N4NaO4 (M+Na)+: 379.1382, found: 379.1382. 
 
Nα‐Cbz‐D‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3a)	
General procedure A1 using Z-D-Ala-OH (313 mg, 1.40 mmol), 
2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC 
(289 mg, 1.40 mmol). The product was obtained as a white 
solid after purification by column chromatography (MeOH in 
CH2Cl2, 13%) (445 mg, 80%). Rf 0.67 (2% MeOH in CH2Cl2). 
Mp 60 °C. []20D +16.4 (c 0.32, CH2Cl2). IR (film) 2976, 2941, 1766, 1719, 1639, 1511, 1412, 1239, 
1152, 1114, 1059 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.63 (s, NH), 10.34 (s, NH), 7.61 (d, J	= 8.4 
Hz, 2H), 7.44-7.27 (m, 5H), 7.04 (d, J = 8.1 Hz, 2H), 5.46 (d, J = 6.7 Hz, NH), 5.13 (s, 2H), 4.67-4.53 
(m, 1H), 1.57-1.46 (m, 21H). 13C NMR (CDCl3, 75 MHz): δ 171.6, 163.4, 155.6, 153.4, 153.2, 
146.9, 136.1, 134.6, 128.5, 128.1, 128.0, 123.1, 121.5, 83.7, 79.6, 66.9, 49.8, 28.1, 28.0, 18.4. 
HRMS (ESI) m/z calcd for C28H37N4O8 (M+H)+: 557.2611, found: 557.2607. 
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Nα‐Cbz‐D‐Alanine	p‐guanidinophenyl	ester	(Z‐D‐Ala‐OGp)	
General procedure B1 using 3a (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.50 
(CHCl3/MeOH/NH4OH, 65:45:20). []20D +33.3 (c 0.23, MeOH). 
IR (film) 3311, 3175, 2940, 1761, 1701, 1672, 1631, 1588, 
1507, 1453, 1258, 1196, 1169, 1067 cm−1. 1H NMR (CD3CN, 
300 MHz): δ 9.89 (s, NH), 7.41-7.24 (m, 7H), 7.18-7.10 (m, 2H), 7.03 (br s, 4NH), 6.30 (d, J = 6.5 
Hz, NH), 5.09 (s, 2H), 4.43 (dq, J = 7.2, 7.3 Hz, 1H), 1.50 (d, J = 7.3 Hz, 3H). 13C NMR (CD3CN, 75 
MHz): δ 172.7, 165.9, 158.1, 157.0, 150.7, 133.0, 129.4, 129.1, 128.9, 128.8, 128.7, 128.0, 124.0, 
67.2, 51.0, 17.4. HRMS (ESI) m/z calcd for C18H20N4NaO4 (M+Na)+: 379.1382, found: 379.1395. 
	
Nα‐Cbz‐β‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3A)	
General procedure A1; using Z-β-Ala-OH (313 mg, 1.40 
mmol), 2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained 
as a white solid after purification by column 
chromatography (MeOH in CH2Cl2, 13%) (490 mg, 88%). 
Rf 0.60 (2% MeOH in CH2Cl2). Mp 56 °C. IR (film) 2980, 2933, 1766, 1717, 1630, 1502, 1409, 
1237, 1149, 1113, 1057, 731cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.62 (s, NH), 10.33 (s, NH), 
7.65-7.56 (m, 2H), 7.42-7.28 (m, 5H), 7.10-6.99 (m, 2H), 5.39-5.29 (m, NH), 5.11 (s, 2H), 3.55 (dt, 
J	= 5.8, 5.9 Hz, 2H), 2.79 (t, J = 5.6 Hz, 2H), 1.53 (s, 9H), 1.50 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 
170.8, 163.4, 156.2, 153.5, 153.2, 146.9, 136.4, 134.5, 128.5, 128.1, 128.0, 123.1, 121.7, 83.8, 
79.7, 66.7, 36.4, 34.6, 28.1, 28.0. HRMS (ESI) m/z calcd for C28H37N4O8 (M+H)+: 557.2611, found: 
557.2604. 
	
Nα‐Cbz‐‐Alanine	p‐guanidinophenyl	ester	(Z‐β‐Ala‐OGp)	
General procedure B1 using 3A (100 mg). The product 
was obtained as a sticky oil (quant). Rf 0.50 
(CHCl3/MeOH/NH4OH, 65:45:20). IR (film) 3330, 3175, 
3062, 2946, 1754, 1701, 1672, 1629, 1588, 1508, 1455, 
1257, 1200, 1166, 1065, 1014 cm−1. 1H NMR (CD3CN, 300 
MHz): δ 9.82 (s, NH), 7.40-7.25 (m, 7H), 7.20 (m, 2H), 6.98 (br s, 3NH), 5.94 (br s, NH), 5.07 (s, 
2H), 3.47 (dt, J = 6.4, 6.4 Hz, 2H), 2.76 (t, J = 6.5 Hz, 2H). 13C NMR (CD3CN, 75 MHz): δ 171.4, 
158.1, 157.3, 150.8, 132.8, 129.4, 128.8, 128.6, 128.0, 124.3, 66.9, 37.5, 35.5. HRMS (ESI) m/z 
calcd for C19H20N4O4 (M+H)+: 357.1563, found: 357.1546. 
 
Nα‐Cbz‐L‐Arginine(diBoc)	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3R)	
General procedure A1 using Z-L-Arg(diBoc)-OH (712 mg, 1.40 
mmol), 2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as a 
white solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (718 mg, 85%). Rf 0.70 (2% MeOH 
in CH2Cl2). Mp 84 °C. []20D +3.6 (c 0.98, CH2Cl2). IR (film) 
2984, 2937, 1766, 1720, 1640, 1511, 1414, 1334, 1240, 1156, 
1056 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.61 (s, NH), 11.48 
(s, NH), 10.34 (s, NH), 8.39 (t, J = 5.4 Hz, NH), 7.62 (d, J	= 8.9 
Hz, 2H), 7.39-7.29 (m, 5H), 7.04 (d, J = 8.6 Hz, 2H), 5.70 (d, J = 
8.0 Hz, NH), 5.14 (s, 2H), 4.68-4.56 (m, 1H), 3.61-3.37 (m, 2H), 2.14-1.95 (m, 1H), 1.83-1.67 (m, 
3H), 1.54 (s, 9H), 1.50 (s, 9H), 1.49 (s, 9H), 1.48 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 170.8, 163.5, 
156.3, 153.5, 153.3, 146.9, 134.8, 128.5, 128.1, 123.2, 121.6, 83.8, 83.2, 79.7, 79.4, 67.1, 54.0, 
N
H
O
Cbz
O
H
N
N
H
N
Boc
Boc
 Synthesis 
 109 
40.2, 29.4, 28.3, 28.2, 28.1, 25.5. HRMS (ESI) m/z calcd for C41H61N7O12 (M+2H)+: 843.4378, 
found: 843.4373. 
 
Nα‐Cbz‐L‐Arginine	p‐guanidinophenyl	ester	(Z‐L‐Arg‐OGp)	
General procedure B1 using 3R (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.50 (CHCl3/MeOH/NH4OH, 
65:45:20). []20D 22.1 (c 0.40, MeOH). IR (film) 3328, 3165, 
2958, 1757, 1668, 1589, 1507, 1262, 1197, 1165 cm−1. 1H NMR 
(DMSO-d6, 300 MHz): δ 10.15 (s, NH), 8.04 (d, J = 7.1 Hz, NH), 
7.94 (t, J = 5.4 Hz, NH), 7.60 (br s, 4NH), 7.42-7.25 (m, 7H), 7.19-
7.11 (m, 2H), 5.08 (s, 2H), 4.34-4.23 (m, 1H), 3.16 (dt, J = 6.3, 6.3 
Hz, 2H), 2.02-1.56 (m, 6H). 13C NMR (DMSO-d6, 75 MHz): δ 170.9, 
157.0, 156.2, 156.1, 148.2, 136.7, 132.9, 128.3, 127.8, 127.7, 
125.6, 122.6, 65.6, 53.7, 31.2, 27.5, 25.0, 21.0. HRMS (ESI) m/z calcd for C21H27N7O4 (M+H)+: 
442.2203, found: 442.2188. 
	
Nα‐Cbz‐L‐Asparagine(Trt)	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3N)	
General procedure A1 using Z-L-Asn(Trt)-OH (356 mg, 0.70 
mmol), 2 (176 mg, 0.50 mmol), DMAP (12 mg, 0.10 mmol) 
and DCC (144 mg, 0.70 mmol). The product was obtained as a 
white solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (339 mg, 81%). Rf 0.18 
(EtOAc/heptane 1:5). Mp 94 °C. []20D +17.8 (c 0.85, CH2Cl2). 
IR (film) 2976, 2924, 1766, 1719, 1640, 1506, 1412, 1239, 1153, 1114, 1057, 699 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 11.61 (s, NH), 10.30 (s, NH), 7.54 (d, J = 9.0 Hz, 2H), 7.37-7.12 (m, 20H), 6.76 
(d, J = 9.0 Hz, 2H), 6.65 (s, NH), 6.11 (d, J = 9.0 Hz, NH), 5.14 (s, 2H), 4.82-4.72 (m, 1H), 3.24 (dd, 
J = 3.7, 16.4, 1H), 2.96 (dd, J = 3.5, 16.1, 1H), 1.54 (s, 9H), 1.52 (s, 9H). 13C NMR (CDCl3, 75 MHz): 
δ 169.9, 169.1, 163.5, 156.2, 153.5, 153.3, 147.2, 144.2, 136.3, 134.5, 128.6, 128.5, 128.3, 128.2, 
128.1, 127.8, 127.2, 123.1, 121.9, 83.8, 79.6, 71.0, 67.0, 50.9, 38.9, 30.9, 28.2, 28.1. HRMS (ESI) 
m/z calcd for C48H52N5O9 (M+H)+: 842.3765, found: 842.3759. 
	
Nα‐Cbz‐L‐Asparagine	p‐guanidinophenyl	ester	(Z‐L‐Asn‐OGp)		
General procedure B1 using 3N (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.50 (CHCl3/MeOH/NH4OH, 
65:45:20). []20D 27.0 (c 0.38, DMSO). 
IR (film) 3329, 3183, 3032, 1761, 1671, 1589, 1507, 1411, 
1269, 1200, 1139, 1061 cm−1. 1H NMR (DMSO-d6, 300 MHz): δ 
9.87 (s, NH), 7.87 (d, J = 7.8 Hz, NH), 7.50 (br s, 4NH), 7.40-
7.21 (m, 7H), 7.18-7.10 (m, 2H), 7.02 (s, 2NH), 5.08 (s, 2H), 4.64 (dt, J = 6.7, 6.7 Hz, 1H), 2.75 (dd, 
J = 6.1, 15.6 Hz, 1H), 2.65 (dd, J = 7.0, 15.6 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): δ 170.6, 170.3, 
155.9, 148.5, 136.7, 132.8, 128.3, 127.8, 127.6, 125.8, 122.6, 65.6, 50.7, 36.7. HRMS (ESI) m/z 
calcd for C19H21N5NaO5 (M+Na)+: 422.1440, found: 422.1440. 
	
Nα‐Cbz‐L‐Glutamate(OtBu)	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3E)	
General procedure A1 using Z-L-Glu(OtBu)-OH (472 mg, 1.40 
mmol), 2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and 
DCC (289 mg, 1.40 mmol). The product was obtained as a 
white solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (608 mg, 91%). Rf 0.22 
(EtOAc/heptane 1:5). Mp 54 °C. []20D 10.4 (c 0.93, CH2Cl2). IR 
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(film) 2976, 2928, 1770, 1719, 1637, 1507, 1411, 1238, 1149, 1113, 1056 cm−1. 1H NMR (CDCl3, 
300 MHz): δ 11.62 (s, NH), 10.34 (s, NH), 7.62 (d, J = 8.8 Hz, 2H), 7.39-7.29 (m, 5H), 7.05 (d, J	= 
8.5 Hz, 2H), 5.52 (d, J = 8.1 Hz, NH), 5.13 (s, 2H), 4.66-4.55 (m, 1H), 2.52-2.24 (m, 3H), 2.19-2.03 
(m, 1H), 1.54 (s, 9H), 1.50 (s, 9H), 1.44 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 171.9, 170.6, 163.4, 
155.9, 153.4, 153.3, 146.9, 136.1, 134.7, 128.5, 128.2, 128.1, 123.1, 121.6, 83.8, 81.0, 79.7, 67.1, 
53.7, 31.4, 28.1, 28.0, 27.4. HRMS (ESI) m/z calcd for C34H47N4O10 (M+H)+: 671.3292, found: 
671.3298. 
	
Nα‐Cbz‐L‐Glutamate	p‐guanidinophenyl	ester	(Z‐L‐Glu‐OGp)	
General procedure B1 using 3E (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.50 (CHCl3/MeOH/NH4OH, 
65:45:20). []20D 28.0 (c 0.36, MeOH). IR (film) 3321, 3168, 
3132, 2950, 1757, 1710, 1671, 1633, 1588, 1507, 1455, 1403, 
1261, 1195, 1165, 1059 cm−1. 1H NMR (DMSO-d6, 300 MHz): δ 
10.07 (s, NH), 8.01 (d, J = 7.2 Hz, NH), 7.58 (br s, 4NH), 7.40-
7.25 (m, 7H), 7.19-7.11 (m, 2H), 5.08 (s, 2H), 4.37-4.27 (m, 
1H), 2.42 (t, J = 7.3 Hz, 2H), 2.21-2.05 (m, 1H), 2.04-1.87 (m, 1H). 13C NMR (DMSO-d6, 75 MHz): δ 
173.5, 170.8, 156.1, 156.0, 148.3, 136.7, 132.9, 128.3, 127.8, 127.7, 125.7, 122.6, 65.6, 53.3, 31.2, 
25.6. HRMS (ESI) m/z calcd for C20H23N4O6 (M+H)+: 415.1618, found: 415.1608. 
	
Nα‐Cbz‐L‐Isoleucine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3I)	
General procedure A1 using Z-L-Ile-OH (372 mg, 1.40 mmol), 
2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC 
(289 mg, 1.40 mmol). The product was obtained as a white 
solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (582 mg, 97%). Rf 0.50 
(EtOAc/heptane 1:2). Mp 49 °C. []20D 5.1 (c 0.87, CH2Cl2). IR 
(film) 2971, 2924, 2868, 1766, 1717, 1636, 1507, 1410, 1237, 1150, 1113, 1057 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 11.62 (s, NH), 10.34 (s, NH), 7.62 (d, J = 8.6 Hz, 2H), 7.42-7.28 (m, 5H), 7.04 
(d, J = 8.6 Hz, 2H), 5.38 (d, J = 8.8 Hz, NH), 5.13 (s, 2H), 4.57 (dd, J = 4.7, 8.6 Hz, 1H), 2.13-1.99 
(m, 1H), 1.81-1.68 (m, 1H), 1.53 (s, 9H), 1.50 (s, 9H), 1.40-1.20 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 
0.98 (t, J = 7.3 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 170.6, 163.4, 156.1, 153.4, 153.2, 146.8, 
136.1, 134.7, 128.5, 128.2, 128.1, 123.1, 121.6, 83.8, 79.6, 67.1, 58.4, 38.1, 28.1, 28.0, 25.1, 15.6, 
11.6. HRMS (ESI) m/z calcd for C31H42N4NaO8 (M+Na)+: 621.2900, found: 621.2897. 
	
Nα‐Cbz‐L‐Isoleucine	p‐guanidinophenyl	ester	(Z‐L‐Ile‐OGp)  
General procedure B1 using 3I (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.46 
(CHCl3/MeOH/NH4OH, 65:45:20). []20D 17.6 (c 0.27, MeOH). 
IR (film) 3312, 3172, 2965, 2928, 1760, 1705, 1673, 1631, 
1588, 1507, 1199, 1135 cm−1. 1H NMR (DMSO-d6, 300 MHz): 
δ 10.18 (s, NH), 7.95 (d, J = 7.3 Hz, NH), 7.63 (br s, 4NH), 
7.43-7.25 (m, 7H), 7.18-7.09 (m, 2H), 5.09 (s, 2H), 4.30-4.09 (m, 1H), 2.03-1.87 (m, 1H), 1.63-
1.25 (m, 2H), 0.99 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (DMSO-d6, 75 MHz): δ 
170.5, 156.4, 156.1, 148.2, 136.8, 132.9, 128.3, 127.8, 127.7, 125.7, 122.6, 65.6, 58.8, 36.0, 24.9, 
15.4, 11.1. HRMS (ESI) m/z calcd for C21H26N4NaO4 (M+Na)+: 421.1852, found: 421.1845. 
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Nα‐Cbz‐L‐Phenylalanine	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3F)	
General procedure A1 using Z-L-Phe-OH (419 mg, 1.40 mmol), 
2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC 
(289 mg, 1.40 mmol). The product was obtained as a white 
solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (563 mg, 89%). Rf 0.80 (2% MeOH 
in CH2Cl2). Mp 62 °C. []20D 10.1 (c 0.98, CH2Cl2). IR (film) 
2978, 2933, 1761, 1719, 1640, 1507, 1412, 1239, 1153, 1114, 
1057, 620, 607 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.62 (s, NH), 10.34 (s, NH), 7.60 (d, J	= 8.8 Hz, 
2H), 7.39-7.17 (m, 10H), 6.95 (d, J	= 8.6 Hz, 2H), 5.30 (d, J	= 8.2 Hz, NH), 5.12 (s, 2H), 4.93-4.83 
(m, 1H), 3.25 (d, J	= 5.8 Hz, 2H), 1.53 (s, 9H), 1.51 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 170.1, 
163.4, 155.6, 153.5, 153.3, 146.8, 135.4, 134.7, 129.4, 128.8, 128.5, 128.2, 128.1, 127.4, 123.2, 
121.6, 83.9, 79.8, 67.1, 54.9, 38.3, 28.2, 28.1. HRMS (ESI) m/z calcd for C34H41N4O8 (M+H)+: 
633.2924, found: 633.2924. 
	
Nα‐Cbz‐L‐Phenylalanine	p‐guanidinophenyl	ester	(Z‐L‐Phe‐OGp)	
General procedure B1 using 3F (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.44 
(CHCl3/MeOH/NH4OH, 65:45:20). [] 20D 10.0 (c 0.62, 
MeOH). IR (film) 3330, 3171, 3032, 2954, 1763, 1701, 1672, 
1630, 1507, 1198, 1169, 1053 cm−1. 1H NMR (CDCl3, 300 
MHz): δ 9.72 (br, NH), 7.79-6.67 (m, 18H), 5.84-5.66 (m, NH), 
5.04 (d, J = 12.0 Hz, 1H), 4.97 (d, J = 12.4 Hz, 1H), 4.84-4.66 
(m, 1H), 3.31-3.01 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ 171.7, 156.7, 155.7, 136.0, 135.5, 135.1, 
133.8, 130.0, 129.2, 128.6, 128.5, 128.2, 128.0, 127.2, 125.5, 66.1, 55.0, 38.1. HRMS (ESI) m/z 
calcd for C24H24N4NaO4 (M+Na)+: 455.1695, found: 455.1693. 
	
Nα‐Cbz‐L‐Proline	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3P)	
General procedure A1 using Z-L-Pro-OH (419 mg, 1.40 mmol), 2 
(351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 
mg, 1.40 mmol). The product was obtained as a white solid 
after purification by column chromatography (MeOH in CH2Cl2, 
12%) (479 mg, 82%). Rf 0.76 (2% MeOH in CH2Cl2). Mp 65 
°C. []20D 55.4 (c 0.72, CH2Cl2). IR (film) 2976, 2932, 2876, 
1761, 1712, 1636, 1502, 1411, 1238, 1148, 1114, 1057 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.62 
(s, NH), 10.32 (s, 0.45NH), 10.31 (s, 0.55NH), 7.60 (d, J = 8.8 Hz, 0.9H), 7.52 (d, J = 8.9 Hz, 1.1H), 
7.44-7.26 (m, 5H), 7.06 (d, J = 8.8 Hz, 0.9H), 6.71 (d, J = 8.9 Hz, 1.1H), 5.26 (d, J = 12.2 Hz, 0.55H), 
5.20 (d, J = 12.5 Hz, 0.45H), 5.14 (d, J = 12.5 Hz, 0.45H), 5.05 (d, J = 12.2 Hz, 0.55H),4.58 (dd, J = 
4.1, 8.5 Hz, 0.45H), 4.52 (dd, J = 4.1, 8.5 Hz, 0.55H), 3.74-3.48 (m, 2H), 2.44-1.71 (m, 4H), 1.53 (s, 
9H), 1.51 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 171.2, 171.1, 163.3, 154.8, 154.1, 153.5, 153.2, 
147.3, 147.0, 136.6, 136.2, 134.3, 128.5, 128.4, 128.1, 127.9, 127.8, 123.2, 121.7, 121.5, 83.8, 
79.7, 67.2, 67.0, 59.3, 58.8, 47.0, 46.4, 31.0, 29.9, 28.1, 28.0, 24.4, 23.6. HRMS (ESI) m/z calcd for 
C30H39N4O8 (M+H)+: 583.2768, found: 583.2765. 
	
Nα‐Cbz‐L‐Proline	p‐guanidinophenyl	ester	(Z‐L‐Pro‐OGp)	
General procedure B1 using 3P (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.45 (CHCl3/MeOH/NH4OH, 
65:45:20). []20D 64.1 (c 0.30, MeOH). IR (film) 3331, 3169, 
2976, 2950, 2885, 1765, 1697, 1671, 1629, 1507, 1198, 1167, 
1142 cm−1. 1H NMR (CD3CN, 300 MHz): δ 9.90 (s, 0.5NH), 9.88 
N
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(s, 0.5NH), 7.43-7.32 (m, 5H), 7.30 (d, J = 9.0 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 8.6 Hz, 
1H), 6.99 (br s, 3NH), 6.92 (d, J = 8.6 Hz, 1H), 5.18 (d, J = 12.4 Hz, 0.5H), 5.16 (d, J = 12.4 Hz, 
0.5H), 5.11 (d, J = 12.6 Hz, 0.5H), 5.04 (d, J = 12.4 Hz, 0.5H), 4.52 (dd, J = 8.8, 16.0 Hz, 0.5H), 4.51 
(dd, J = 8.6, 16.6 Hz, 0.5H), 3.59-3.45 (m, 2H), 2.49-1.91 (m, 4H). 13C NMR (CD3CN, 75 MHz): δ 
158.1, 155.7, 154.9, 153.8, 150.7, 150.5, 147.7, 133.0, 129.5, 129.4, 129.1, 128.9, 128.6, 128.1, 
128.0, 124.0, 123.9, 67.6, 60.4, 59.8, 47.9, 47.4, 30.8, 30.5, 25.2, 24.3. HRMS (ESI) m/z calcd for 
C20H23N4O4 (M+H)+: 383.1719, found: 383.1706. 
	
Nα‐Cbz‐L‐Threonine(OTBS)	p‐[N’,N’’‐di(Boc)guanidino]phenyl	ester	(3T)	
General procedure A1 using Z-L-Thr(OTBS)-OH (515 mg, 1.40 
mmol), 2 (351 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as a 
white solid after purification by column chromatography 
(EtOAc/heptane 1:91:2) (692 mg, 98%). Rf 0.58 
(EtOAc/heptane 1:2). Mp 59 °C. []20D 14.3 (c 0.84, CH2Cl2). 
IR (film) 2928, 2854, 1766, 1718, 1638, 1506, 1410, 1237, 1150, 1113, 1058 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 11.63 (s, NH), 10.35 (s, NH), 7.61 (d, J = 9.0 Hz, 2H), 7.42-7.31 (s, 5H), 7.08 
(d, J = 9.0 Hz, 2H), 5.53 (d, J = 9.6 Hz, NH), 5.16 (s, 2H), 4.65-4.57 (m, 1H) 4.48 (dd, J = 1.7, 9.7 Hz, 
1H) 1.54 (s, 9H) 1.51 (s, 9H) 1.29 (d, J = 6.2 Hz, 3H) 0.86 (s, 9H) 0.08 (s, 3H), 0.03 (s, 3H). 13C 
NMR (CDCl3, 75 MHz): δ 169.3, 163.5, 156.8, 153.5, 153.3, 147.2, 136.2, 134.5, 128.6, 128.2, 
123.0, 121.5, 83.8, 79.8, 68.7, 67.2, 60.2, 28.2, 28.1, 25.7, 21.0, 17.9, -4.2, -4.9. HRMS (ESI) m/z 
calcd for C35H53N4O9Si (M+H)+:701.3582, found: 701.3580. 
 
	Nα‐Cbz‐L‐Threonine	p‐guanidinophenyl	ester (Z‐L‐Thr‐OGp) 
General procedure B1 using 3T (100 mg). The product was 
obtained as a sticky oil (quant). Rf 0.45 (CHCl3/MeOH/NH4OH, 
65:45:20). []20D 27.5 (c 0.21, MeOH). IR (film) 3330, 3182, 
3088, 2980, 1765, 1701, 1671, 1633, 1507, 1196, 1165, 1068 
cm−1. 1H NMR (DMSO-d6, 300 MHz): δ 10.00 (s, NH), 8.65 (br s, 
NH), 7.64-7.23 (m, 11H), 7.19-7.13 (m, 2H), 5.09 (s, 2H), 4.38-
4.19 (m, 2H), 1.20 (d, J = 6.3 Hz, 3H). 13C NMR (DMSO-d6, 75 MHz): δ 169.6, 156.4, 156.0, 148.4, 
136.8, 132.8, 128.3, 127.8, 127.6, 125.7, 122.6, 122.5, 66.4, 65.6, 60.3, 19.9. HRMS (ESI) m/z 
calcd for C19H22N4NaO5 (M+Na)+: 409.1488, found: 409.1489. 
	
p‐[N’,	N’’‐Di(Boc)guanidino]benzylalcohol	(5)	
	N,N′-Di(Boc)-S-methylisothiourea (4.03 g, 13.9 mmol, 1 equiv) and p-
aminobenzylalcohol (2.56 g, 20.8 mmol, 1.5 equiv) were dissolved in 
dry THF (80 mL) and this mixture was cooled to 0 °C before HgCl2 
(4.14 g, 15.3 mmol, 1.1 equiv) was added. After stirring for 20 min 
under argon, the temperature was raised to room temperature and 
the mixture was stirred for 20 h. The reaction mixture was diluted with CH2Cl2, filtered and the 
filtrate was concentrated under reduced pressure. The remaining solid was purified by column 
chromatography (EtOAc/heptane 1:2) to afford 5 (2.384 g, 65%) as an off-white solid. Rf	0.35 
(EtOAc/heptane 1:2). Mp point 25.0 °C. IR (film) 3287, 3261, 2978, 2928, 1719, 1629, 1605, 
1563, 1408, 1368, 1337, 1235, 1150, 1118, 1100, 1057, 1028 cm−1. 1H NMR (CDCl3, 400 MHz): δ 
11.63 (s, NH), 10.33 (s, NH), 7.60-7.55 (m, 2H), 7.33-7.28 (m, 2H), 4.63 (s, 2H), 1.53 (s, 9H), 1.50 
(s, 9H). 13C NMR (CDCl3, 75 MHz): δ 163.1, 153.1, 152.8, 136.9, 135.7, 128.0, 127.1, 121.9, 83.3, 
79.2, 64.5, 27.6. HRMS (ESI) m/z calcd for C18H28N3O5 (M+H)+: 366.2029, found: 366.2006. 
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Nα‐Cbz‐Glycine	p‐[N’,N’’‐di(Boc)guanidino]benzyl	ester	(6G)	
General procedure A2 using Z-Gly-OH (1,47 g, 7.01 mmol), 5 
(1.83 g, 5.02 mmol), DMAP (124 mg, 1.02 mmol) and DCC 
(1.45 g, 7.02 mmol). The product was obtained as an oil 
after purification by column chromatography 
(EtOAc/heptane 1:3) (2.72 g, 97%). Rf	0.25 (EtOAc/heptane 
1:3). IR (film) 3283, 3257, 2976, 2933, 1718, 1634, 1605, 
1558, 1517, 1409, 1368, 1338, 1300, 1236, 1150, 1118, 1100, 1056, 1028 cm−1. 1H-NMR (CDCl3 , 
400 MHz): δ 11.63 (s, NH), 10.36 (s, NH), 7.63-7.57 (m, 2H), 7.38-7.28 (m, 7H), 5.27(t, J = 5.6, 
NH), 5.13 (ds, 4H), 4.01 (d, J = 5.6 Hz, 2H), 1.54 (s, 9H), 1.51 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 
169.8, 163.4, 156.2, 153.5, 153.3, 137.1, 136.2, 131.2, 129.2, 128.5, 128.2, 128.1, 122.2, 83.8, 
79.7, 67.1, 66.8, 42.8, 28.1. HRMS (ESI) m/z calcd for C28H37N4O8 (M+H)+: 557.2611, found: 
557.2607.  
	
Nα‐Cbz‐Glycine	p‐guanidinobenzyl	ester	(Z‐Gly‐OGb)	
General procedure B2 using 6G (900 mg, 1.62 mmol). The 
product was obtained as oily TFA salt (734 mg, quant). IR 
(film) 3503, 3355, 3179, 1779, 1743, 1725, 1690, 1675, 
1640, 1516, 1453, 1409, 1361, 1282, 1256, 1191, 1173, 
1051, 1003 cm−1. 1H NMR (CD3OD, 400 MHz): δ 7.50-7.45 
(m, 2H), 7.38-7.29 (m, 5H), 7.29-7.25 (m, 2H), 5.21 (s, 2H), 
5.10 (s, 2H), 3.91 (s, 2H). 13C NMR (CD3OD, 75 MHz): δ 171.7, 161.7, 161.2, 159.2, 137.0, 136.1, 
130.8, 129.5, 129.1, 128.8, 126.6, 67.8, 67.0, 43.5. HRMS (ESI) m/z calcd for C18H21N4O4 (M+H)+: 
357.1563, found: 357.1557.  
 
Nα‐Cbz‐L‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6A)	
General procedure A2 using Z-L-Ala-OH (295 mg, 1.32 
mmol), 5 (345 mg, 0.94 mmol), DMAP (23 mg, 0.19 mmol) 
and DCC (275 mg, 1.33 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:2) (533 mg, 99%). Rf 0.45 
(EtOAc/heptane 1:2). Mp 45.2 °C. []20D 2.97 (c 2.12, 
CH2Cl2). IR (film) 3285, 3259, 2979, 2930, 1717, 1635, 1605, 1561, 1517, 1453, 1409, 1367, 
1333, 1301, 1235, 1150, 1121, 1100, 1057, 1028 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, 
NH), 10.37 (s, NH), 7.63-7.57 (m, 2H), 7.38-7.27 (m, 7H), 5.31 (d, J = 7.7 Hz, NH), 5.18-5.06 (m, 
2H), 5.11 (s, 2H), 4.42 (dq, J = 7.3, 7.4 Hz, 1H), 1.54 (s, 9H), 1.51 (s, 9H), 1.41 (d, J = 7.2 Hz, 1H) . 
13C NMR (CDCl3, 75 MHz): δ 172.7, 163.5, 155.5, 153.4, 153.3, 137.0, 136.3, 131.5, 129.0, 128.5, 
128.1, 128.0, 122.1, 83.8, 79.7, 66.9, 66.8, 49.7, 28.2, 28.1, 18.7. HRMS (ESI) m/z calcd for 
C29H39N4O8 (M+H)+: 571.2768, found: 571.2755. 
 
Nα‐Cbz‐L‐Alanine	p‐guanidinobenyl	ester	(Z‐L‐Ala‐OGb)	
General procedure B2 using 6A (290 mg, 0.51 mmol). The 
product was obtained as a sticky oil (quant). []20D 7.8 (c 
1.28, MeOH). IR (film) 3343, 3174, 1783, 1673, 1610, 1580, 
1531, 1517, 1454, 1340, 1299, 1258, 1199, 1174, 1140, 
1070 cm−1. 1H NMR (CDCl3, 400 MHz): δ 9.49 (s, NH), 8.61 
(br s, 2NH), 7.46-7.22 (m, 7H), 7.22-7.12 (m, 2H), 6.86 (br s, 3NH), 5.40 (d, J = 7.7 Hz, NH), 5.25-
5.01 (m, 4H), 4.42-4.30 (m, 1H), 1.43 (d, J = 7.2 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 172.9, 
161.3, 160.7, 156.3, 135.7, 133.6, 129.9, 128.6, 128.4, 127.9, 125.7, 67.4, 66.2, 49.8, 30.9, 18.0. 
HRMS (ESI) m/z calcd for C19H22N4O4 (M+H)+: 371. 1719, found: 371.1695. 
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Nα‐Cbz‐D‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6a)	
General procedure A2 using Z-D-Ala-OH (313 mg, 1.40 
mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:2) (524 mg, 92%). Rf 0.40 
(EtOAc/heptane 1:2). Mp 47.9 °C. []20D +3.0 (c 2.06, CH2Cl2). 
IR (film) 3281, 3255, 2979, 2937, 1717, 1635, 1606, 1561, 1517, 1410, 1367, 1338, 1301, 1235, 
1150, 1121, 1100, 1057, 1028 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, NH), 10.36 (s, NH), 
7.64-7.58 (m, 2H), 7.38-7.27 (m, 7H), 5.32 (d, J = 7.5 Hz, NH), 5.18-5.06 (m, 2H) 5.11 (s, 2H), 
4.42 (dq, J = 7.2, 7.4 Hz, 1H), 1.54 (s, 9H), 1.51 (s, 9H), 1.40 (d, J = 7.2 Hz, 3H). 13C NMR (CDCl3, 75 
MHz): δ 172.7, 163.4, 155.5, 153.4, 153.3, 137.0, 131.5, 129.0, 128.5, 128.1, 128.0, 122.1, 83.8, 
79.7, 66.9, 66.8, 49.7, 28.2, 28.1, 18.7. HRMS (ESI) m/z calcd for C29H39N4O8 (M+H)+: 571.2768, 
found: 571.2756. 
 
Nα‐Cbz‐D‐Alanine	p‐guanidinobenyl	ester	(Z‐D‐Ala‐OGb)	
General procedure B2 using 6a (100 mg). The product was 
obtained as a sticky oil (quant). []20D +6.1 (c 0.86, MeOH). 
IR (film) 3345, 3188, 1783, 1673, 1601, 1580, 1517, 1454, 
1341, 1295, 1256, 1200, 1168, 1139, 1071 cm−1. 1H NMR 
(CD3CN, 400 MHz): δ 9.39 (s, NH), 7.48-7.42 (m, 2H), 7.41-
7.29 (m, 5H), 7.29-7.22 (m, 2H), 6.75 (br s, 3NH), 6.03 (d, J = 7.6 Hz, NH), 5.16 (s, 2H), 5.06 (s, 
2H) 4.26 (dq, J = 7.3, 7.4 Hz, 1H), 1.37 (d, J = 7.3 Hz, 3H). 13C NMR (CD3CN, 75 MHz): δ 173.8, 
157.7, 136.7, 135.3, 130.3, 129.4, 128.9, 128.7, 126.6, 67.1, 66.6, 50.8, 17.7. HRMS (ESI) m/z 
calcd for C19H22N4O4 (M+H)+: 371. 1719, found: 371.1709. 
 
Nα‐Cbz‐β‐Alanine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6A)	
General procedure A2; using Z-β-Ala-OH (313 mg, 1.40 
mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 
mmol) and DCC (289 mg, 1.40 mmol). The product was 
obtained as a white solid after purification by column 
chromatography (EtOAc/heptane 1:2) (516 mg, 93%). Rf 
0.45 (EtOAc/heptane 1:2). Mp 25 °C. IR (film) 3291, 3265, 
2978, 2937, 1717, 1634, 1605, 1560, 1517, 1409, 1367, 1338, 1301, 1234, 1149, 1121, 1100, 
1057, 1027 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, NH), 10.35 (s, NH), 7.62-7.57 (m, 2H), 
7.38-7.27 (m, 7H), 5.29 (br s, NH), 5.09 (s, 2H), 5.07 (s, 2H), 3.47 (dt, J	= 6.0, 6.1 Hz, 2H), 2.57 (t, J 
= 6.0 Hz, 2H), 1.54 (s, 9H), 1.50 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 172.0, 163.4, 156.2, 153.4, 
153.2, 136.9, 136.4, 131.8, 129.0, 128.5, 128.1, 128.0, 122.2, 83.8, 79.7, 66.6, 66.1, 36.5, 34.4, 
28.1, 28.0. HRMS (ESI) m/z calcd for C29H39N4O8 (M+H)+: 571.2768, found: 571.2789. 
 
Nα‐Cbz‐‐Alanine	p‐guanidinobenyl	ester	(Z‐β‐Ala‐OGb)		
General procedure B2 using 6A (100 mg). The product 
was obtained as a sticky oil (quant). IR (film) 3330, 3175, 
3062, 2946, 1754, 1701, 1672, 1629, 1588, 1508, 1455, 
1257, 1200, 1166, 1065, 1014 cm−1. 1H NMR (CD3CN, 400 
MHz): δ 9.46 (s, NH), 7.49-7.42 (m, 2H), 7.39-7.21 (m, 
7H), 6.79 (br s, 4NH), 5.74 (br s, NH), 5.11 (s, 2H), 5.03 
(s, 2H), 3.37 (dt, J = 6.3, 6.5 Hz, 2H), 2.55 (t, J = 6.6 Hz, 2H). 13C NMR (CD3CN, 75 MHz): δ 171.4, 
158.1, 157.3, 150.8, 132.8, 129.4, 128.8, 128.6, 128.0, 124.3, 66.9, 37.5, 35.5. HRMS (ESI) m/z 
calcd for C19H23N4O4 (M+H)+: 371.1719, found: 371.1700. 
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Nα‐Cbz‐L‐Aspartate(OtBu)	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6D)		
General procedure A2 using Z-L-Asn(OtBu)-OH (453 mg, 
1.40 mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 
mmol) and DCC (289 mg, 1.40 mmol). The product was 
obtained as a white solid after purification by column 
chromatography (EtOAc/heptane 1:2) (599 mg, 89%). Rf 
0.55 (EtOAc/heptane 1:2). Mp 46.6 °C. []20D +7.3 (c 2.08, 
CH2Cl2). IR (film) 3447, 3417, 3287, 3252, 2977, 2932, 
1719, 1636, 1606, 1561, 1504, 1454, 1410, 1367, 1337, 1300, 1234, 1149, 1122, 1100, 1057, 
1027 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, NH), 10.35 (s, NH), 7.62-7.57 (m, 2H), 7.38-
7.25 (m, 7H), 5.75 (d, J = 8.6 Hz, NH), 5.18-5.08 (m, 2H), 5.12 (s, 2H), 4.61 (dt, J = 4.5, 8.7, 1H), 
2.94 (dd, J = 4.6, 17.0, 1H), 2.75 (dd, J = 4.5, 17.0, 1H), 1.54 (s, 9H), 1.50 (s, 9H), 1.40 (s, 9H). 13C 
NMR (CDCl3, 75 MHz): δ 170.7, 169.9, 163.5, 156.0, 153.4, 153.3, 137.0, 131.4, 129.0, 128.5, 
128.1, 128.0, 122.1, 83.8, 81.8, 79.7, 67.1, 50.6, 37.7, 28.2, 28.1, 28.0. HRMS (ESI) m/z calcd for 
C34H47N4O10 (M+H)+: 671.3292, found: 671.3251. 
 
Nα‐Cbz‐L‐Aspartate	p‐guanidinobenyl	ester	(Z‐L‐Asp‐OGb)		
General procedure B2 using 6D (150 mg). The product was 
obtained as a sticky oil (quant). []20D 5.7 (c 0.38, MeOH). 
IR (film) 3331, 3179, 3032, 2935, 2850, 1689, 1580, 1517, 
1454, 1411, 1368, 1339, 1260, 1200, 1140, 1064 cm−1. 1H 
NMR (CD3CN, 400 MHz): δ 9.46 (s, NH), 7.46-7.40 (m, 2H), 
7.40-7.29 (m, 5H), 7.27-7.22 (m, 2H), 6.78 (br s, 3NH), 6.15 
(d, J = 8.7, NH), 5.16 (s, 2H), 5.10 (d, J = 12.6 Hz, 1H), 5.06 (d, J = 12.5 Hz, 1H), 4.58 (dt, J = 5.8, 
8.6 Hz, 1H), 2.90-2.79 (m, 2H). 13C NMR (CD3CN, 75 MHz): δ 172.2, 171.8, 157.7, 136.4, 135.3, 
130.3, 129.4, 128.9, 128.7, 126.6, 67.3, 67.0, 51.6, 36.5. HRMS (ESI) m/z calcd for C20H23N4O6 
(M+H)+: 415.1618, found: 415.1615. 
 
Nα‐Cbz‐L‐Glutamine(Trt)	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6Q)		
General procedure A2 using Z-L-Glu(Trt)-OH (731 mg, 1.40 
mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:2) (864 mg, 99%). Rf 0.352 
(EtOAc/heptane 1:2). Mp 157.2 °C. []20D +3.4 (c 1.96, 
CH2Cl2). IR (film) 3408, 3264, 3062, 3032, 2949, 2924, 
1720, 1638, 1606, 1535, 1492, 1446, 1410, 1365, 1338, 1235, 1149, 1122, 1100, 1057 cm−1. 1H 
NMR (CDCl3, 300 MHz): δ 11.62 (s, NH), 10.34 (s, NH), 7.59-7.52 (m, 2H), 7.38-7.13 (m, 22H), 
6.78 (br s, NH), 5.57 (d, J = 7.6 Hz, NH), 5.14-5.02 (m, 2H), 5.09 (s, 2H), 4.41-4.31 (m, 1H), 2.46-
2.24 (m, 2H), 2.04-1.88 (m, 2H), 1.54 (s, 9H), 1.50 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 171.7, 
170.7, 163.4, 156.3, 153.4, 144.5, 137.1, 136.2, 131.4, 129.2, 128.7, 128.5, 128.1, 128.0, 83.8, 
79.7, 67.0, 66.9, 53.7, 35.4, 33.3, 28.1. HRMS (ESI) m/z calcd for C50H56N5O9 (M+H)+: 870.4078, 
found: 870.4043. 
 
Nα‐Cbz‐L‐Glutamine	p‐guanidinobenyl	ester	(Z‐L‐Gln‐OGb)		
General procedure B1 using 6Q (200 mg, 0.23 mmol) in the 
presence of triethylsilane (37 μL, 0.23 mmol). The product 
was obtained as a sticky oil (90 mg, 82%). []20D 6.3 (c 0.99, 
MeOH). IR (film) 3330, 3067, 3028, 2954, 1702, 1666, 1531, 
1453, 1413, 1341, 1215, 1056 cm−1. 1H NMR (DMSO-d6, 400 
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MHz): δ 10.09 (s, NH), 7.81 (d, J = 7.7 Hz, NH), 7.58 (br s, 4NH), 7.45-7.17 (m, 9H), 6.79 (br s, 
2NH), 5.18-4.99 (m, 2H), 4.13-4.05 (m, 1H), 2.16 (t, J = 7.4 Hz, 2H), 2.05-1.93 (m, 1H), 1.82-1.71 
(m, 1H). 13C NMR (DMSO-d6, 75 MHz): δ 173.2, 172.1, 156.1, 155.9, 136.8, 135.1, 133.8, 129.1, 
128.3, 127.8, 127.7, 124.1, 65.5, 65.3, 53.5, 30.9, 26.2. HRMS (ESI) m/z calcd for C21H26N5O5 
(M+H)+: 428.1934, found: 428.1922. 
 
Nα‐Cbz‐L‐Isoleucine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6I)		
General procedure A2 using Z-L-Ile-OH (372 mg, 1.40 
mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:2) (577 mg, 94%). Rf 0.55 
(EtOAc/heptane 1:2). Mp 46.0 °C. []20D +5.1 (c 2.02, CH2Cl2). 
IR (film) 3432, 3287, 3253, 2974, 2928, 1717, 1636, 1606, 1561, 1515, 1454, 1410, 1367, 1337, 
1301, 1233, 1150, 1122, 1099, 1057, 1028 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, NH), 
10.37 (s, NH), 7.64-7.58 (m, 2H), 7.40-7.27 (m, 7H), 5.27 (d, J = 8.8 Hz, NH), 5.15 (d, J = 12.2 Hz, 
1H), 5.11 (s, 2H), 5.08 (d, J = 12.2 Hz, 1H), 4.37 (dd, J = 4.7, 9.0 Hz, 1H), 1.93-1.84 (m, 1H), 1.54 
(s, 9H), 1.51 (s, 9H), 1.44-1.29 (m, 1H), 1.21-1.07 (m, 1H), 0.94-0.84 (m, 6H). 13C NMR (CDCl3, 75 
MHz): δ 171.8, 163.5, 156.1, 153.4, 153.3, 137.1, 136.3, 131.5, 129.2, 128.5, 128.3, 128.1, 128.0, 
122.1, 83.8, 79.7, 67.0, 66.6, 58.4, 38.1, 28.2, 28.1, 24.9, 15.5, 11.6. HRMS (ESI) m/z calcd for 
C32H45N4NaO8 (M+H)+: 613.3237, found: 613.3209. 
 
Nα‐Cbz‐L‐Isoleucine	p‐guanidinobenyl	ester	(Z‐L‐Ile‐OGb)  
General procedure B1 using 6I (270 mg). The product was 
obtained as a sticky oil (331 mg, quant). []20D +0.9 (c 2.10, 
MeOH). IR (film) 3347, 3179, 2967, 2932, 2889, 1779, 1674, 
1606, 1581, 1517, 1455, 1260, 1338, 1200, 1157, 1091, 
1042 cm−1. 1H NMR (CD3CN, 400 MHz): δ 9.05 (s, NH), 7.49-
7.43 (m, 2H), 7.40-7.29 (m, 5H), 7.28-7.22 (m, 2H), 6.62 (br s, 3NH), 5.98 (d, J = 8.6 Hz, NH), 5.17 
(s, 2H), 5.07 (s, 2H), 4.18 (dd J = 5.9, 8.6 Hz, 1H), 1.91-1.81 (m, 1H), 1.48-1.37 (m, 1H), 1.26-1.11 
(m, 1H), 0.90 (d, J = 6.9 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR (CD3CN, 75 MHz): δ 172.7, 
160.5, 160.0, 157.6, 136.7, 135.1, 130.5, 129.4, 128.9, 128.6, 126.7, 67.2, 66.5, 59.9, 37.9, 25.8, 
15.9, 11.6. HRMS (ESI) m/z calcd for C22H29N4O4 (M+H)+: 413.2189, found: 413.2197. 
 
Nα‐Cbz‐L‐Lysine(Boc)	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6K)		
General procedure A2 using Z-L-Lys(Boc)-OH (1028 mg, 
2.70 mmol), 5 (703 mg, 1.92 mmol), DMAP (48 mg, 0.39 
mmol) and DCC (558 mg, 2.70 mmol). The product was 
obtained as a white solid after purification by column 
chromatography (EtOAc/heptane 1:3) (1.26 g, 90%). Rf 0.60 
(EtOAc/heptane 1:2). Mp 50.7 °C. []20D 3.8 (c 1.96, CH2Cl2). 
IR (film) 3291, 3257, 2975, 2928, 2860, 2245, 1714, 1631, 
1605, 1516, 1410, 1366, 1338, 1301, 1238, 1152, 1057, 1121, 1100, 1057 cm−1. 1H NMR (CDCl3, 
400 MHz): δ 11.62 (s, NH), 10.36 (s, NH), 7.62-7.56 (m, 2H), 7.38-7.27 (m, 7H), 5.37 (d, J = 7.5 Hz, 
NH), 5.15 (d, J = 12.2 Hz, 1H), 5.10 (s, 2H), 5.07 (d, J = 12.0 Hz, 1H), 4.58 (br s, NH), 4.42-4.34 (m, 
1H), 3.12-2.98 (m, 2H), 1.89-1.75 (m, 2H), 1.73-1.59 (m, 2H), 1.54 (s, 9H), 1.50 (s, 9H), 1.42 (s, 
9H), 1.39-1.21 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ 172.2, 163.5, 156.0, 153.5, 153.3, 137.1, 
131.5, 129.2, 128.5, 128.1, 122.2, 83.8, 79.7, 66.8, 53.8, 40.0, 32.2, 29.5, 28.4, 28.2, 28.1, 22.3. 
HRMS (ESI) m/z calcd for C37H54N5O10 (M+H)+: 728.3871, found: 728.3856. 
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Nα‐Cbz‐L‐Lysine	p‐guanidinobenyl	ester	(Z‐L‐Lys‐OGb)		
General procedure B1 using 6K (500 mg, 0.69 mmol). The 
product was obtained as a sticky oil (221 mg, 65%). []20D
5.5 (c 1.32, MeOH). IR (film) 3321, 3144, 3032, 2950, 
1705, 1671, 1631, 1605, 1579, 1516, 1454, 1395, 1338, 
1256, 1202, 1170, 1135, 1049, 1025 cm−1. 1H NMR 
(CD3OD, 400 MHz): δ 7.49-7.44 (m, 2H), 7.37-7.24 (m, 7H), 
5.23 (d, J = 12.7 Hz, 1H) 5.18 (d, J = 12.6 Hz, 1H), 5.11 (d, J 
= 12.6 Hz, 1H), 5.07 (d, J = 12.4 Hz, 1H), 4.22 (dd, J = 4.8, 9.6 Hz, 1H), 2.96-2.83 (m, 2H), 1.95-
1.84 (m, 1H), 1.79-1.59 (m, 3H), 1.57-1.41 (m, 2H). 13C NMR (CD3OD, 75 MHz): δ 173.7, 158.8, 
136.9, 136.1, 130.8, 129.5, 129.1, 128.9, 126.5, 67.7, 67.2, 55.4, 40.6, 32.0, 28.0, 24.0. HRMS 
(ESI) m/z calcd for C22H30N5O4 (M+H)+: 428.2298, found: 428.2286. 
 
Nα‐Cbz‐L‐Phenylalanine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6F)		
General procedure A1 using Z-L-Phe-OH (419 mg, 1.40 
mmol), 5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) 
and DCC (289 mg, 1.40 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:51:2) (352 mg, 54%). Rf 0.20 
(EtOAc/heptane 1:5). []20D +1.4 (c 1.97, CH2Cl2). IR (film) 
3417, 3261, 2979, 2928, 1711, 1640, 1625, 1603, 1505, 1409, 1392, 1304, 1236, 1150, 1056 
cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.64 (s, NH), 10.36 (s, NH), 7.65-7.56 (m, 2H), 7.41-7.17 (m, 
10H), 7.07-6.98 (m, 2H), 5.26 (d, J	= 7.9 Hz, NH), 5.15-5.01 (m, 2H), 5.08 (s, 2H), 4.76-4.63 (m, 
1H), 3.17-3.01 (m, 2H), 1.54 (s, 9H), 1.51 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 171.2, 163.4, 
155.5, 153.4, 153.2, 137.0, 136.2, 135.5, 131.2, 129.3, 129.2, 128.5, 128.4, 128.1, 128.0, 122.1, 
83.7, 79.6, 66.9, 66.8, 54.8, 38.1, 28.1, 28.0. HRMS (ESI) m/z calcd for C35H43N4O8 (M+H)+: 
647.3081, found: 647.3075. 
	
Nα‐Cbz‐L‐Phenylalanine	p‐guanidinobenyl	ester	(Z‐L‐Phe‐OGb)		
General procedure B1 using 6F (103 mg). The product was 
obtained as a sticky oil (110 mg, quant). []20D 1.8 (c 1.01, 
MeOH). IR (film) 3417, 3365, 3257, 2980, 1710, 1625, 1602, 
1506, 1409, 1341, 1304, 1234, 1151, 1121, 1055 cm−1. 1H 
NMR (CDCl3, 300 MHz): δ 9.90 (br s, NH), 7.38-7.01 (m, 
14H), 5.37 (d, J = 7.5 Hz, NH), 5.17-4.94 (m, 4H), 4.69-4.57 
(m, 1H), 3.15-3.01 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ 173.3, 158.4, 158.1, 138.2, 136.8, 130.8, 
130.2, 129.6, 129.5, 129.0, 128.7, 127.9, 126.5, 67.6, 67.2, 57.2, 38.6. HRMS (ESI) m/z calcd for 
C25H27N4O4 (M+H)+: 447.2032, found: 447.2049. 
 
Nα‐Cbz‐D‐Phenylalanine	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6f)		
General procedure A2 using Z-D-Phe-OH (421 mg, 1.41 
mmol), 5 (365 mg, 1.00 mmol), DMAP (28 mg, 0.23 mmol) 
and DCC (290 mg, 1.41 mmol). The product was obtained as 
a white solid after purification by column chromatography 
(EtOAc/heptane 1:3) (567 mg, 88%). Rf 0.60 
(EtOAc/heptane 1:2). Mp 132.2 °C. []20D 2.4 (c 2.07, 
CH2Cl2). IR (film) 3278, 3265, 2971, 2928, 1717, 1633, 1605, 1563, 1515, 1411, 1368, 1340, 
1301, 1237, 1151, 1122, 1100, 1057, 1028 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.63 (s, NH), 
10.37 (s, NH), 7.63-7.57 (m, 2H), 7.39-7.29 (m, 5H), 7.25-7.20 (m, 5H), 7.06-6.99 (m, 2H), 5.21 
(d, J	= 7.9 Hz, NH), 5.14-5.01 (m, 2H), 5.10 (s, 2H), 4.69 (dt, J	= 5.9, 14.0 Hz, 1H), 3.16-3.03 (m, 
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2H), 1.54 (s, 9H), 1.51 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 171.3, 163.5, 155.6, 153.5, 153.3, 
137.1, 136.2, 135.5, 131.2, 129.3, 128.6, 128.5, 128.2, 128.1, 127.1, 122.2, 83.8, 79.7, 66.9, 66.8, 
54.8, 38.2, 28.2, 28.1. HRMS (ESI) m/z calcd for C35H43N4O8 (M+H)+: 647.3081, found: 647.3064. 
	
Nα‐Cbz‐D‐Phenylalanine	p‐guanidinobenyl	ester	(Z‐D‐Phe‐OGb)		
General procedure B2 using 6f (175 mg). The product was 
obtained as a sticky oil (150 mg, quant). []20D 1.5 (c 1.45, 
MeOH). IR (film) 3322, 3179, 3032, 2937, 2855, 1673, 
1602, 1517, 1453, 1429, 1344, 1259, 1200, 1182, 1082, 
1056, 1022 cm−1. 1H NMR (CD3OD, 400 MHz): δ 7.41-7.36 
(m, 2H), 7.35-7.16 (m, 12H), 5.18 (d, J = 12.5 Hz, 1H), 5.12 
(d, J = 12.6 Hz, 1H), 5.04 (s, 2H), 4.49-4.43 (m, 1H), 3.14 (dd, J = 6.0, 13.9 Hz, 1H), 2.97 (dd, J = 
9.0, 13.8 Hz, 1H) . 13C NMR (CD3OD, 75 MHz): δ 173.3, 161.5, 161.0, 138.2, 136.8, 136.1, 130.8, 
130.3, 129.6, 129.5, 129.0, 128.7, 127.9, 126.5, 67.6, 67.2, 57.2, 38.6. HRMS (ESI) m/z calcd for 
C25H27N4O4 (M+H)+: 447.2032, found: 447.2017. 
 
Nα‐Cbz‐L‐Proline	p‐[N’,N’’‐di(Boc)guanidino]benyl	ester	(6P)		
General procedure A1 using Z-L-Pro-OH (349 mg, 1.40 mmol), 
5 (365 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC 
(289 mg, 1.40 mmol). The product was obtained as a white 
solid after purification by column chromatography (MeOH in 
CH2Cl2, 12.5%) (495 mg, 83%). Rf 0.45 (5% MeOH in 
CH2Cl2). []20D 30.8 (c 2.00, CH2Cl2). IR (film) 3257, 2977, 
2872, 1710, 1634, 1605, 1410, 1341, 1301, 1235, 1150, 1120, 1100, 1057 cm−1. 1H NMR (CDCl3, 
300 MHz): δ 11.63 (s, NH), 10.36 (s, 0.5NH), 10.34 (s, 0.5NH), 7.63-7.50 (m, 2H), 7.42-7.24 (m, 
6H), 7.21-7.13 (m, 1H), 5.24-4.89 (m, 4H), 4.43 (dd, J = 3.4, 8.6 Hz, 0.5H), 4.32 (dd, J = 3.4, 8.6 Hz, 
0.5H), 3.69-3.41 (m, 2H), 2.30-2.11 (m, 1H), 2.05-1.80 (m, 3H), 1.54 (s, 9H), 1.51 (s, 9H). 13C 
NMR (CDCl3, 75 MHz): δ 172.5, 172.3, 163.3, 154.8, 154.2, 153.4, 153.2, 136.7, 136.6, 136.5, 
132.0, 131.8, 128.8, 128.3, 127.8, 127.7, 127.7, 122.1, 83.7, 79.7, 66.9, 66.3, 66.2, 59.2, 58.8, 46.8, 
46.3, 30.8, 29.7, 28.1, 28.0, 24.2, 23.4. HRMS (ESI) m/z calcd for C31H41N4O8 (M+H)+: 597.2924, 
found: 597.2924. 
	
Nα‐Cbz‐L‐Proline	p‐guanidinobenyl	ester	(Z‐L‐Pro‐OGb)		
General procedure B2 using 6P (103 mg). The product was 
obtained as a sticky oil (108 mg, quant). []20D 24.0 (c 1.06, 
MeOH). IR (film) 3329, 3166, 2967, 2281, 1745, 1680, 1597, 
1576, 1517, 1425, 1354, 1273, 1201, 1174, 1133, 1089 cm−1. 
1H NMR (CD3OD, 400 MHz): δ 7.48-7.45 (m, 1H), 7.38-7.24 
(m, 7H), 7.23-7.18 (m, 1H), 5.23 (d, J = 12.6 Hz, 0.5H), 5.18 (d, J = 12.3 Hz, 0.5H), 5.13 (d, J = 2.2 
Hz, 1H), 5.10 (d, J = 12.6 Hz, 0.5H), 5.08 (d, J = 12.5 Hz, 0.5H), 5.04 (d, J = 12.7 Hz, 0.5H), 5.03 (d, 
J = 12.5 Hz, 0.5H), 4.43 (dd, J = 3.9, 8.8 Hz, 0.5H), 4.39 (dd, J = 3.7, 8.7 Hz, 0.5H), 3.62-3.46 (m, 
2H), 2.37-2.26 (m, 1H), 2.06-1.88 (m, 3H). 13C NMR (CD3OD, 75 MHz): δ 174.2, 174.0, 138.1, 
137.9, 137.0, 136.7, 136.1, 130.7, 129.6, 129.2, 128.8, 126.6, 126.4, 68.3, 67.1, 60.8, 60.4, 31.8, 
30.9, 25.3, 24.5, 19.2, 18.4. HRMS (ESI) m/z calcd for C21H25N4O4 (M+H)+: 397.1876, found: 
397.1856. 
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p‐[N’,	N’’‐Di(Boc)guanidino]aniline	(8)	
 N,N′-di(Boc)-S-methylisothiourea (2.90 g, 10.0 mmol, 1 equiv) and 1,4-
diaminobenzene (3.24 g, 30.0 mmol, 3 equiv) were dissolved in dry 
THF (50 mL) and this mixture was cooled to 0 °C before HgCl2 (2.99 g, 
11.0 mmol, 1.1 equiv) was added. After stirring for 20 min under argon, 
the temperature was raised to room temperature and the mixture was 
stirred for 20 h. The white precipitate that was formed during the reaction was filtered off and 
the filtrate was concentrated under reduced pressure. The remaining solid was purified by 
column chromatography (EtOAc/heptane 1:2) to afford 8 (1.93 g, 55%) as an off-white solid. Rf 
0.31( EtOAc/heptane 1:2). Mp dec at > 300 °C. IR (film) 3430, 3339, 3257, 2976, 1717, 1635, 
1621, 1601, 1408, 1332, 1151, 1106, 1061, 610 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.63 (s, NH), 
10.09 (s, NH), 7.37-7.31 (m, 2H), 6.67-6.61 (m, 2H), 3.59 (br s, 2NH), 1.53 (s, 9H), 1.49 (s, 9H). 
13C NMR (CDCl3, 75 MHz): δ 163.7, 153.6, 143.7, 128.0, 124.0, 115.3, 83.4, 79.3, 28.2, 28.1. HRMS 
(ESI) m/z calcd for C17H27N4O4 (M+H)+: 351.2032, found: 351.2039. Spectral data were in 
accordance with those reported in literature.[10] 
 
Nα‐Cbz‐Glycine	p‐[N’,N’’‐di(Boc)guanidino]anilide	(9G)	
General procedure A1 using Z-Gly-OH (146 mg, 0.70 mmol), 8 
(175 mg, 0.50 mmol), DMAP (12 mg, 0.1 mmol) and DCC (144 
mg, 0.70 mmol). The product was obtained as a white solid 
after purification by column chromatography (2% MeOH in 
CH2Cl2) (282 mg, quant). Rf 0.27 (2% MeOH in CH2Cl2). Mp 
121 °C. IR (film) 3283, 2980, 2928, 1718, 1640, 1515, 1409, 1232, 1152, 1057 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 11.61 (s, NH), 10.26 (s, NH), 7.97 (br s, NH), 7.52-7.45 (m, 2H), 7.44-7.32 
(m, 7H), 5.45 (br s, NH), 5.17 (s, 2H), 3.96 (d, J = 5.8 Hz, 2H), 1.54 (s, 9H), 1.48 (s, 9H). 13C NMR 
(CDCl3, 75 MHz): δ 166.7, 163.3, 154.6, 153.2, 136.1, 135.1, 132.4, 128.6, 128.3, 128.1, 124.0, 
120.3, 83.9, 79.8, 67.3, 45.1, 28.2, 28.1. HRMS (ESI) m/z calcd for C27H35N5NaO7 (M+Na)+: 
564.2434, found: 564.2441. 
	
Nα‐Cbz‐Glycine	p‐guanidino	anilide	(Z‐Gly‐NGp)	
General procedure B1 using 9G (100 mg, 0.185 mmol). The 
product was obtained as an amorphous solid (69.8 mg, 
quant). IR (film) 3365, 2920, 2846, 1668, 1614, 1515, 1455, 
1260, 1053, 699 cm−1. 1H NMR (CD3OD, 300 MHz): δ 7.72-7.62 
(m, 2H), 7.42-7.20 (m, 7H), 5.12 (s, 2H), 3.95 (s, 2H). 13C NMR 
(CD3OD, 75 MHz): δ 170.6, 158.3, 139.3, 131.6, 129.5, 129.1, 128.9, 127.5, 122.6, 67.9, 45.4. 
HRMS (ESI) m/z calcd for C17H20N5O3 (M+H)+: 342.1566, found: 342.1573. 
	
p‐Amidinobenzyl	alcohol·HCl	(12)	
Hydrochloric acid (g) was dried by guiding it through two washing 
bottles of conc. H2SO4. A cooled (0 °C) solution of p-
(hydroxymethyl)benzonitrile	(2.0 g, 15 mmol, 1 equiv) in abs. EtOH (10 
mL) was saturated with dry HCl (g). The resulting reaction mixture was 
kept at –20 °C for 48 hours to induce crystallization of the imidate·HCl 
salt. The clear crystals were filtered and immediately 10% NH3 in abs. EtOH (10 mL) was added 
in portions and stirred during 24 hours. The following 48 hours ammoniumchloride 
precipitated at room temperature. After filtration and in	vacuo evaporation, the crude product 
was dissolved in water and acidified with conc. HCl (aq). The pure product crystallized as a 
white solid, was filtered and further dried under high vacuum to afford 12·HCl (2.3 g, 80%). Rf 
0.0 (5% MeOH in CH2Cl2). IR (film) 3342, 3135, 3052, 2858, 1667, 1612, 1480, 1397, 1210, 
1162, 1051, 1009, 815, 705, 532 cm−1. 1H NMR (CD3OD, 300 MHz): δ 7.80 (d, J = 10.5 Hz, 2H), 
7.59 (d, J = 8.7 Hz, 2H), 4.73 (s, 2H). 13C NMR (CD3OD, 75 MHz): δ 150.1, 129.0, 128.3, 64.2. 
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HRMS (ESI) m/z calcd for C8H11N2O (M+H)+: 151.0871, found: 151.0871. Spectral data were in 
accordance with those reported in literature.[11] 
 
p‐[N’‐Boc‐amidino]benzyl	alcohol	(13)	
To a solution 12·HCl (111 mg, 0.6 mmol, 1.0 equiv) in MeOH (30 mL) and 
TEA (2 mL) was added di-tbutyl-dicarbonate (705 mg, 3.2 mmol, 5.4 
equiv) and the mixture was refluxed for 5 hours. The reaction mixture was 
evaporated to dryness and purified with column chromatography 
(EtOAc/heptane 1:13:1) to afford 13 (96 mg, 65%) as a white solid. Rf	
0.72 (EtOAc/heptane 3:1). IR (film) 3340, 3129, 3052, 2858, 1667, 1612, 1458, 1320, 1238, 
1162, 1044, 870, 746, 536 cm−1. 1H NMR (CD3OD, 300 MHz): δ 7.79 (d, J = 8.4 Hz, 2H), 7.44 (d, J 
= 8.7 Hz, 2H), 4.67 (s, 2H), 1.53 (s, 9H). 13C NMR (CD3OD, 75 MHz): δ 209.9, 149.8, 128.9, 127.8, 
64.6, 28.5. HRMS (ESI) m/z calcd for C13H19N2O3 (M+H)+: 251.1396, found: 251.393. 
	
Nα‐Cbz‐Glycine	p‐[N’‐Boc‐amidino]benzyl	ester	(14)	
General procedure A1 with adjusted amounts of every 
component using 13 (96 mg, 0.4 mmol, 1.0 equiv), DCC (106 mg, 
0.5 mmol, 1.2 equiv), DMAP (56 mg, 0.5 mmol, 1.2 equiv) and Z-
Gly-OH (100 mg, 0.5 mmol, 1.2 equiv). The product was obtained 
as a white solid after purification by column chromatography 
(EtOAc/heptane 1:1) (162 mg, 95%). Rf 0.28 (EtOAc/heptane 
1:1). IR (film) 3391, 2975, 2498, 1715, 1612, 1528, 1494, 1452, 1355, 1286, 1238, 1162, 1134, 
1044, 988, 878, 836, 746, 691 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.79 (d, J = 8.1 Hz, 2H), 7.27-
7.39 (m, 7H), 5.47 (t, J = 5.7 Hz, NH), 5.17 (s, 2H), 5.10 (s, 2H), 3.98 (d, J = 5.7 Hz, 2H), 1.54 (s, 
9H). 13C NMR (CD3OD, 75 MHz): δ 171.7, 159.1, 147.2, 141.3, 138.1, 136.0, 129.5, 129.3, 129.0, 
128.9, 128.8, 127.7, 80.5, 67.8, 67.0, 43.5. The product was contaminated with ~ 10% DCU 
according to NMR. HRMS (ESI) m/z calcd for C23H28N3O6 (M+H)+: 442.1978, found: 442.1979. 
	
Nα‐Cbz‐glycine	p‐amidinobenzyl	ester	(Z‐Gly‐OAb)	
To a suspension of 14	(89 mg, 0.2 mmol) in CH2Cl2 (1 mL) 
was added TFA (1 mL) resulting in a clear solution. After 
stirring for 2 hours the solvent was evaporated in	vacuo, the 
residue was co-evaporated with tBuOH (3 × 5 mL) and 
additionally dried under high vacuum to afford Z‐Gly‐
OAb·TFA (67 mg, 73%) as a white solid. Rf 0.0 (5% MeOH in 
CH2Cl2). IR (film) 3322, 2920, 2851, 1646, 1563, 1522, 1425, 1314, 1231, 1168, 1085, 885, 608, 
428 cm−1. 1H NMR (CD3OD, 300 MHz): δ 7.78 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.35-7.31 
(m, 5H), 5.30 (s, 2H), 5.11 (s, 2H), 3.96 (s, 2H). 13C NMR (CD3OD, 75 MHz): δ 210.1, 129.5, 129.4, 
129.2, 129.0, 128.8, 128.3, 67.8, 66.6, 64.2, 34.8, 30.7, 26.1. HRMS (ESI) m/z calcd for 
C18H20N3O4 (M+H)+: 342.1454, found: 342.1443. 
	
3‐[N’,N’’‐di(Boc)guanidino]‐propanol	(16)	
N,N′-Di(Boc)-S-methylisothiourea (2.90 g, 10.0 mmol, 1 equiv) and 
DMAP (1.83 mg, 15.0 mmol, 1.5 equiv) were dissolved in CH2Cl2 (20 mL) 
and this mixture was cooled to 0 °C before 3-aminopropanol (765 μl, 
10.0 mmol, 1 equiv) was added. After stirring for 10 min, the 
temperature was raised to room temperature and the mixture was 
stirred for 48 h. The reaction mixture was poured in citric acid (5%, 10 mL) and extracted with 
EtOAc (3 × 50 ml). The organic layers were combined and washed with saturated NaHCO3 (10 
mL) and brine (10 mL), dried over Na2SO4 and then evaporated to dryness. The remaining solid 
was purified by column chromatography (MeOH in CH2Cl2, 13%) to afford 16 (3.00 g, 95%) as 
an off-white solid. 1H NMR (CDCl3, 300 MHz): δ 11.46 (s, NH), 8.47 (s, NH), 4.77 (s, OH), 3.70-
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3.50 (m, 4H), 1.80-1.62 (m, 2H), 1.51 (s, 9H), 1.48 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 162.7, 
156.5, 152.9, 83.1, 79.2, 57.7, 36.8, 32.5, 28.0, 27.8. HRMS (ESI) m/z calcd for C14H27N3NaO5 
(M+Na)+: 340.1848, found: 340.1839. Spectral data were in accordance with those reported in 
literature.[12] 
	
Nα‐Cbz‐Glycine‐3‐[N’,N’’‐di(Boc)guanidino]‐propyl	ester	(17)	
General procedure A1 using Z-Gly-OH (586 mg, 2.80 mmol), 16 
(635 mg, 2.00 mmol), DMAP (49 mg, 0.20 mmol) and DCC (578 
mg, 2.80 mmol). The product was obtained as a solid after 
purification by column chromatography (MeOH in CH2Cl2, 
13%) (716 mg, 70%). Rf 0.37 (EtOAc/heptane 1:1). Mp 37 
°C. IR (film) 3326, 3278, 2976, 2928, 1719, 1638, 1615, 1326, 1157, 1134, 1052 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 11.51 (s, NH), 8.44 (t, J = 5.2 Hz, NH), 7.39-7.27 (m, 5H), 5.44 (t, J = 5.5 Hz, 
NH), 5.13 (s, 2H), 4.24 (t, J = 5.8 Hz, 2H), 4.03 (d, J = 5.7 Hz, 2H), 3.54 (dt, J = 5.2, 6.3 Hz, 2H), 1.93 
(tt, J = 6.2, 6.2 Hz, 2H), 1.50 (s, 9H), 1.49 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 170.0, 163.4, 156.3, 
156.1, 153.3, 136.3, 128.4, 128.1, 128.0, 83.2, 79.3, 67.0, 63.6, 42.8, 38.2, 28.2, 28.0, 27.9. HRMS 
(ESI) m/z calcd for C24H37N4O8 (M+H)+: 509.2611, found: 509.2598. 
	
Nα‐Cbz‐Glycine	3‐guanidinopropyl	ester	(Z‐Gly‐O3G)	
General procedure B2 using 17 (200 mg, 0.394 mmol). The 
product was obtained as a sticky oil (143 mg, quant). Rf 0.16 
(10% MeOH in CH2Cl2). IR (film) 3345, 3188, 2954, 1667, 
1530, 1199, 1135, 1055 cm−1. 1H NMR (CD3CN, 300 MHz): δ 
7.53 (br s, NH), 7.42-7.29 (m, 5H), 6.75 (br s, 3NH), 6.11 (br s, NH), 5.09 (s, 2H), 4.16 (t, J = 6.0 
Hz, 2H), 3.84 (d, J = 6.2 Hz, 2H), 3.16 (dt, J = 6.1, 6.5 Hz, 2H), 1.86 (tt, J = 6.3, 6.3 Hz, 2H). 13C NMR 
(CD3CN, 75 MHz): δ 171.2, 158.5, 157.9, 138.0, 129.4, 128.9, 128.7, 67.3, 63.1, 43.4, 39.2, 28.5. 
HRMS (ESI) m/z calcd for C14H20N4NaO4 (M+Na)+: 331.1382, found: 331.1378. 
 
4‐[N’,N’’‐di(Boc)guanidino]‐butanol	(19)	
N,N′-Di(Boc)-S-methylisothiourea (1.06 g, 3.64 mmol, 1 equiv) and 
DMAP (667 mg, 5.47 mmol, 1.5 equiv) were dissolved in CH2Cl2 (20 
mL) and this mixture was cooled to 0 °C before 4-aminobutanol (0.50 
mL, 3.64 mmol, 1 equiv) was added. After stirring for 10 min, the 
temperature was raised to room temperature and the mixture was 
stirred for 48 h. The reaction mixture was poured in citric acid (5%, 10 mL) and extracted with 
EtOAc (3 × 50 ml). The organic layers were combined and washed with saturated NaHCO3 (10 
mL) and brine (10 mL), dried over Na2SO4 and then evaporated to dryness. The remaining solid 
was purified by column chromatography (EtOAc/heptane 1:1) to afford 19 (943 mg, 78%) as an 
off-white solid. Rf	0.25 (EtOAc/heptane 1:1). Mp 119.2 °C. IR (film) 3330, 3278, 2976, 2933, 
1718, 1636, 1614, 1574, 1328, 1155, 1131, 1051, 1026 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.48 
(s, NH), 8.37 (s, NH), 3.69 (t, J = 5.6 Hz, 2H), 3.44 (dt, J = 6.0, 6.0 Hz, 2H), 2.00 (s, OH), 1.73-1.56 
(m, 4H), 1.49 (s, 18H). 13C NMR (CDCl3, 75 MHz): δ 163.5, 156.2, 153.3, 83.1, 79.3, 62.2, 40.3, 
29.5, 28.3, 28.1, 25.6. HRMS (ESI) m/z calcd for C15H30N3O5 (M+H)+: 332.2186, found: 332.2183. 
Spectral data were in accordance with those reported in literature.[12] 
 
Nα‐Cbz‐Glycine‐4‐[N’,N’’‐di(Boc)guanidino]‐butyl	ester	(20)	
General procedure A2 using Z-Gly-OH (147 mg, 0.703 
mmol), 19 (166 mg, 0.501 mmol), DMAP (12 mg, 0.10 
mmol) and DCC (144 mg, 0.701 mmol). The product was 
obtained as an oil after purification by column 
chromatography (EtOAc/heptane 1:2) (250 mg, 96%). Rf	
0.20 (EtOAc/heptane 1:2). IR (film) 3331, 2977, 2933, 1719, 1638, 1615, 1414, 1365, 1329, 
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1158, 1134, 1052, 1026 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.49 (s, NH), 8.32 (s, NH), 7.38-7.26 
(m, 5H), 5.36 (t, J = 5.5 Hz, NH), 5.13 (s, 2H), 4.18 (t, J = 6.1 Hz, 2H), 3.99 (d, J = 5.6 Hz, 2H), 3.44 
(dt, J = 6.6, 6.6 Hz, 2H), 1.76-1.58 (m, 4H), 1.50 (s, 9H), 1.49 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 
169.9, 163.6, 156.2, 153.3, 136.2, 128.5, 128.2, 128.1, 127.9, 83.2, 79.3, 67.0, 65.0, 42.8, 40.3, 
28.3, 28.1, 25.8, 25.7. HRMS (ESI) m/z calcd for C25H38Na1N4O8 (M+Na)+: 545.2587, found: 
545.2631. 
 
Nα‐Cbz‐Glycine	4‐guanidinobutyl	ester	(Z‐Gly‐O4G)	
General procedure B1 using 20 (185 mg, 0.354 mmol). The 
product was obtained as a sticky oil (127 mg, quant). 
IR (film) 3317, 3161, 2946, 1704, 1664, 1528, 1453, 1396, 
1362, 1279, 1261, 1196, 1053 cm−1. 1H NMR (CD3OD, 400 
MHz): δ 7.38-7.27 (m, 5H), 5.11 (s, 2H), 4.19 (t, J = 6.1 Hz, 
2H), 3.86 (s, 2H), 3.27-3.15 (m, 2H), 1.77-1.60 (m, 4H). 13C NMR (CD3OD, 75 MHz): δ 172.0, 
165.6, 158.7, 138.2, 129.5, 129.1, 128.8, 67.8, 65.6, 43.5, 42.1, 26.9, 26.5. HRMS (ESI) m/z calcd 
for C15H22NaN4O4 (M+Na)+: 345.1539, found: 345.1540. 
 
5‐[N’,N’’‐di(Boc)guanidino]‐pentanol	(22)	
	N,N′-Di-Boc-S-methylisothiourea (1.09 g, 3.78 mmol, 1 equiv) and 
DMAP (693 mg, 5.66 mmol, 1.5 equiv) were dissolved in CH2Cl2 (20 
mL) and this mixture was cooled to 0 °C before 5-aminopentanol 
(404 mg, 3.92 mmol, 1 equiv) was added. After stirring for 10 min, 
the temperature was raised to room temperature and the mixture 
was stirred for 48 h. The reaction mixture was poured in citric acid (5%, 10 mL) and extracted 
with EtOAc (3 × 50 ml). The organic layers were combined and washed with saturated NaHCO3 
(10 mL) and brine (10 mL), dried over Na2SO4 and then evaporated to dryness. The remaining 
solid was purified by column chromatography (EtOAc/heptane 1:1) to afford 22 (1.3 g, 99%) as 
an off-white solid. Rf	0.25 (EtOAc/heptane 1:1). Mp 93.7 °C. IR (film) 3326, 3283, 2976, 2933, 
1720, 1640, 1616, 1575, 1414, 1366, 1157, 1134, 1053 cm−1. 1H NMR (CDCl3 , 400 Mhz): δ 11.50 
(s, NH), 8.31 (s, NH), 3.65 (t, J = 6.5 Hz, 2H), 3.43 (dt, J = 5.3, 7.0 Hz, 2H), 1.67-1.56 (m, 4H), 1.50 
(s, 9H), 1.49 (s, 9H), 1.48-1.38 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ 163.6, 153.3, 83.1, 79.2, 
62.7, 40.7, 32.3, 28.8, 28.3, 28.0, 23.0. HRMS (ESI) m/z calcd for C16H31Na1N3O5 (M+Na)+: 
368.2161, found: 368.2172. Spectral data were in accordance with those reported in 
literature.[13] 
	
Nα‐Cbz‐Glycine	5‐[N’,N’’‐di(Boc)guanidino]pentyl	ester	(23)	
General procedure A2 using Z-Gly-OH (187 mg, 0.895 
mmol), 22	 (220 mg, 0.638 mmol), DMAP (15 mg, 0.123 
mmol) and DCC (184 mg, 0.895 mmol). The product was 
obtained as a white solid after purification by column 
chromatography (EtOAc/heptane 1:2) (344 mg, quant). 
Rf 0.30 (EtOAc/heptane 1:2). IR (film) 3331, 3278, 2980, 2934, 2863, 1718, 1637, 1615, 1413, 
1364, 1330, 1155, 1133, 1053, 1027 cm−1. 1H NMR (CDCl3, 400 MHz): δ 11.50 (s, NH), 8.32 (t, J = 
5.4 Hz, NH),	7.40-7.28 (m, 5H), 5.27 (t, J = 5.5 Hz, NH), 5.13 (s, 2H), 4.16 (t, J = 6.5 Hz, 2H), 3.98 
(d, J	= 5.6 Hz, 2H), 3.42 (dt, J = 5.4, 7.1 Hz, 2H), 1.73-1.53 (m, 4H), 1.50 (s, 9H), 1.49 (s, 9H), 1.46-
1.35 (m, 2H). 13C NMR (CD3OD, 75 MHz): δ 172.0, 164.5, 159.1, 157.6, 154.3, 138.2, 129.5, 129.2, 
129.0, 128.9, 128.7, 84.5, 80.5, 67.8, 66.1, 43.5, 41.7, 29.7, 29.3, 28.6, 28.5, 28.3, 24.2. HRMS 
(ESI) m/z calcd for C26H41N4O8 (M+H)+: 537.2924, found: 537.2933. 
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Nα‐Cbz‐Glycine	5‐guanidinopentyl	ester	(Z‐Gly‐O5G)	
General procedure B2. using 23 (195 mg, 0.364 mmol). 
The product was obtained as an oily TFA salt (192 mg, 
96%). IR (film) 3331, 2932, 2850, 1703, 1666, 1527, 
1454, 1406, 1349, 1277, 1260, 1204, 1054 cm−1. 1H NMR 
(CD3OD, 400 MHz): δ 7.38-7.27 (m, 5H), 5.11 (s, 2H), 4.17 (t, J	= 6.4 Hz, 2H), 3.85 (s, 2H), 3.16 (t, 
J	= 7.0 Hz, 2H), 1.75-1.53 (m, 4H), 1.49-1.38 (m, 2H). 13C NMR (CD3OD, 75 MHz): δ 170.2, 162.8, 
161.7, 136.5, 129.5, 129.1, 128.8, 67.8, 65.9, 43.4, 42.4, 29.4, 29.3, 24.0. HRMS (ESI) m/z calcd 
for C16H25N4O4 (M+H)+: 337.1876, found: 337.1891. 
 
4‐[N‐(Boc)amino]‐butanol	(25)		
Preparation according to literature procedure.[14] 4-Aminobutanol (510 
mg, 5.62 mmol, 1 equiv) and sulfamic acid (28 mg, 5 mol%) were 
dissolved in water (5 mL) and to this mixture di-tbutyl dicarbonate (1.30 g, 
1.1 equiv) was added in portions. After stirring for 1 h, MeOH was added and the reaction 
mixture was evaporated to dryness to afford 25 (1.14 g, quant) as an oily substance. Mp 25 °C. 
IR (film) 3353, 3278, 2980, 2934, 2868, 1682, 1528, 1424, 1365, 1273, 1250, 1167, 1041 cm−1. 
1H NMR (CD3OD, 400 MHz): δ 3.55 (t, J = 6.2 Hz, 2H), 3.05 (t, J = 6.6 Hz, 2H), 1.58-1.49 (m, 4H), 
1.43 (s, 9H). 13C NMR (CD3OD, 75 MHz): δ 158.7, 79.8, 62.7, 41.2, 30.9, 28.8, 27.5. HRMS (ESI) 
m/z calcd for C9H20N1O3 (M+H)+: 190.1443, found: 190.1438. Spectral data were in accordance 
with those reported in literature.[12] 
 
Nα‐Cbz‐Glycine	4‐[N‐(Boc)amino]butyl	ester	(26)	
General procedure A2 using Z-Gly-OH (301 mg, 1.44 mmol), 25 
(194 mg, 1.03 mmol), DMAP (26 mg, 0.210 mmol) and DCC (298 
mg, 1.45 mmol). The product was obtained as a white solid after 
purification by column chromatography (1% MeOH in CHCl2) 
(328 mg, 83%). Rf 0.82 (MeOH/CHCl2, 9:1). Mp 83.9 °C. IR (film) 3354, 2967, 2933, 1694, 1521, 
1454, 1365, 1277, 1251, 1169, 1134, 1054, 1002 cm−1. 1H NMR (CD3OD, 400 MHz): δ 7.37-7.29 
(m, 5H), 5.31 (br s, NH), 5.13 (s, 2H), 4.16 (t, J = 6.4 Hz, 2H), 3.97 (d, J = 5.6 Hz, 2H), 3.19-3.08 
(m, 2H), 1.72-1.48 (m, 4H), 1.43 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 169.9, 156.2, 155.9, 136.2, 
128.5, 128.2, 128.1, 79.2, 67.1, 65.1, 42.8, 40.1, 28.4, 26.6, 25.8. HRMS (ESI) m/z calcd for 
C19H29Na1N2O6 (M+Na)+: 403.1845, found: 403.1833. 
	
Nα‐Cbz‐Glycine	4‐aminobutyl	ester	(Z‐Gly‐O4A)	
 General procedure B1 using 26 (307 mg, 0.808 mmol) for the 
deprotection and 61 mg (0.155 mmol) for lyophilisation to give 
an off-white HCl salt (47 mg, 97%). Mp range 50.4 °C. IR (film) 
3061, 2949, 1678, 1529, 1277, 1201, 1135, 1055, 1005 cm−1. 1H 
NMR (CD3OD, 400 MHz): δ 7.39-7.27 (m, 5H), 5.11 (s, 2H), 4.19 (t, J = 5.7 Hz, 2H), 3.86 (s, 2H), 
2.94 (t, J = 7.0 Hz, 2H), 1.78-1.68 (m, 4H). 13C NMR (CD3OD, 75 MHz): δ 171.9, 159.2, 138.2, 
129.5, 129.1, 128.8, 67.8, 65.3, 43.4, 40.4, 26.7, 25.2. HRMS (ESI) m/z calcd for C14H21N2O4 
(M+H)+: 281.1501, found: 281.1486.  
 
5‐[N‐(Boc)amino]‐pentanol	(28)	
Preparation according to literature procedure.[14] 5-Aminopentanol 
(518 mg, 5.03 mmol, 1 equiv) and sulfamic acid (24 mg, 5 mol%) were 
dissolved in water (5 mL) and to this mixture di-tbutyl-dicarbonate 
(1.20 mg, 1.1 equiv) was added in portions. After stirring for 1 hour, MeOH was added and the 
reaction mixture was evaporated to dryness to afford 28 (1.02 g, 99%) as an oil. IR (film) 3334, 
2971, 2931, 2855, 1686, 1528, 1450, 1365, 1276, 1249, 1168, 1047, 1013 cm−1. 1H NMR 
(CD3OD, 400 MHz): δ 3.55 (t, J = 6.7 Hz, 2H), 3.03 (t, J = 7.0 Hz, 2H), 1.62-1.32 (m, 15H). 13C NMR 
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(CDCl3, 75 MHz): δ 156.1, 79.1, 62.6, 40.4, 32.2, 29.8, 28.4, 22.9. HRMS (ESI) m/z calcd for 
C10H21Na1N1O3 (M+Na)+: 226.1419, found: 226.1416. Spectral data were in accordance with 
those reported in literature.[15] 
	
Nα‐Cbz‐Glycine	5‐[N‐(Boc)amino]pentyl	ester	(29)		
General procedure A2 using Z-Gly-OH (295 mg, 1.41 mmol), 
28 (204 mg, 1.00 mmol), DMAP (25 mg, 0.205 mmol) and DCC 
(290 mg, 1.41 mmol). The product was obtained as a white 
solid after purification by column chromatography (1% MeOH 
in CHCl2 (251 mg, 64%). Rf	0.80 (MeOH/CHCl2, 9:1). Mp 51.3 °C. IR (film) 3354, 2976, 2934, 
2863, 1697, 1520, 1456, 1365, 1274, 1250, 1171, 1053, 998 cm−1. 1H NMR (CDCl3, 400 MHz): δ 
7.27-7.38 (m, 5H), 5.36, (br s, NH), 5.12 (s, 2H), 4.14 (t, J = 6.6 Hz, 2H), 3.96 (d, J = 5.6 Hz, 2H), 
3.15-3.05 (m, 2H), 1.72-1.56 (m, 2H), 1.54-1.40 (m, 11H), 1.40-1.30 (m, 2H). 13C NMR (CDCl3, 75 
MHz): δ 170.0, 156.2, 156.0, 136.2, 128.5, 128.2, 128.1, 79.1, 67.1, 65.3, 42.8, 40.3, 29.6, 28.4, 
28.1, 23.0. HRMS (ESI) m/z calcd for C20H31 Na1N2O6 (M+H)+: 417.2002, found: 417.1994. 
	
Nα‐Cbz‐Glycine	5‐aminopentyl	ester	(Z‐Gly‐O5A)	
General procedure B2 using 29 (204 mg, 0.518 mmol). The 
product was obtained as an oily TFA salt (203 mg, quant). IR 
(film) 3071, 2940, 1677, 1529, 1281, 1201, 1135, 1055, 1001 
cm−1. 1H NMR (CD3OD, 400 MHz): δ 7.39-7.26 (m, 5H), 5.11 (s, 
2H), 4.17 (t, J = 6.1 Hz, 2H), 3.86 (s, 2H), 2.91 (t, J = 7.6 Hz, 2H), 1.75-1.62 (m, 4H), 1.50-1.41 (m, 
2H). 13C NMR (CD3OD, 75 MHz): δ 172.0, 159.2, 138.2, 129.5, 129.5, 128.8, 67.8, 65.7, 43.4, 40.6, 
29.1, 28.1, 23.8. HRMS (ESI) m/z calcd for C15H23N2O4 (M+H)+: 295.1659, found: 295.1650. 
	
p‐(Dimethylamino)phenol	(31)	
Preparation according to adapted literature procedure.[16] p-Aminophenol (546 
mg, 5.00 mmol, 1 equiv) was dissolved in glacial acetic acid (15 mL) and heated 
to 40 °C under N2. To this stirred solution paraformaldehyde (1.501 g, 50.00 
mmol, 10 equiv) was added. The solution was cooled to ROOM TEMPERATURE 
and sodium cyanoborohydride (943 mg, 15.00 mmol, 3 equiv) was added over 
the course of 60 minutes. The solution was stirred overnight at 40 °C under N2. The reaction 
was quenched using sodium hydroxide (20 g in 50 mL water) until pH 14 and brought back to 
pH 7 using 1 M HCl. After extraction with CH2Cl2 (8 × 30 mL), 31	(0.564 g, 82%) was obtained as 
an off-white solid after purification by column chromatography (MeOH in CH2Cl2, 13.5%). Rf 
0.51 (10% MeOH in CH2Cl2). Mp 74.5-75.9 °C. IR (film) 2946, 2881, 2796, 1512, 1443, 1367, 
1236, 1178, 1145, 819, 694 cm−1. 1H NMR (CDCl3, 300 MHz): δ 6.76 (d, J	=	8.8 Hz, 2H), 6.70 (d, J	
=	9.3 Hz, 2H), 4.60 (s, OH), 2.86 (s, 6H).13C NMR (CDCl3,75 MHz): δ 148.9, 145.2, 116.2, 1161, 
42.5. HRMS (ESI) m/z calcd for C8H12NO (M+H)+: 138.0919, found: 138.0941. Spectral data were 
in accordance with those reported in literature.[16-17] 
	
Nα‐Cbz‐Glycine	p‐(dimethylamino)phenyl	ester	(Z‐Gly‐ODmap)	
General procedure A1 using Z-Gly-OH (200 mg, 0.96 mmol), 31 (95.0 
mg, 0.69 mmol), DMAP (170 mg, 1.39 mmol, 2 equiv) and DCC (173 
mg, 0.84 mmol, 1.2 equiv). The product was obtained as a white solid 
after purification by column chromatography (2% MeOH in CH2Cl2) 
(34 mg, 15%). IR (film) 3300, 1765, 1710, 1510, 1205, 697 cm-1. 1H 
NMR (300 MHz, CDCl3): δ 7.35-7.25 (m, 5H), 6.96 (d, J	= 8.4 Hz, 2H), 6.68 (d,	J = 8.6 Hz, 2H), 5.59 
(br s, NH), 5.14 (s, 2H), 4.19 (d, J = 5.1 Hz, 2H), 2.92 (s, 6H). 13C NMR (75 MHz, CD3OD): δ 169.2, 
156.2, 148.6, 140.9, 136.1, 128.3, 128.0, 127.9, 121.4, 112.8, 66.9, 42.7, 40.6. HRMS (ESI) m/z 
calcd for C18H21N2O4 (M+H)+ 329.1501, found 329.1511.  
 
 Synthesis 
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Nα‐Cbz‐L‐Alanine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Ala‐ODmap)	
General procedure A1 using Z-L-Ala-OH (313 mg, 1.40 mmol), 31 
(137 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 mg, 
1.40 mmol). Z‐L‐Ala‐ODmap (100 mg, 29%) was obtained as fluffy 
powder after purification by column chromatography 
(EtOAc/heptane 1:91:2). Rf 0.42 (EtOAc/heptane 1:2). Mp 85.8-
86.2 °C. []20D +36.9 (c 1.00, CH2Cl2). IR (film) 3330, 3031, 2928, 2803, 2358, 1759, 1721, 1608, 
1511, 1453, 1341, 1202, 1066, 965, 877, 810, 740, 698, 579, 530 cm−1. 1H NMR (CDCl3, 300 
MHz): δ 7.39-7.28 (m, 5H), 6.95 (d, J = 8.9 Hz, 2 H), 6.69 (d, J = 9.1 Hz, 2H), 5.37 (d, J = 5.9 Hz, 
NH), 5.14 (s, 2H), 4.67-4.57 (m, 1H), 2.93 (s, 6H), 1.57 (d, J = 11.0 Hz, 3H). 13C NMR (CDCl3,75 
MHz): δ 172.40, 155.74, 149.02, 141.31, 136.38, 128.68, 128.31, 128.24, 121.60, 113.13, 67.12, 
49.94, 41.02, 18.94. HRMS (ESI) m/z calcd for C19H22N2NaO4 (M+Na)+: 365.1477, found: 
365.1481. 
	
Nα‐Cbz‐D‐Alanine	p‐(dimethylamino)phenyl	ester	(Z‐D‐Ala‐ODmap)	
Z-D-Ala-OH (167 mg, 0.750 mmol, 1 equiv), 31 (137 mg, 1.00 mmol, 
1.33 equiv) and DMAP (23 mg, 0.19 mmol, 0.25 equiv) were 
dissolved in dry THF and the resulting mixture was stirred under N2 
at room temperature. After the addition of Et3N (4.60 mL, 33 mmol, 
44 equiv), the mixture was cooled to 0 °C, whereupon a commercial 
solution of 50% propylphosphonic anhydride[4] in DMF (0.782 mL, 
1.313 mmol, 1.75 equiv) was slowly added. The mixture was stirred for 30 min at 0 °C, then for 
12 h at room temperature and subsequently diluted with CH2Cl2 (100 mL). The organic layer 
was washed with aq. HCl (1M, 4 × 50 mL), saturated NaHCO3 (1 × 50 mL), concentrated and the 
residue was purified by column chromatography (EtOAc/heptane 1:91:2). Z‐D‐Ala‐ODmap 
was obtained as a fluffy white powder (279 mg, 81%). Rf 0.43 (EtOAc/heptane 1:2). Mp 89.0-
89.3 °C. []20D 28.6 (c 0.98, CH2Cl2). IR (film) 3363, 2942, 2885, 2794, 1764, 1703, 1608, 1515, 
1453, 1344, 1292, 1204, 1116, 1064, 1014, 945, 876, 807, 747, 699, 613 cm−1. 1H NMR (CDCl3, 
300 MHz): δ 7.41-7.29 (m, 5H), 6.95 (d, J = 8.7 Hz, 2 H), 6.69 (d, J = 9.0 Hz, 2H), 5.37 (d, J = 8.2 
Hz, NH), 5.14 (s, 2H), 4.66-4.55 (m, 1H), 2.93 (s, 6H), 1.57 (d, J = 7.2 Hz, 3H).13C NMR (CDCl3,75 
MHz): δ 172.4, 155.7, 149.0, 141.3, 136.4, 128.7, 128.3, 128.2, 121.6, 113.1, 67.1, 49.9, 41.0, 
19.0. HRMS (ESI) m/z calcd for C19H22N2NaO4 (M+Na)+: 365.1477, found: 365.1477.  
	
Nα‐Cbz‐β‐Alanine	p‐(dimethylamino)phenyl	ester	(Z‐β‐Ala‐ODmap)	
General procedure A1 using Z-β-Ala-OH (313 mg, 1.40 mmol), 31 
(137 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 mg, 
1.40 mmol). Z‐β‐Ala‐ODmap was obtained as an off-white solid 
after purification by column chromatography (MeOH in CH2Cl2, 
14%) (314 mg, 92%). Rf 0.34 (EtOAc/heptane 1:2). Mp 71.8-73.9 
°C. IR (film) 2931, 1750, 1718, 1515, 1208, 1154, 1006, 699 cm−1. 1H NMR (CDCl3, 300 MHz):δ 
7.29-7.37 (m, 5H), 6.93 (d, J = 9.2 Hz, 2H), 6.69 (d, J = 9.2 Hz, 2H), 5.29 (d, J = 7.1 Hz, NH) 5.11 (s, 
2H), 3.56 (dt, J = 6.1, 12.1 Hz, 2H), 2.93 (s, 6H), 2.78 (t,	J	=	5.9 Hz, 2H). 13C NMR (75 MHz, CDCl3) 
δ 171.7, 156.4, 148.9, 141.3, 136.6, 128.7, 128.2, 128.2, 121.8, 113.2, 66.9, 41.0, 36.7, 34.7. 
HRMS (ESI) m/z calcd for C19H22N2NaO4 (M+Na)+: 365.1477, found: 365.1481. 
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Nα‐Cbz‐L‐Arginine(diBoc)	p‐(dimethylamino)phenyl	ester	(32R)		
General procedure A2 using Z-L-Arg(diBoc)-OH (254 mg, 0.50 mmol, 
1 equiv), 31 (69 mg, 0.50 mmol), DMAP (12 mg, 0.10 mmol) and DCC 
(144 mg, 0.70 mmol). 32R	 was obtained as a white solid after 
purification by column chromatography (EtOAc/heptane 1:31:2) 
(270 mg, 86%). Rf 0.30 (EtOAc/heptane 1:2). Mp 47 °C. []20D +6.1 (c 
1.47, CH2Cl2). IR (film) 3334, 3283, 2967, 2924, 1753, 1716, 1636, 
1613, 1513, 1329, 1131, 1050 cm−1. 1H NMR (300 MHz, CDCl3) δ 
11.55 (s, NH), 8.26 (br t, J = 5.7 Hz, NH), 7.41-7.27 (m, 5H), 6.93-6.83 
(m, 2H), 6.76-6.67 (m, 2H), 6.25 (d, J = 7.1 Hz, NH), 5.11 (s, 2H), 4.44-
4.35 (m, 1H), 3.48-3.29 (m, 2H), 2.90 (s, 6H), 1.92-1.58 (m, 4H), 1.48 
(s, 9H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 172.7, 164.6, 157.3, 153.9, 150.0, 142.2, 129.4, 
128.9, 128.7, 122.6, 113.8, 83.9, 79.4, 67.1, 55.1, 41.0, 40.7, 29.3, 28.4, 28.4, 28.1, 26.3. HRMS 
(ESI) m/z calcd for C32H46N5O8 (M+H)+: 628.3346, found: 628.3304.		
 
Nα‐Cbz‐L‐Arginine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Arg‐ODmap)	
To a stirred solution of 32R (100 mg, 0.16 mmol, 1 equiv) in CH2Cl2 
(2 mL), TFA (0.5 mL) and triethylsilane (80 µL) were added and the 
resulting mixture was stirred for 1 hour. The solvent was removed 
under reduced pressure, redissolved in water/dioxane (1:2 v/v) and 
washed with heptane. The waterlayer was lyophilised in the 
presence of 2M HCl to obtain the product as an off-white HCl salt (70 
mg, quant). Mp 42.5 °C. []20D 19.6 (c 1.95, MeOH). IR (film) 3330, 
3261, 3170, 2954, 1765, 1668, 1509, 1203, 1175, 1130 cm−1. 1H NMR 
(300 MHz, CD3CN) δ 7.74 (br s, NH), 7.65-7.57 (m, 2H), 7.41-7.29 (m, 
5H), 7.24-7.16 (m, 2H), 6.66-6.50 (br m, 4NH), 5.11 (s, 2H), 4.44-4.34 (m, 1H), 3.24-3.11 (m, 2H), 
3.08 (s, 6H), 2.10-1.68 (m, 4H, excl CD3CN). 13C NMR (CD3CN, 75 MHz) δ 171.9, 158.4, 157.4, 
150.4, 143.2, 138.0, 129.4, 128.9, 128.7, 124.0, 122.0, 67.3, 55.0, 45.9, 41.7, 29.0, 25.7. HRMS 
(ESI) m/z calcd for C22H30N5O4 (M+H)+: 428.2298, found: 428.2288.  
	
Nα‐Cbz‐L‐Asparagine(Trt)	p‐(dimethylamino)phenyl	ester	(32N)	
Z-L-Asn(Trt)-OH (678 mg, 1.33 mmol, 1.33 equiv), 31 (137 mg, 1.00 
mmol, 1 equiv) and DMAP (41 mg, 0.33 mmol, 0.3 equiv) were 
dissolved in dry THF and the resulting mixture was stirred under N2 
at room temperature. After the addition of Et3N (8.18 mL, 58.7 mmol, 
44 equiv), the mixture was cooled to 0 °C, whereupon a commercial 
solution of 50% propylphosphonic anhydride[4] in DMF (1.389 mL, 
2.33 mmol, 1.75 equiv) was slowly added. The mixture was stirred 
for 30 min at 0 °C, then for 12 h at room temperature and 
subsequently diluted with CH2Cl2 (100 mL). The organic layer was washed with aq. HCl (1M, 4 × 
20 mL), saturated NaHCO3 (1 × 25 mL), concentrated and the residue was purified by column 
chromatography (EtOAc/heptane 1:51:2). 32N	was obtained as a white powder (333 mg, 
40%). Rf 0.31 (EtOAc/heptane 1:2). Mp 179.3-188.2 °C. []20D +15.8 (c 0.99, CH2Cl2). IR (film) 
3316, 3029, 1763, 1718, 1511, 1447, 1336, 1261, 1204, 1129, 1045, 902, 804, 750, 700, 623, 
614, 605 cm−1. 1H NMR (300 MHz, CDCl3) δ 7.40-7.11 (m, 20H), 6.78 (d, J = 9.1 Hz, 2H), 6.64 (d, J 
= 9.2 Hz, 2H), 6.11 (d, J = 7.4 Hz, NH), 5.13 (s, 2H), 4.80-4.73 (m, 1H), 3.22 (dd, J = 15.7, 4.7 Hz, 
1H), 2.95 (dd, J = 15.7, 4.7 Hz, 1H), 2.93 (s, 6H). 13C NMR (CDCl3,75 MHz) δ 170.5, 169.2, 156.4, 
150.0, 144.4, 141.7, 136.5, 128.8, 128.6, 128.2, 128.0, 127.3, 121.9, 113.2, 71.1, 67.1, 51.1, 41.1, 
39.0. HRMS (ESI) m/z calcd for C39H38N3O5 (M+H)+: 628.2812, found: 628.2813. 	
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Nα‐Cbz‐L‐Asparagine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Asn‐ODmap)	
To a stirred solution of 32N (150 mg, 0.24 mmol, 1 equiv) in CH2Cl2 
(2 mL), TFA (552 μL, 7.17 mmol, 30 equiv) and triethylsilane (43 µL, 
0.27 mmol, 1.13 equiv) were added and the resulting mixture was 
stirred overnight. After precipitation with Et2O, Z‐L‐Asn‐ODmap was 
obtained as a white powder (46 mg, 50%). Rf 0.47 (10% MeOH in 
CH2Cl2). Mp 136.2-139.3 °C. []20D 3.1 (c 0.14, CH2Cl2). IR (film) 3316, 
1757, 1694, 1655, 1516, 1446, 1281, 1205, 1058, 808, 698, 613, 603, 
417 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.39-7.19 (m, 5H), 7.00 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 9.0 
Hz, 2H), 6.10 (d, J = 8.4 Hz, NH), 5.63 (d, J = 13.9 Hz, NH2), 5.14 (s, 2H), 4.85-4.74 (m, 1H), 2.95 
(s, 6H), 3.19-2.80 (m, 2H). 13C NMR (CDCl3,75 MHz): δ 172.1, 170.5, 156.4, 147.7, 143.3, 136.3, 
129.6, 128.7, 128.4, 128.3, 128.2, 126.4, 122.1, 114.8, 67.3, 50.9, 42.0, 37.6. HRMS (ESI) m/z 
calcd for C20H23N3NaO5 (M+Na)+: 408.1535, found: 408.1548. 
	
Nα‐Cbz‐L‐Glutamate	(OtBu)	p‐(dimethylamino)phenyl	ester	(32E)	
General procedure A1 using Z-L-Glu(OtBu)-OH (472 mg, 1.40 mmol), 
31 (137 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 
mg, 1.40 mmol). 32E was obtained as a white solid after purification 
by column chromatography (EtOAc/heptane 1:91:2) (442 mg, 
97%). Rf 0.48 (EtOAc/heptane 1:2). Mp 62.2-64.2 °C. []20D 12.7 (c 
0.99, CH2Cl2). IR (film) 3338, 2976, 1724, 1609, 1511, 1453, 1203, 
1151, 1057, 947, 811, 739, 698, 512 cm−1. 1H NMR (CDCl3, 300 MHz): 
δ 7.38-7.27 (m, 5H), 6.95 (d, J = 8.8 Hz, 2H), 6.68 (d, J = 9.1 Hz, 2H), 5.48 (d, J = 7.7 Hz, NH), 5.13 
(s, 2H), 4.66-4.57 (m, 1H), 2.93 (s, 6H), 2.50-2.38 (m, 1H), 2.37-2.23 (m, 1H), 2.18-2.02 (m, 1H), 
1.44 (s, 9H).13C NMR (CDCl3,75 MHz): δ 149.1, 141.2, 128.7, 128.3, 128.3, 121.7, 113.1, 67.2, 
53.8, 41.0, 31.6, 28.2, 27.9. HRMS (ESI) m/z calcd for C25H32N2NaO6 (M+Na)+: 479.2158, found: 
479.2154. 	
 
Nα‐Cbz‐L‐Glutamate	p‐(dimethylamino)phenyl	ester	(Z‐L‐Glu‐ODmap)	
General procedure B2 using 32E (200 mg, 0.438 mmol). Z‐L‐Glu‐
ODmap was obtained as a thick dark yellow oil (175 mg, quant). Rf 
0.44 (10% MeOH in CH2Cl2). []20D 10.1 (c 0.80, CH2Cl2). IR (film) 
3308, 2962, 1766, 1705, 1671, 1508, 1455, 1398, 1174, 1174, 1130, 
1058, 836, 798, 722, 700, 607, 553 cm−1. 1H NMR (CDCl3, 300 MHz): δ 
7.52 (d, J = 8.5 Hz, 2H), 7.40-7.30 (m, 5H), 7.24 (d, J = 10.6 Hz, 2H), 
6.19 (s, OH), 5.62 (d, J = 6.4 Hz, NH), 5.13 (s, 2H), 4.70-4.58 (m, 1H), 
3.17 (s, J = 6.2 Hz, 6H), 2.56 (t, J = 6.6 Hz, 1H), 2.44 – 2.28 (m, 1H), 2.24 – 2.09 (m, 1H). 13C NMR 
(CDCl3,75 MHz): δ 176.3, 161.3, 156.4, 150.7, 141.1, 128.8, 128.5, 128.3, 123.7, 121.7, 67.6, 53.6, 
46.5, 31.2, 29.7, 26.9. HRMS (ESI) m/z calcd for C21H24N2NaO6 (M+Na)+: 423.1553, found: 
423.1532. 
	
Nα‐Cbz‐L‐Isoleucine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Ile‐ODmap)	
General procedure A1 using Z-L-Ile-OH (371 mg, 1.40 mmol), 31 (137 
mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 mg, 1.40 
mmol). Z‐L‐Ile‐ODmap	 was obtained as an off-white solid after 
purification by column chromatography (EtOAc/heptane 1:91:2) 
(375 mg, 98%). Rf 0.56 (EtOAc/heptane 1:2). Mp 90.6-91.7 °C. []20D
7.3 (c 0.94, CH2Cl2). IR (film) 2963, 2928, 1720, 1513, 1206, 1163, 
698 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.39-7.31 (m, 5H), 6.94 (d, J = 8.9 Hz, 2H), 6.69 (d, J = 9.1 
Hz, 2H), 5.36 (d, J = 8.8 Hz, NH), 5.14 (s, 2H), 4.57 (dd, J = 4.8, 8.9 Hz, 1H), 2.93 (s, 6H), 2.04 (s, 
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1H), 1.63-1.50 (m, 2H), 1.04 (d, J = 6.9 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H).13C NMR (CDCl3,75 MHz): 
δ 171.4, 156.3, 149.0, 141.3, 136.4, 128.7, 128.3, 128.3, 121.7, 113.2, 67.2, 58.5, 41.0, 38.5, 25.3, 
15.7, 11.9. HRMS (ESI) m/z calcd for C22H28N2NaO4 (M+Na)+: 407.1947, found: 407.1951. 	
 
Nα‐Cbz‐L‐Phenylalanine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Phe‐ODmap)	
General procedure A1 using Z-L-Phe-OH (419 mg, 1.40 mmol), 31 
(137 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 mg, 
1.40 mmol). Z‐L‐Phe‐ODmap	was obtained as a white fluffy powder 
after purification by column chromatography (EtOAc/heptane 
1:91:2) (376 mg, 90%). Rf 0.47 (EtOAc/heptane 1:2). Mp 79.8-80.4 
°C. []20D 9.3 (c 1.00, CH2Cl2). IR (film) 1721, 1515, 1348, 1204, 1054, 
746, 699, 611, cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.37 – 7.19 (m, 
10H), 6.84 (s, 2H), 6.67 (d, J = 9.0 Hz, 2H), 5.31 (d, J = 8.1 Hz, NH), 5.12 (s, 2H), 4.88 (dt, J = 13.4, 
6.0 Hz, 1H), 3.26 (d, J = 6.2 Hz, 2H), 2.92 (s, 6H).13C NMR (CDCl3,75 MHz): δ 170.7, 155.6, 148.8, 
141.1, 136.2, 135.5, 129.4, 128.5, 128.2, 128.1, 127.2, 121.4, 112.9, 67.0, 40.8, 38.3. HRMS (ESI) 
m/z calcd for C25H26N2NaO4 (M+Na)+: 441.1790, found: 441.1800.	
 
Nα‐Cbz‐L‐Proline	p‐(dimethylamino)phenyl	ester	(Z‐L‐Pro‐ODmap)	
General procedure A1 using Z-L-Pro-OH (349 mg, 1.40 mmol), 31 (137 
mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 mg, 1.40 
mmol). Z‐L‐Pro‐ODmap was obtained as a white solid after 
purification by column chromatography (EtOAc/heptane 1:91:2) 
(325 mg, 88%). Rf 0.35 (EtOAc/heptane 1:2). MP 71.1-72.0 []20D 88.7 
(c1.00, CH2Cl2). IR (film) 3321, 3274, 3058, 3028, 2353, 1692, 1640, 1527, 1493, 1450, 1290, 
1238, 1048, 996, 745, 694, 625, 569 cm−1.1H NMR (CDCl3, 300 MHz): δ 7.44-7.23 (m, 5H), 6.97 
(d, J = 9.1 Hz, 2H), 6.71 (d, J = 8.9 Hz, 2H), 5.30-5.07 (m, 2H), 4.63-4.48 (m, 1H), 3.85-3.47 (m, 
2H), 2.91 (s, 6H), 2.45-2.12 (m, 2H), 2.11 (s, 2H) .13C NMR (CDCl3,75 MHz): δ 172.0, 171.9, 155.0, 
154.4, 148.9, 141.7, 141.4, 136.9, 136.6, 128.6, 128.1, 128.0, 121.8, 121.6, 113.2, 113.1, 67.3, 
67.2, 59.5, 59.1, 47.2, 46.6, 41.0, 31.2, 30.2, 24.5, 23.7. (HRMS (ESI) m/z calcd for C21H24N2NaO4 
(M+Na)+: 391.1634, found: 391.1639. 	
 
Nα‐Cbz‐L‐Threonine	(OtBu)	p‐(dimethylamino)phenyl	ester	(32T)	
General procedure A1 using Z-L-Thr(t‐Bu)-OH (433 mg, 1.40 mmol), 
31 (137 mg, 1.00 mmol), DMAP (24 mg, 0.20 mmol) and DCC (289 
mg, 1.40 mmol). 32T was obtained as a white solid after purification 
by column chromatography using (EtOAc/heptane 1:91:2) (358 
mg, 86%). Rf	0.45 (EtOAc/heptane 1:2). Mp 90.8-91.7 °C. []20D 17.9 
(c 1.00, CH2Cl2). IR (film) 3446, 2975, 1765, 1725, 1609, 1511, 1454, 
1346, 1309, 1195, 1091, 1068, 969, 739, 698, 511 cm−1. 1H NMR 
(CDCl3, 300 MHz):δ 7.42-7.27 (m, 5H), 6.97 (d, J = 9.1 Hz, 2H), 6.69 (d, J = 9.2 Hz, 2H), 5.67 (d, J = 
9.5 Hz, NH), 5.15 (s, 2H), 4.45-4.38 (m, 1H), 2.92 (s, 6H), 1.28 (d, J = 13.8 Hz, 3H), 1.17 (s, 9H), 
0.89-0.84 (m, 1H). 13C NMR (CDCl3,75 MHz): δ 170.4, 157.0, 148.9, 141.6, 136.5, 128.7, 128.3, 
121.7, 113.2, 74.3, 67.5, 67.2, 60.3, 41.1, 28.8, 24.8, 21.2.HRMS (ESI) m/z calcd for C24H32N2 
NaO5 (M+Na)+: 451.2209, found: 451.2218. 
 
Nα‐Cbz‐L‐Threonine	p‐(dimethylamino)phenyl	ester	(Z‐L‐Thr‐ODmap)	
General procedure B1 using 32T (100 mg, 0.233 mmol). Instead of 
lyophilisation, the resulting mixture was purified by column 
chromatography (EtOAc/heptane, 5:11:5). Z‐L‐Thr‐ODmap was 
obtained as a brown oil (87 mg, quant). []20D 24.7 (c 0.40, CH2Cl2). 
N
Cbz O
O
N
 Synthesis 
 129 
IR (film) 3375, 2925, 1761, 1677, 1609, 1513, 1455, 1202, 1131, 1066, 1006, 836, 799, 722, 
698, 552 cm−1. 1H NMR (CDCl3, 300 MHz: δ 7.42-7.28 (m, 5H), 7.02 (dd, J = 21.5, 9.1 Hz, 4H), 5.70 
(d, J = 8.9 Hz, 1H), 5.16 (s, 2H), 4.64-4.45 (m, J = 7.4 Hz, 3H), 2.99 (s, 6H), 1.33 (d, J = 6.3 Hz, 3H). 
13C NMR (CDCl3,75 MHz): δ 170.3, 146.4, 136.3, 128.7, 128.4, 128.2, 122.4, 116.3, 68.3, 67.5, 
59.5, 42.9, 29.8, 20.3, 14.3. HRMS (ESI) m/z calcd for C21H24N2NaO6 (M+Na)+: 395.1583, found: 
395.1583. 
	
Nα‐Cbz‐Glycine	p‐(trimethylammonium)phenyl	ester	(Z‐Gly‐OTmap)	
Preparation according to literature procedure.[18] To a solution of 
Z‐Gly‐ODmap (40 mg, 0.12 mmol, 1 equiv) in MeCN (5 mL) was 
added methyl iodide (0.30 mL, 4.8 mmol, 40 equiv). The mixture 
was refluxed for at least 2 hours. Afterwards, the solvent and 
methyl iodide were evaporated and the resulting mixture was 
purified with column chromatography (EtOAc) to afford a white powder (34 mg, 59%). IR (film) 
1765, 1711, 1512, 1160, 697 cm-1. 1H NMR (300 MHz, CD3OD): δ 7.99 (d, J = 9.5 Hz, 2H), 7.43 (d, 
J = 9.4 Hz, 2H), 7.33 (m, 5H), 5.14 (s, 2H), 4.16 (s, 2H), 3.69 (s, 9H). 13C NMR (75 MHz, CD3OD): δ 
176.7, 171.7, 143.6, 132.1, 129.5, 129.5, 129.0, 158.7, 121.1, 120.9, 67.7, 57.8, 43.4. HRMS (ESI) 
m/z calcd for C19H23N2O4+ (M) + 343.1658, found 343.1641. 
	
Nα‐Cbz‐Glycine	p‐(dimethylamino)phenethyl	ester	(Z‐Gly‐ODmape)	
General procedure A1 using Z-Gly-OH (146 mg, 0.70 mmol), p-
(dimethylamino)phenethyl alcohol (82 mg, 0.50 mmol), DMAP 
(122 mg, 1.0 mmol, 2 equiv) and DCC (144 mg, 0.7 mmol) in 
EtOAc (3 mL). The product was obtained by silica gel column 
purification (2% MeOH in CH2Cl2) (132 mg, 75%). IR (film) 
3300, 1720, 1520, 1189, 698 cm-1. 1H NMR (300 MHz, CDCl3): δ 7.34 (m, 5H) 7.07 (d, J = 8.6 Hz, 
2H,) 6.68 (d, J = 8.7 Hz, 2H), 5.22 (br s, NH), 5.13 (s, 2H), 4.30 (t, J = 7.2 Hz, 2H) 3.97 (d, J = 5.5 
Hz, 2H), 2.91 (s, 6H), 2.85 (t, J = 7.1 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 169.9, 149.5, 135.8, 
129.5, 128.5, 128.2, 128.1, 125.0, 122.9, 67.1, 66.4, 42.8, 40.7, 34.0. HRMS (ESI+) m/z calcd for 
C20H25N2O4 (M+H)+ 357.1814, found 357.1710. 
 
Nα‐Cbz‐Glycine	p‐(trimethylammonium)phenethyl	ester	(Z‐Gly‐OTmape)	
To a solution of Z‐Gly‐ODmape (77 mg, 0.22 mmol, 1 equiv) 
in MeCN (5 mL) was added methyl iodide (0.30 mL, 4.8 
mmol, 22 equiv). The mixture was refluxed for at least 2 
hours. Afterwards, the solvent and methyl iodide were 
evaporated and the resulting mixture was purified with 
column chromatography (EtOAc) to afford a light yellow powder (110 mg, quant). 1H NMR (300 
MHz, CD3OD): δ 7.81 (d, J = 9.0 Hz, 2H), 7.52 (d, J = 9.0 Hz, 2H), 7.32 (m, 5H), 5.10 (s, 2H), 4.38 (t, 
J = 6.5 Hz, 2H,), 3.80 (s, 2H), 3.63 (s, 9H), 3.04 (t, J = 6.5 Hz, 2H). 13C NMR (75 MHz, CD3OD): δ 
171.7, 151.7, 142.6, 132.2, 129.5, 129.5, 129.1, 128.7, 121.1, 120.9, 67.8, 66.0, 57.8, 43.4, 35.2. 
HRMS (ESI) m/z calcd for C21H27N2O4+ (M)+ 371.1974, found 371.1978. 
 
p‐(Dimethylamino)benzylalcohol	(35)	
To a solution of p-(dimethylamino)benzaldehyde (149 mg, 1.00 mmol, 1 
equiv) in MeOH (2.5 mL) was added sodium borohydride (45 mg, 1.2 mmol, 
1.2 equiv,). After stirring for 10 minutes, the mixture was concentrated, 
dissolved in EtOAc and washed with water (3 × 5 mL) and concentrated 
again in	 vacuo to afford product 35 (121 mg, 80%). 1H NMR (300 MHz, 
CDCl3): δ 7.19 (d, J	= 8.8 Hz, 2H), 6.69 (d, J	= 8.8 Hz, 2H), 4.49 (s, 2H), 2.90 (s, 6H), 2.32 (br s, 
OH). HRMS (ESI+) m/z calcd for C9H13NO (M+H)+ 151.10, found . Spectral data were in 
accordance with those reported in literature.[19] 
N
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γ‐Hydroxybutyramide	(37)	
Preparation according to literature procedure.[20] To cooled (–78 °C) γ-
butyrolactone (5.00 g, 58.1 mmol, 1.0 equiv) in a sealed tube was added 
liquid ammonia (40 mL). The tube was warmed to 40 °C and stirred for 5 
days. The excess ammonia was evaporated and the crude product was 
recrystallised from EtOAc to afford 37 (5.81 g, 97%) as white needles that liquified upon 
standing. Rf	0.40 (5% MeOH in CH2Cl2). IR (film) 3342, 3197, 2941, 2858, 1653, 1605, 1404, 
1051, 926, 580 cm−1. 1H NMR (CD3OD, 300 MHz): δ 3.57 (t, J = 6.6 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 
1.81 (dt, J = 6.6, 7.5 Hz, 2H). 13C NMR (CD3OD, 75 MHz): δ 210.1, 128.8, 64.6, 30.7. HRMS (ESI) 
m/z calcd for C4H10NO2 (M+H)+: 104.0712 found: 104.0716. Spectral data were in accordance 
with those reported in literature.[21] 
 
Nα‐Cbz‐Glycine	3‐carbamoylpropyl	ester	(Z‐Gly‐O3Cam)	
A solution of 37 (242 mg, 2.3 mmol, 1.1 equiv) in CH2Cl2 (4 mL) 
was cooled to 0 °C. Subsequently, EDC·HCl (408 mg, 2.1 mmol, 1.0 
equiv), DMAP (260 mg, 2.1 mmol, 1.0 equiv) and Cbz-Gly-OH (446 
mg, 2.1 mmol, 1.0 equiv) were added. The reaction mixture was 
allowed to slowly warm to room temperature and stirred during 6 
hours. Work-up was performed by diluting with CH2Cl2 (10 mL), washing with 5% NaHCO3 (2 × 
5 mL) and brine (1 × 5 mL), drying with Na2SO4, filtration and evaporation to dryness. The 
crude product was purified by column chromatography (MeOH in CH2Cl2, 14%) to afford Z‐
Gly‐O3Cam (286 mg, 46%) as a white solid. Rf	0.56 (5% MeOH in CH2Cl2). IR (film) 3349, 2920, 
2553, 1708, 1667, 1646, 1625, 1522, 1432, 1348, 1272, 1189, 1058, 1009, 608 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ 7.36 (m, 5H), 5.58 (br s, NH), 5.30 (br s, 2NH), 5.13 (s, 2H), 4.23 (t, J = 6.0 
Hz, 2H), 3.96 (s, 2H), 2.28 (t, J = 2.7 Hz, 2H), 1.98 (dt, J = 6.0, 2.7 Hz, 2H). 13C NMR (CDCl3, 75 
MHz): δ 173.9, 136.1, 128.6, 128.3, 128.0, 67.2, 64.4, 42.9, 42.8, 31.7, 30.9, 24.3. HRMS (ESI) m/z 
calcd for C14H18N2NaO5 (M+Na)+: 317.1113, found: 317.1106.  
 
δ‐Hydroxyvaleramide	(39)	
Preparation according to literature procedure.[20] To cooled (–78 °C) δ-
valerolactone (1.03 g, 10.3 mmol, 1.0 equiv) in a sealed tube was added 
liquid ammonia (20 mL). The tube was warmed to 40 °C and stirred for 5 
days. The excess ammonia was evaporated and the crude product was 
purified by column chromatography (MeOH in CH2Cl2, 320%) (746 mg, 62%). 1H NMR 
(CD3CN, 300 MHz): δ 6.06 (br s, NH), 5.54 (br s, NH), 3.48 (dt, J = 5.5, 6.2 Hz, 2H), 2.60 (t, J = 5.5 
Hz, OH), 2.15 (t, J = 7.3 Hz, 2H), 1.65-1.42 (m, 4H). 13C NMR (CD3CN, 75 MHz): δ 175.9, 62.1, 35.7, 
33.0, 22.5. HRMS (ESI) m/z calcd for C5H11NO2 (M+H)+: 118.0868, found: 118.0869. Spectral 
data were in accordance with those reported in literature.[22] 
	
Nα‐Cbz‐Glycine	4‐carbamoylbutyl	ester	(Z‐Gly‐O4Cam)	
General procedure A1 using Z-Gly-OH (586 mg, 2.80 mmol) 39 
(234 mg, 2.00 mmol), DMAP (49 mg, 0.4 mmol) and DCC (578 
mg, 2.80 mmol). The product was obtained as a white solid after 
purification by column chromatography (MeOH in CH2Cl2, 
38%) (578 mg, 94%). Rf 0.24 (5% MeOH in CH2Cl2). Mp 77 °C. IR (film) 3334, 2950, 1709, 
1662, 1524, 1282, 1195, 1057 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.41-7.28 (m, 5H), 5.60 (br s, 
NH), 5.53 (br s, NH), 5.38 (t,	J = 5.7 Hz, 2H), 5.13 (s, 2H), 4.18 (t, J = 5.9 Hz, 2H), 3.96 (d, J = 5.7 
Hz, 2H), 2.24 (t, J = 6.9 Hz, 2H), 1.76-1.65 (m, 4H). 13C NMR (CDCl3, 75 MHz): δ 174.8, 170.0, 
156.4, 136.2, 128.5, 128.2, 128.0, 67.1, 64.9, 42.8, 35.0, 27.9, 21.8. HRMS (ESI) m/z calcd for 
C15H21N2O5 (M+H)+: 309.1451, found: 309.1444. 
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Nα‐Cbz‐Glycine carbamoylmethyl	ester	(Z‐Gly‐OCam)	
Preparation according to literature procedure.[5] Z-Gly-OH (2.50 g, 12.0 
mmol, 1 equiv) was dissolved in EtOH (10 mL) and diluted with water 
(3 mL) and KOH (671 mg, 12.0 mmol, 1 equiv) was added to form the 
potassium salt. After 5 minutes the mixture was concentrated in	vacuo 
and co-evaporated with toluene (3 × 20 mL). The residue was 
dissolved in dry DMF (6 mL) and chloroacetamide (1.34 g, 14.3 mmol, 1.2 equiv) was added. 
The mixture was stirred overnight at 50°C. During the reaction KCl precipitated as a white 
powder. After filtration, DMF was removed in	vacuo, the product was dissolved in EtOAc and 
washed with a saturated NaHCO3 solution (3 × 20 mL), and water (3 × 20 mL). The organic layer 
was dried over Na2SO4, the solvent was removed in	vacuo and the product was obtained as a 
white powder (1.57 g, 49%). 1H NMR (400 MHz, CD3OD): δ 7.32-7.27 (m, 5H), 5.11 (s, 2H), 4.60 
(s, 2H), 4.00 (s, 2H). 13C NMR (75 MHz, CD3OD) δ (ppm) 178.4, 172.5, 159.1, 138.1, 129.5, 129.0, 
128.8, 67.8, 62.4, 43.3 HRMS (ESI) m/z calcd for C12H14N2NaO5 (M+Na)+: 289.0800, found: 
289.0810. Spectral data were in accordance with those reported in literature.[23] 
 
Nα‐Cbz‐Glycine	[2,2,2‐trifluoro]ethyl	ester	(Z‐Gly‐OTfe)	
General procedure A3 using Z-Gly-OH (1.40 g, 6.7 mmol), DMAP (819 
mg, 6.7 mmol), trifluoroethanol (0.48 mL, 6.7 mmol) and EDC (1.54 g, 8.0 
mmol. The product was obtained as a white powder after purification by 
column chromatography (EtOAc/heptane 1:1) (1.25 g, 64%). 1H NMR 
(300 MHz, CDCl3): δ 7.37-7.29 (m, 5H), 5.21 (br s, NH), 5.14 (s, 2H), 4.53 (q, J = 8.2 Hz, 2H), 4.10 
(d, J = 5.9 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 168.7, 156.2, 136.0, 128.6, 128.3, 128.1, 122.6 (q, 
J = 278 Hz, 1C), 67.3, 61.9 (q, J = 37 Hz, 1C), 42.2. HRMS (ESI) m/z calcd for C12H12F3NNaO4 
(M+Na)+: 314.0616, found: 314.0613.  
	
Nα‐Cbz‐Glycine	methyl	ester	(Z‐Gly‐OMe)	
To a solution of Z-Gly-OH (2.09 g, 10 mmol, 1 equiv) in dry THF (10 mL) at 
0°C, triethylamine (1.39 mL, 10 mmol, 1 equiv) was added as well as 
methylchloroformate (1.40 mL, 18 mmol, 1.8 equiv). The mixture was 
concentrated and diluted in MeOH. This mixture was refluxed for 1 hour, 
concentrated and purified by column chromatography (2.14 g, 96%). 1H NMR (300 MHz, 
CD3OD): δ 7.35-7.20 (m, 5H), 5.09 (s, 2H), 3.85 (s, 2H), 3.69 (s, 3H). 13C NMR (CD3OD, 75 MHz): δ 
172.4, 159.2, 138.2, 129.5, 129.1, 128.8, 67.8, 52.6, 43.3. HRMS (ESI) m/z calcd for C11H13NNaO4 
(M+Na)+: 246.0742, found: 246.0752. Spectral data were in accordance with those reported in 
literature.[24] 
 
Nα‐Cbz‐Glycine	p‐nitrobenzyl	ester	(Z‐Gly‐ONb)	
General procedure A2 using Z-Gly-OH (295 mg, 1.41 mmol), p-
nitrobenzyl alcohol	 (155 mg, 1.01 mmol), DMAP (25 mg, 0.20 
mmol) and DCC (300 mg, 1.46 mmol). The product was obtained 
as an off- white solid after purification by column chromatography 
(EtOAc/heptane 1:2) (290 mg, 83%). Rf 0.25 (EtOAc/heptane 1:2). 
Mp 109.5 °C. IR (film) 3347, 2928, 1736, 1717, 1513, 1351, 1212, 1011, 734 cm−1. 1H NMR 
(CD3CN, 400 MHz): δ 8.23-8.18 (m, 2H), 7.60-7.55 (m, 2H), 7.38-7.29 (m, 5H), 6.04 (br t, NH), 
5.26 (s, 2H), 5.09 (s, 2H), 3.94 (d, J = 6.2 Hz, 2H). 13C NMR (CDCl3, 75 MHz): δ 169.7, 156.3, 147.8, 
142.3, 136.0, 128.5, 128.4, 128.2, 123.8, 67.2, 65.5, 42.7. Physical data were in accordance with 
those reported in literature.[25] 
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Nα‐Cbz‐Glycine	benzyl	ester	(Z‐Gly‐OBn)	
General procedure C using Z-Gly-OH (418 mg, 2.0 mmol), K2CO3 (276 
mg, 2.0 mmol) and benzyl bromide (262 μl, 2.2 mmol) in DMF (1.5 mL). 
The product was obtained as a colourless oil after purification by 
column chromatography (EtOAc/heptane 1:101:2) (503 mg, 84%). Rf 
0.47 (EtOAc/heptane 1:2). IR (film) 3412, 3027, 2950, 1748, 1717, 
1520, 1260, 1189, 1053, 697 cm−1. 1H NMR (CD3CN, 300 MHz): δ 7.42-7.28 (m, 10H), 5.96 (br s, 
NH), 5.15 (s, 2H), 5.08 (s, 2H), 3.89 (d, J = 6.3 Hz, 2H). 13C NMR (CD3CN, 75 MHz): δ 171.0, 157.5, 
138.0, 137.0, 129.4, 129.4, 129.1, 129.0, 128.9, 128.7, 67.3, 67.2, 43.3. HRMS (ESI) m/z calcd for 
C17H18NO4 (M+H)+: 300.1236, found: 300.1238. Spectral data were in accordance with those 
reported in literature.[26] 
 
Nα‐Cbz‐L‐Alanine	benzyl	ester	(Z‐L‐Ala‐OBn)	
General procedure C using Z-L-Ala-OH (1.12 g, 5.00 mmol), K2CO3 (691 
mg, 5.00 mmol) and benzyl bromide (654 μl, 5.50 mmol) in DMF (4 
mL). The product was obtained as a colourless oil after purification by 
column chromatography (EtOAc/heptane 1:91:2) (1.40 g, 89%). Rf 
0.44 (EtOAc/heptane 1:2). []20D 6.0 (c 1.02, CH2Cl2). IR (film) 3343, 
2958, 1719, 1525, 1454, 1257, 1211, 1173, 1069 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.41-7.25 
(m, 10H), 5.39 (d, J = 6.3 Hz, NH), 5.16 (s, 2H), 5.09 (s, 2H), 4.50-4.36 (m, 1H), 1.40 (d, J = 7.2 Hz, 
3H). 13C NMR (CDCl3, 75 MHz): δ 172.7, 155.5, 136.2, 135.3, 128.5, 128.4, 128.3, 128.1, 67.0, 
66.8, 49.6, 18.5. HRMS (ESI) m/z calcd for C18H19NNaO4 (M+Na)+: 336.1212, found: 336.1207. 
Spectral data were in accordance with those reported in literature.[25] 
	
Nα‐Cbz‐D‐Alanine	benzyl	ester	(Z‐D‐Ala‐OBn)	
General procedure C using Z-D-Ala-OH (558 mg, 2.50 mmol), K2CO3 
(346 mg, 2.50 mmol) and benzyl bromide (325 μl, 2.75 mmol) in DMF 
(2 mL). The product was obtained as a colourless oil after purification 
by column chromatography (EtOAc/heptane 1:91:2) (758 mg, 97%). 
Rf 0.44 (EtOAc/heptane 1:2). []20D +5.9 (c 1.08, CH2Cl2). IR (film) 3334, 
3027, 1714, 1524, 1454, 1255, 1209, 1172, 1069 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.41-7.25 
(m, 10H), 5.37 (d, J = 7.0 Hz, NH), 5.16 (s, 2H), 5.10 (s, 2H), 4.50-4.36 (m, 1H), 1.41 (d, J = 7.2 Hz, 
3H). 13C NMR (CDCl3, 75 MHz): δ 172.6, 155.5, 136.2, 135.3, 128.5, 128.4, 128.4, 128.1, 67.1, 
66.9, 49.7, 18.6. HRMS (ESI) m/z calcd for C18H20NO4 (M+H)+: 314.1392, found: 314.1385. 
Spectral data were in accordance with those reported in literature.[27] 
	
Nα‐Cbz‐β‐Alanine	benzyl	ester	(Z‐β‐Ala‐OBn)	
General procedure C using Z-β-Ala-OH (1.12 g, 5.00 mmol), K2CO3 
(691 mg, 5.00 mmol) and benzyl bromide (654 μl, 5.50 mmol) in DMF 
(4 mL). The product was obtained as a colourless oil after 
purification by column chromatography (EtOAc/heptane 1:91:2) 
(1.46 g, 93%). Rf 0.36 (EtOAc/heptane 1:2). IR (film) 3356, 3032, 
1716, 1519, 1454, 1245, 1173, cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.40-7.25 (m, 10H), 5.31 (br s, 
NH), 5.11 (s, 2H), 5.08 (s,2H), 3.47 (dt, J	= 6.1, 6.1 Hz, 2H), 2.60 (t, J = 6.0 Hz, 2H). 13C NMR 
(CDCl3, 75 MHz): δ 172.0, 156.2, 136.4, 135.5, 128.5, 128.4, 128.3, 128.1, 128.0, 66.6, 66.4, 36.5, 
34.4. HRMS (ESI) m/z calcd for C18H19NNaO4 (M+Na)+: 336.1212, found: 336.1202. Spectral data 
were in accordance with those reported in literature.[28] 
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Nα‐Cbz‐L‐Arginine(diBoc)	benzyl	ester	(40R)	
General procedure C using Z-L-Arg(diBoc)-OH (509 mg, 1.00 mmol), 
K2CO3 (138 mg, 1.00 mmol) and benzyl bromide (131 μl, 1.10 mmol). 
The product was obtained as a colourless oil after purification by 
column chromatography (EtOAc/heptane 1:31:2) (548 mg, 92%). Rf 
0.25 (EtOAc/heptane 1:3). []20D 9.1 (c 2.74, MeOH). IR (film) 3328, 
2958, 2924, 1718, 1637, 1615, 1365, 1329, 1334, 1154, 1132, 1050, 
1025 cm−1. 1H NMR (CDCl3, 300 MHz): δ 11.47 (s, NH), 8.29 (t, J = 4.9 Hz, 
NH), 7.39-7.29 (m, 10H), 5.52 (d, J = 8.0 Hz, NH), 5.19 (d, J = 12.4 Hz, 
1H), 5.14 (d, J = 12.4 Hz, 1H), 5.11 (s, 2H), 4.48-4.38 (m, 1H), 3.49-3.27 (m, 2H), 1.95-1.52 (m, 
4H). 13C NMR (CDCl3, 75 MHz): δ 172.0, 163.5, 156.2, 155.9, 153.3, 136.2, 135.2, 128.6, 128.5, 
128.3, 128.2, 128.1, 83.2, 79.3, 67.3, 67.0, 53.8, 40.2, 29.7, 28.3, 28.1, 25.2. HRMS (ESI) m/z calcd 
for C31H43N4O8 (M+H)+: 599.3081, found: 599.3075. 
	
Nα‐Cbz‐L‐Arginine	benzyl	ester	(Z‐L‐Arg‐OBn)	
General procedure B1 using 40R (183 mg, 0.306 mmol), The product 
was obtained as a colourless oil (127 mg, 95%). []20D 18.3 (c 0.95, 
MeOH). IR (film) 3330, 3162, 2954, 2917, 1701, 1664, 1528, 1263, 
1189, 1053 cm−1. 1H NMR (CD3CN, 300 MHz): δ 7.80 (t, J = 4.9 Hz, NH), 
7.40-7.25 (m, 10H), 6.83 (br s, 3NH), 6.60 (d, J = 7.6 Hz, NH), 5.12 (s, 
2H), 5.05 (s, 2H), 4.24-4.12 (m, 1H), 3.15-3.04 (m, 2H), 1.87-1.67 (m, 
2H), 1.67-1.54 (s, 2H). 13C NMR (CD3CN, 75 MHz): δ 173.1, 158.5, 
157.4, 138.0, 136.9, 129.5, 129.4, 129.1, 128.9, 128.8, 128.5, 67.5, 67.1, 
54.9, 41.6, 29.1, 25.8. HRMS (ESI) m/z calcd for C21H27N4O4 (M+H)+: 399.2032, found: 399.2045. 
	
Nα‐Cbz‐L‐Asparagine(Trt)	benzyl	ester	(40N)	
General procedure C using Z-L-Asn(Trt)-OH (509 mg, 1.00 mmol), 
K2CO3 (138 mg, 1.00 mmol) and benzyl bromide (131 μl, 1.10 mmol). 
The product was obtained as an off-white powder after purification by 
column chromatography (EtOAc/heptane 1:31:2) (481 mg, 82%). Rf 
0.35 (EtOAc/heptane 1:3). Mp 133.7 °C. []20D +2.2 (c 2.28, CH2Cl2). IR 
(film) 3325, 3059, 3031, 1722, 1671, 1493, 1448, 1338, 1282, 1256, 
1212, 1044 cm−1. 1H NMR (CDCl3, 400 MHz): δ 7.34-7.22 (m, 20H), 7.16-7.10 (m, 5H), 6.67 (s, 
NH), 6.06 (d, J = 8.4 Hz, NH), 5.13 (d, J = 12.3 Hz, 1H), 5.09 (d, J = 12.3 Hz, 1H), 5.09 (s, 2H) 4.64-
4.57 (m, 1H), 3.08 (dd, J = 4.5, 15.6, 1H), 2.84 (dd, J = 4.2, 15.6, 1H). 13C NMR (CDCl3, 75 MHz): δ 
170.8, 169.0, 156.2, 144.3, 136.3, 135.3, 128.6, 128.5, 128.4, 128.2, 128.0, 127.8, 127.2, 70.9, 
67.4, 66.9, 51.1, 38.6. HRMS (ESI) m/z calcd for C38H34Na1N2O5 (M+Na)+: 621.2365, found: 
621.2405. 
	
Nα‐Cbz‐L‐Asparagine	benzyl	ester	(Z‐L‐Asn‐OBn)	
General procedure B2 using 40N	 (144 mg, 0.241 mmol) and 
additionally triethylsilane (40 μL, 6.49 mmol) was added. After stirring 
for 1 hour, the product was obtained as an off-white TFA salt after 
extraction with Et2O (3 x 20 mL) from water/dioxane (1:2 v/v), 
washed with heptane and filtrated (70 mg, 61%). Rf 0.40 
(EtOAc/heptane 1:4). Mp 126.5 °C. []20D 13.6 (c 2.15, MeOH). IR (film) 
3404, 3312, 3205, 3067, 3032, 1742, 1696, 1657, 1542, 1339, 1258, 1218, 1059 cm−1. 1H NMR 
(CD3CN, 400 MHz): δ 7.39-7.29 (m, 10H), 6.26-6.16 (m, 2NH), 5.75 (br s, NH), 5.13 (s, 2H), 5.09 
(d, J = 12.8 Hz, 1H), 5.06 (d, J = 12.4 Hz, 1H), 4.55 (dt, J = 5.7, 8.8 Hz, 1H), 2.75 (dd, J = 6.0, 16.1 
Hz, 1H), 2.69 (dd, J = 5.0, 16.0 Hz, 1H). 13C NMR (CD3CN, 75 MHz): δ 172.2, 157.0, 145.0, 130.1, 
N
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129.4, 129.3, 129.0, 128.9, 128.8, 128.6, 127.3, 67.6, 67.2, 51.8, 37.3. HRMS (ESI) m/z	calcd for 
C19H20Na1N2O5 (M+Na)+: 379.1270, found: 379.1271. 
	
Nα‐Cbz‐L‐Glutamate(OtBu)	benzyl	ester	(40E)	
General procedure C using Z-L-Glu(OtBu)-OH (337 mg, 1.00 mmol), 
K2CO3 (138 mg, 1.00 mmol) and benzyl bromide (131 μl, 1.10 mmol). 
The product was obtained as an off-white powder after purification by 
column chromatography (EtOAc/heptane 1:31:2) (363 mg, 85%). Rf 
0.35 (EtOAc/heptane 1:3). Mp 47.5 °C. []20D 1.3 (c 2.39, CH2Cl2). IR 
(film) 3339, 3028, 2976, 2885, 1722, 1525, 1455, 1367, 1256, 1212, 
1151, 1056 cm−1. 1H NMR (CDCl3, 400 MHz): δ 7.39-7.29 (m, 10H), 5.43 (d, J = 8.2 Hz, NH), 5.17 
(s, 2H), 5.10 (s, 2H), 4.48-4.40 (m, 1H), 2.36-2.10 (m, 3H), 2.01-1.90 (m, 1H), 1.42 (s, 9H). 13C 
NMR (CDCl3, 75 MHz): δ 171.9, 171.8, 155.9, 136.2, 135.2, 128.6, 128.5, 128.3, 128.1, 128.0, 80.8, 
67.3, 67.0, 53.5, 31.3, 28.0, 27.6. HRMS (ESI) m/z calcd for C24H30N1O6 (M+H)+: 428.2073, found: 
428.2067. Spectral data were in accordance with those reported in literature.[29] 
	
Nα‐Cbz‐L‐Glutamate	benzyl	ester	(Z‐L‐Glu‐OBn)	
General procedure B2 using 40E	 (106 mg, 0.234 mmol) and 
additionally Et3SiH (40 μL, 6.49 mmol) was added. After stirring for 1 
hour, the product was obtained as a colourless oil (89 mg, 78%). []20D
21.4 (c 1.54, MeOH). IR (film) 3327, 3057, 3033, 2956, 1706, 1525, 
1454, 1343, 1256, 1211, 1154, 739, 697 cm−1. 1H NMR (CD3CN, 300 
MHz): δ 7.39-7.29 (m, 10H), 6.04 (d, J	= 7.5 Hz, NH), 5.14 (s, 2H), 5.07 (s, 
2H), 4.30-4.21 (m, 1H), 2.37 (t, J	= 7.3 Hz, 2H), 2.15-2.03 (m, 1H), 1.95-1.83 (m, 1H). 13C NMR 
(CD3CN, 75 MHz): δ 174.1, 172.7, 157.1, 138.0, 137.0, 129.5, 129.4, 129.1, 129.0, 128.9, 128.6, 
67.6, 67.2, 54.5, 30.2, 27.3. HRMS (ESI) m/z calcd for C20H21Na1N1O6 (M+Na)+: 394.1267, found: 
394.1269. Spectral data were in accordance with those reported in literature.[30] 
	
Nα‐Cbz‐L‐Isoleucine	benzyl	ester	(Z‐L‐Ile‐OBn)	
General procedure C using Z-L-Ile-OH (1.33 g, 5.00 mmol), K2CO3 (691 
mg, 5.00 mmol) and benzyl bromide (654 μl, 5.50 mmol) in DMF (4 
mL). The product was obtained as a colourless oil after purification by 
column chromatography (EtOAc/heptane 1:91:2) (1.63 g, 91%). Rf 
0.56 (EtOAc/heptane 1:2). []20D +1.5 (c 1.02, CH2Cl2). IR (film) 3343, 
3067, 1716, 1518, 1455, 1335, 1192 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.48-7.24 (m, 10H), 5.35 
(d, J = 7.1 Hz, NH), 5.19 (d, J = 12.1 Hz, 1H), 5.12 (d, J = 12.1 Hz, 1H), 5.09 (s, 2H), 4.46-433 (m, 
1H), 1.99-1.73 (m, 1H), 1.46-1.23 (m, 1H), 1.23-1.00 (m, 1H), 1.00-0.74 (m, 6H). 13C NMR (CDCl3, 
75 MHz): δ 171.8, 156.0, 136.2, 135.2, 128.5, 128.4, 128.3, 128,2, 128.0, 128.0, 66.9, 58.3, 37.9, 
24.8, 15.4, 11.5. HRMS (ESI) m/z calcd for C21H26NO4 (M+H)+: 356.1862, found: 356.1863. 
	
Nα‐Cbz‐L‐Proline	benzyl	ester	(Z‐L‐Pro‐OBn)	
General procedure C using Z-L-Pro-OH (1.25 g, 5.00 mmol), K2CO3 (691 
mg, 5.00 mmol) and benzyl bromide (654 μl, 5.50 mmol) in DMF (4 mL). 
The product was obtained as a colourless oil after purification by column 
chromatography (EtOAc/heptane 1:91:2) (1.66 g, 98%). Rf 0.36 
(EtOAc/heptane 1:2). []20D 47.3 (c 2.01, CH2Cl2). IR (film) 3062, 3032, 
1744, 1703, 1415, 1350, 1166, 1118 cm−1. 1H NMR (CDCl3, 300 MHz): δ 7.39-7.18 (m, 10H), 
5.24-4.94 (m, 4H), 4.44 (dd, J = 3.4, 8.6 Hz, 0.45H), 4.36 (dd, J = 3.7, 8.6 Hz, 0.55H), 3.68-3.40 (m, 
2H), 2.28-2.09 (m, 1H), 2.06-1.76 (m, 3H). 13C NMR (CDCl3, 75 MHz): δ 172.4, 172.2, 154.6, 
154.0, 136.5, 136.3, 135.5, 135.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.6, 
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127.6, 127.5, 66.7, 66.7, 66.5, 66.4, 59.1, 58.7, 46.7, 46.2, 30.6, 29.6, 24.0, 23.3. HRMS (ESI) m/z 
calcd for C20H21NNaO4 (M+Na)+: 362.1368, found: 362.1364. Spectral data were in accordance 
with those reported in literature.[31] 
 
3‐Amino‐2‐cyclopropylpropanol	(42)	
To a solution of LiAlH4 (244 mg, 6.43 mmol, 6.4 equiv) in anhydrous THF (5 
mL) containing 4 Å MS was added 1-(aminocarbonyl)cyclopropanecarboxylic 
acid (129 mg, 1.0 mmol, 1.0 equiv) and the mixture was refluxed overnight. 
Work-up was performed by evaporation of the solvent and slow addition of water (5 mL). 
Subsequently, THF (20 mL) was added and stirred for 30 minutes The resulting reaction 
mixture was evaporated in	vacuo, and Et2O (50 mL) was added to form a precipitate, which was 
filtered off. The residue was washed with Et2O ( 3 × 50 mL) and the organic layers were 
combined, dried over Na2SO4, filtered, and evaporated in	vacuo to afford 42 (74 mg, 55%) as a 
yellow oil. Rf 0.16 (10% MeOH in CH2Cl2). IR (film) 3356, 3280, 2996, 2920, 2865, 1653, 1598, 
1425, 1023, 988, 933 cm−1. 1H NMR (CDCl3, 300 MHz): 3.62 (s, 2H), 2.82 (s, 2H), 2.48 (br s, 
2NH, 1OH), 0.51-0.46 (m, 2H), 0.42-0.37 (m, 2H). 13C NMR (CDCl3, 75 MHz): 68.2, 49.7, 30.9, 
10.1, 9.8. HRMS (ESI) m/z calcd for C5H12NO (M+H)+: 102.0919, found: 102.0902. 
 
3‐[N,N’‐di(Boc)guanidino]‐2‐cyclopropylpropanol	(43)	
To a solution of N,N′-di(Boc)-S-methylisothiourea (290 mg, 1.0 mmol, 
1.0 equiv) and DMAP (183 mg, 1.5 mmol, 1.5 equiv) in CH2Cl2 (5 mL) 
was added 42 (0.101 g, 1.0 mmol, 1.0 equiv) and stirred at room 
temperature for 5 hours. The reaction mixture was evaporated to 
dryness and purified by means of column chromatography (MeOH in 
CH2Cl2, 05%) to afford 43 (341 mg, 99%) as a white fluffy solid. Rf	0.32 (5% MeOH in CH2Cl2). 
IR (film) 3328, 2968, 2920, 1722, 1660, 1612, 1556, 1425, 1369, 1314, 1238, 1162, 1134, 1058, 
815, 753 cm−1. 1H NMR (CDCl3, 300 MHz):11.43 (br s, NH), 8.57 (br s, NH), 5.03 (t, J = 7.5 Hz, 
1H, OH), 3.35-3.29 (m, 4H), 1.51 (s, 9H), 1.48 (s, 9H), 0.50-0.45 (m, 4H). 13C NMR (CDCl3, 75 
MHz):  162.8, 157.0, 153.1, 83.5, 79.5, 66.0, 45.6, 30.9, 28.1, 23.4, 9.3. HRMS (ESI) m/z calcd for 
C16H30N3O5 (M+H)+: 344.2186, found: 344.2172. 
 
Nα‐Cbz‐Glycine	3‐[N,N’‐di(Boc)guanidino]‐2‐cyclopropylpropyl	ester	(44)	
General procedure A1 with adjusted amounts of every 
component using 43 (100 mg, 0.29 mmol, 1.0 equiv), DCC (72 
mg, 0.35 mmol, 1.2 equiv), DMAP (43 mg, 0.35 mmol, 1.2 
equiv) and Z-Gly-OH (73 mg, 0.35 mmol, 1.2 equiv) in CH2Cl2 
(2 mL). The product (44) was obtained as a white solid after 
purification by column chromatography (MeOH in CH2Cl2, 05%) (155 mg, quant). Rf	0.44 (5% 
MeOH in CH2Cl2). IR (film) 3315, 2982, 1715, 1639, 1605, 1563, 1425, 1362, 1328, 1168, 1134, 
1058, 815, 746, 691 cm−1. 1H NMR (CDCl3, 300 MHz): 11.52 (s, 1H, NH), 8.59 (s, 1H, NH), 7.36-
7.33 (m, 5H), 5.57 (s, 1H, NH), 5.13 (s, 2H), 4.09-4.06 (m, 4H), 3.41 (s, 2H), 1.49 (s, 18H), 0.88-
0.62 (m, 4H). 13C NMR (CDCl3, 75 MHz):  206.8, 170.1, 163.4, 156.3, 156.0, 153.2, 136.3, 128.4, 
128.2, 128.2, 128.1, 83.2, 71.4, 67.2, 66.9, 47.3, 43.1, 29.3, 18.9, 10.8. HRMS (ESI) m/z calcd for 
C26H39N4O8 (M+H)+: 535.2768, found: 535.2747. 
 
Nα‐Cbz‐Glycine	3‐guanidino‐2‐cyclopropylpropyl	ester	(Z‐Gly‐O3G)	
Compound 44 (65 mg, 0.12 mmol) was treated with 
CH2Cl2/TFA (2 mL, 1:1) overnight, the solvents were 
removed under reduced pressure and co-evaporated with 
tBuOH (3 × 10 mL). Z‐Gly‐O3G (55 mg, quant) was 
obtained as a colourless oil. IR (film) 3349, 3169, 1674, 1535, 1258, 1189, 1134, 1037, 988, 836, 
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788, 760, 718, 712 cm−1. 1H NMR (CDCl3, 300 MHz): 7.35-7.33 (m, 5H), 7.26 (br s, 2NH), 6.84 
(br s, 3NH), 5.76 (br s, NH), 5.10 (s, 2H), 4.02 (s, 2H), 3.90 (s, 2H), 3.03 (s, 2H), 0.61-0.57 (m, 
4H). 13C NMR (CDCl3, 75 MHz):  170.0, 157.5, 157.2, 135.8, 128.6, 128.4, 127.8, 70.1, 67.5, 46.9, 
43.1, 31.0, 19.4, 9.8. HRMS (ESI) m/z calcd for C16H23N4O4 (M+H)+: 335.1719, found: 335.1713. 
 
5‐Methylene‐2‐oxo[1,3,2]dioxathiane	(46)	
To an emulsion of diol 2-methylene-1,3-propanediol (1.76 g, 20 mmol, 1.0 equiv) in 
CCl4 (12 mL) at 0 °C was added dropwise a solution of thionyl chloride (3.53 g, 30 
mmol, 1.5 equiv) in CCl4 (6 mL) under vigorous stirring. When the evolution of HCl had 
ceased after approximately 30 minutes, the solution was stirred for an additional 15 
minutes Evaporation of the solvent at 0 °C and 5 mbar, followed by Kugelrohr 
distillation (b.p. 90-110 °C/ >10 Torr) yielded 46 (1.95 g, 73 % yield) as a colourless 
liquid. Rf	0.55 (EtOAc/pentane 1:4). IR (film) 3088, 2991, 2938, 2873, 1461, 1446, 1416, 1342, 
1300, 1239, 1195, 1177, 982, 958, 926, 870, 759, 717, 692, 663 cm−1. 1H NMR (CDCl3, 300 
MHz): 5.35 (dt, J = 1.5, 13.2 Hz, 2H), 5.13-5.11 (m, 2H), 4.24 (dt, J =1.5, 13.2 Hz, 2H). 13C NMR 
(CDCl3, 75 MHz):  135.5, 114.4, 61.6. Spectral data were in accordance with those reported in 
literature.[7]  
 
3‐Azido‐2‐methylenepropanol	(47)	
To a solution of 46 (630 mg, 4.7 mmol, 1.0 equiv) in DMF (10 mL) was added 
sodium azide (366 mg, 5.6 mmol, 1.2 equiv) and the mixture was heated to 80 
°C. After 30 minutes, the reaction was quenched by addition of water (20 mL) 
and extracted with Et2O (3 × 10 mL). The combined organic extracts were washed with water 
(20 mL), dried with MgSO4 and concentrated in	vacuo at 0 °C and 5 mbar. The crude product 
was purified by column chromatography (EtOAc/pentane 1:4) to obtain 47 (478 mg, 90%) as a 
yellow oil. Rf	0.24 (EtOAc/pentane 1:4). IR (film) 3308, 2913, 2858, 2089, 1653, 1445, 1238, 
1072, 1016, 919, 871, 656, 559 cm−1. 1H NMR (CDCl3, 300 MHz): 5.28 (s, 1H), 5.18 (s, 1H), 4.19 
(s, 2H), 3.86 (s, 2H), 1.72 (s, 2H). 13C NMR (CDCl3, 75 MHz):  142.7, 114.6, 64.0, 53.3. Spectral 
data were in accordance with those reported in literature.[7] 
 
3‐[N,N’‐di(Boc)guanidino]‐2‐methylenepropanol	(49)	
To a solution of 47 (113 mg, 1.0 mmol, 1.1 equiv) in water/THF (30 mL, 
1:5) was added trimethylphosphine (84 mg, 1.1 mmol, 1.1 equiv) and 
the resulting mixture was stirred at room temperature overnight. 
Subsequently, HCl (1.5 mL, 1.0 M) was added and the solvent was 
evaporated in	vacuo to afford crude 48 as a yellow oil. Without further 
purification crude 48	was added to a solution of N,N′-di(Boc)-S-methylisothiourea (145 mg, 
0.50 mmol) and DMAP (92 mg, 0.75 mmol) in CH2Cl2 (5 mL) and the mixture was stirred at 
room temperature for 5 h. After evaporation to dryness and purification by means of column 
chromatography (MeOH in CH2Cl2, 05%) 49 was obtained as a white fluffy solid (242 mg, 
74% over two steps). Rf	0.63 (5% MeOH in CH2Cl2). IR (film) 3324, 2952, 2927, 1729, 1653, 
1612, 1432, 1301, 1245, 1167, 1127, 1085, 760, 680, 615 cm−1. 1H NMR (CDCl3, 300 MHz): 
11.43 (br s, NH), 8.57 (br s, NH), 5.05 (s, 1H), 4.99 (s, 1H), 4.87 (br s, OH), 4.08-4.04 (m, 4H), 
1.50 (s, 9H), 1.48 (s, 9H). 13C NMR (CDCl3, 75 MHz): 162.6, 156.7, 153.1, 145.8, 114.0, 83.6, 
79.6, 63.4, 43.0, 28.2, 28.0.  
 
Nα‐Cbz‐Glycine	3‐[N,N’‐di(Boc)guanidino]‐2‐methylenepropyl	ester	(50)	
General procedure A1 with adjusted amounts of every 
component using 49	(120 mg, 0.40 mmol, 1.0 equiv), DCC (83 
mg, 0.40 mmol, 1.0 equiv), DMAP (49 mg, 0.40 mmol, 1.0 
equiv) and Z-Gly-OH (84 mg, 0.40 mmol, 1.0 equiv) in EtOAc 
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(2 mL). Purification was performed by column chromatography (EtOAc/heptane 1:3) to afford 
50 as a white solid (181 mg, 95%). Rf 0.41 (EtOAc/heptane 1:1). IR (film) 3328, 2982, 2927, 
1729, 1653, 1612, 1411, 1369, 1321, 1245, 1168, 1127, 1092, 1072, 822, 760, 691, 615 cm−1. 1H 
NMR (CDCl3, 300 MHz): 11.52 (br s, NH), 8.48 (br s, NH), 7.41-7.32 (m, 5H), 5.45 (br s, NH), 
5.24 (s, 2H), 5.13 (s, 2H), 4.66 (s, 2H), 4.16-4.10 (m, 2H), 4.09-4.00 (m, 2H), 1.49 (s, 18H). 13C 
NMR (CDCl3, 75 MHz):  163.4, 156.2, 153.3, 139.1, 136.3, 128.5, 128.2, 128.1, 117.1, 83.4, 79.5, 
67.0, 66.4, 43.2, 42.9, 34.0, 28.2, 28.1, 24.9. HRMS (ESI) m/z calcd for C25H37N4O8 (M+H)+: 
521.2611, found: 521.2592. 
 
Nα‐Cbz‐Glycine	3‐guanidino‐2‐methylenepropyl	ester	(Z‐Gly‐O3G=)	
Compound 50 (100 mg, 0.20 mmol) was treated with 
CH2Cl2/TFA (6 mL, 1:1) overnight, the solvents were removed 
under reduced pressure and co-evaporated with tBuOH (3 × 
10 mL). Z‐Gly‐O3G= was obtained as a colourless oil (83 mg, 
quant). IR (film) 3356, 3190, 2941, 1667, 1528, 1452, 1272, 1182, 1044, 975, 836, 795, 732, 691 
cm−1. 1H NMR (CDCl3, 300 MHz): 7.67 (br s, NH), 7.34-7.32 (m, 5H), 6.91 (br s, 2NH), 5.59 (br s, 
NH), 5.33 (d, J	= 11.1 Hz, 2H), 5.10 (s, 2H), 4.67 (s, 2H), 3.92 (d, J = 6.0 Hz, 2H), 3.77 (d, J = 6.3 Hz, 
2H), 3.38 (br s, 2H). 13C NMR (CDCl3, 75 MHz):  169.7, 157.6, 137.8, 135.8, 128.6, 128.4, 127.8, 
118.9, 67.5, 66.0, 43.9, 43.0, 33.2, 31.2. HRMS (ESI) m/z calcd for C15H21N4O4 (M+H)+: 321.1563, 
found: 321.1555. 
 
Nα‐Cbz‐Glycine‐3‐[N,N’‐di(Boc)guanidino]‐2‐carbonylpropyl	ester	(51)	
A solution of 50 (260 mg, 0.50 mmol, 1.0 equiv) in CH2Cl2 (10 
mL) was stirred and cooled to –78 °C. Subsequently, ozone 
was bubbled through the solution for 30 minutes. The 
solution turned light blue and TLC-analysis indicated the 
disappearence of the substrate. Then DMS (34 mg, 0.55 mmol, 
1.1 equiv) was added in one portion, stirring still continued at –78 °C for 10 minutes. The 
reaction mixture was brought to room temperature and stirred for an additional 10 minutes. 
Then the reaction was quenched with water (10 mL), the layers were separated and the 
waterlayer was washed with CH2Cl2 (3 × 5 mL). The combined organic layers were dried with 
Na2SO4 and the solvent was evaporated in	 vacuo. Purification was performed by means of 
column chromatography (EtOAc/heptane 1:4) to afford 51	 (159 mg, 61%). Rf	 0.50 
(EtOAc/heptane 1:1). IR (film) 3322, 2975, 2920, 1715, 1646, 1618, 1563, 1411, 1355, 1300, 
1155, 1065, 753 cm−1. 1H NMR (CDCl3, 300 MHz): 11.39 (br s, NH), 8.96 (br s, NH), 7.36-7.32 
(m, 5H), 5.52 (br s, NH), 5.13 (s, 2H), 4.81 (s, 2H), 4.36 (s, 2H), 4.12 (d, J = 5.7 Hz, 2H), 1.50 (s, 
18H). 13C NMR (CDCl3, 75 MHz):  209.1, 170.4, 157.6, 136.8, 136.4, 128.6, 128.4, 127.8, 115.9, 
67.5, 67.1, 66.0, 42.8, 30.1.  
 
Nα‐Boc‐L‐Proline‐p‐nitroanilide	(Boc‐Pro‐pNA)	
General procedure D using Boc-Pro-OH (2.15 g, 10 mmol), p-
nitroaniline (1.38 g, 10 mmol) and phosphorus oxychloride (1.01 ml, 
11 mmol). After recrystallisation with isopropyl alcohol and heptane 
the product was obtained as a slightly yellowish solid (2.19 g, 65%). 
1H NMR (CDCl3, 300 MHz): δ 10.24 (br s, NH), 8.23-8.14 (m, 2H), 7.72-
7.63 (m, 2H), 4.49 (br s, NH), 3.52-3.26 (m, 2H), 2.66-2.47 (m, 1H), 2.04-1.89 (m, 3H), 1.51 (s, 
9H). 13C NMR (CDCl3 , 75 MHz): δ 170.6, 156.7, 144.3, 143.1, 124.9, 118.9, 81.4, 60.6, 47.4, 28.4, 
27.3, 24.5. HRMS (ESI) m/z calcd for C16H21N3NaO5 (M+Na)+: 358.1379, found: 358.1377. 
Spectral data were in accordance with those reported in literature.[32] 
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L‐Proline‐p‐nitroanilide	(Pro‐pNA) 
Nα-Boc-L-Proline-p-nitroanilide (700 mg, 2.09 mmol, 1 equiv) was 
dissolved in CH2Cl2 (10 mL) to which TFA was added (2.5 mL). 
The reaction mixture was stirred at room temperature overnight. 
The solvents were removed under reduced pressure and co-
evaporated with CH2Cl2 (3 × 20 mL). The resulting solid was 
purified by recrystallisation with EtOAc and heptane (652 mg, 94%). 1H NMR (CD3CN, 300 
MHz): δ 10.14 (s, NH), 8.24-8.16 (m, 2H), 7.84-7.77 (m, 2H), 4.65-4.56 (m, 1H), 3.48-3.31 (m, 
2H), 2.54-2.40 (m, 2H), 2.10-1.95 (m, 2H). 13C NMR (CD3CN, 75 MHz): δ 168.7, 144.8, 141.2, 
125.8, 120.4, 118.2, 61.3, 47.5, 30.4, 25.1. HRMS (ESI) m/z calcd for C11H14N3O3 (M+H)+: 
236.1035, found: 236.1035. Spectral data were in accordance with those reported in 
literature.[33] 
 
Nα‐Boc‐L‐Serine(OtBu)‐p‐nitroanilide	(Boc‐Ser(OtBu)‐pNA)		
General procedure D using Boc-Ser(OtBu)-OH (862 mg, 3.3 mmol), p-
nitroaniline (456 mg, 3.3 mmol) and phosphorus oxychloride (332 
l, 3.6 mmol). After purification by column chromatography 
(EtOAc/heptane 1:101:1) the product was obtained as a slightly 
yellowish solid (573 mg, 46%). Rf 0.49 (EtOAc/heptane 1:1). Mp 55 
°C. []20D 24.8 (c 0.75, CH2Cl2). IR (film) 3296, 2976, 2928, 1679, 
1511, 1341, 1162 cm−1. 1H NMR (CDCl3, 300 MHz): δ 9.14 (s, NH), 
8.26-8.17 (m, 2H), 7.72-7.63 (m, 2H), 5.53-5.41 (m, NH), 4.41-4.27 (m, 1H), 3.90 (dd, J = 3.9, 8.6 
Hz, 1H), 3.48 (dd, J = 8.4, 8.4 Hz), 1.48 (s, 9H), 1.26 (s, 9H). 13C NMR (CDCl3, 75 MHz): δ 169.5, 
155.6, 143.6, 143.4, 125.1, 119.0, 80.7, 74.9, 61.6, 54.9, 28.3, 27.5. HRMS (ESI) m/z calcd for 
C18H28N3O6 (M+H)+: 382.1978, found: 382.1978. 
 
L‐Serine‐p‐nitroanilide	(Ser‐pNA)	
Nα-Boc-L-Serine(OtBu)-p-nitroanilide (500 mg, 1.31 mmol, 1 
equiv) was treated with a commercially available solution of ~ 4 
M HCl in dioxane (10 mL) and stirred at room temperature 
overnight. The solvents were removed under reduced pressure 
and co-evaporated with n-BuOH (3 × 20 mL). The resulting solid 
was purified by recrystallisation with isopropyl alcohol and 
heptane (290 mg, 85%). Rf 0.16 (10% MeOH in CH2Cl2). Mp 170 °C. []20D +13.8 (c 0.33, MeOH). 
IR (film) 3204, 3047, 1702, 1569, 1506, 1351, 1261 cm−1. 1H NMR (DMSO-d6, 300 MHz): δ 8.30-
8.26 (m, 2H), 7.95-7.88 (m, 2H), 5.59 (t, J = 5.0 Hz, NH), 4.14 (t, J = 4.4 Hz, 1H), 4.00-3.80 (m, 
2H). 13C NMR (DMSO-d6, 75 MHz): δ 166.7, 144.3, 142.6, 124.9, 119.1, 60.0, 55.1. HRMS (ESI) 
m/z calcd for C9H12N3O4 (M+H)+: 226.0828, found: 226.0822. 
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 	Chapter 8
	
Perspective	
 
This chapter provides my personal view on the research described in this thesis and the 
options that I see for chemoenzymatic peptide synthesis based on either substrate 
mimetics or enzymatic activation in the future. 
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8.1 Theoretical potential of the substrate mimetics concept 
I was charmed by the concept that a hydrolytic enzyme can be misled by a substrate 
mimetic in such a way that it catalyses synthesis under aqueous circumstances. Substrate 
specificity is often quite strict, which generally serves a good reason in the native 
environment. It is remarkable that the addition of a specific element required for 
recognition to an amino acid of choice, can bring about its acceptance as a substrate. This 
sounds like an ideal situation for synthetic purposes. 
More particularly, the key players in the substrate mimetics approach are the 
guanidinophenyl ester (the mimetic) and the arginine-specific serine protease trypsin. For 
a viable industrial process, the OGp ester needs to be simplified and the alternative moiety 
should preferably be enzymatically coupled to the amino acid or peptide. Whether this 
should be carried out in separate steps or in a two-enzyme-one-pot process is not yet the 
subject of debate. If these goals could be realised, industry would be provided with a 
promising chemoenzymatic peptide synthesis strategy. 
 
8.2 Comprehensive overview of the results described in this thesis  
First a proper insight was required into the applicability of the substrate mimetics strategy. 
Although we wanted to replace the OGp ester in the end, we started out to subject this 
ester to the cysteine protease papain, in order to potentially widen the scope of the 
substrate mimetics strategy. Possibly due to the broad substrate specificity of papain, this 
mimetic – enzyme combination turned out to work well. Various dipeptides were 
successfully synthesised in aqueous media. A computational docking study, intended to 
provide insight into the molecular interactions, revealed that the OGp ester binds to the 
active site of papain in a different manner than the natural substrate arginine. This was 
reason for us to henceforth refer to enzyme-specific activation, a more comprehensive 
designation for this phenomenon, which also covers substrate mimetics. 
This finding made it more likely to find a simpler alternative for OGp. From a set of 
potentially activating esters, two compounds appeared to be good replacements. The 
ODmap esters reacted significantly faster than the OBn esters, but the scope of the 
dipeptide synthesis reaction remained similar compared to OGp in both cases. To really 
establish the potential of these alternative esters, two relevant dipeptides were 
synthesised on gram scale. Z-Gly-Phe-NH2 starting from Z-Gly-ODmap and H-L-Glu-Trp-OH 
starting from Z-L-Glu-OBn, which itself was enzymatically prepared with Alcalase-CLEA in 
anhydrous media, a system developed by DSM. Now full advantage is taken from the 
enzymatic coupling. 
Thorough evaluation of the potentially activating esters gave rise to the question to what 
extent recognition is actually important and to what extent the leaving group ability of the 
ester is determining for its activity. Experimental research combined with computational 
methods such as docking and ab	initio calculations on trypsin, the most studied enzyme in 
this context, showed that electronic properties are decisive. Obviously, as a precondition, 
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the ester has to fit in the active site, and a nice fit certainly contributes to a higher activity, 
but that alone is insufficient. 
In this light it is less surprising that OGp, OTmap, ODmap, OTfe and OCam structurally 
outrival the other esters, even in enzymes which favour large aromatic or hydrophobic 
residues in their S1 subsite such as α-chymotrypsin and Alcalase and even when the 
reaction is performed in organic solvents. They are simply the most active esters present 
in the set. The initially remarkable observation that the phenolic esters containing a 
positive charge give the highest activity, despite the native preference of α-chymotrypsin 
and Alcalase, may be rationalised by the nature of the interactions that can be made. Ionic 
interactions are much stronger than for example Van der Waals interactions, so, if it is 
possible to make such an interaction, this is relatively favourable. 
The results obtained from an attempt to design mimetics for the proline protease 
MaxiPro,[1] not previously described in this thesis, are nicely in keeping with this view too. 
In Figure 8.1 potential proline mimetics are depicted. 
 
 
 
Figure 8.1  Set of potentially activating esters for proline protease MaxiPro 
 
Most esters appeared to be slightly active in a dipeptide synthesis assay with H-Phe-NH2, 
but no reaction was fast and promising, for none of them is a good leaving group. The set 
was supplemented with OGp, OCam and OTfe, which were additionally evaluated. 
Interesting in this respect is the complete inactivity of the OGp ester. As it is presumed that 
the S1 subsite of the enzyme is built in such a manner that it specifically disposes proline,[2] 
probably based on the β-turn that is induced by the presence of this amino acid in a 
peptide chain, it is likely that OGp does not fit in the active site. Due to the unavailability of 
a crystal structure of MaxiPro, this hypothesis could not be tested. OTfe and OCam on the 
other hand performed similarly well as the other esters, indicating that these small esters 
do fit. 
 
8.3 Bottlenecks encountered throughout the project 
In an early stage of the research, lack of insight into the enzymes hindered the progress. 
The collaboration with a computational modelling group has proven to be extremely 
Chapter 8 
 
 144 
valuable to gain insight into the active site of our enzymes. A working model for papain 
was built, which at least helped rationalising the functioning of our activating esters, and 
gave direction to our search. Yet, it remains a model, so a critical attitude is appropriate. A 
crystal structure of papain co-crystallised with an inactive analogue of an OGp ester, could 
have confirmed the model. Unfortunately, this could not be realised within the timeframe 
of the research. 
The activity of all the activating esters was determined using HPLC analysis, which is a 
time consuming technique. Nevertheless, it was the method of choice to distinguish 
between synthesis and hydrolysis and quantify the products. It would have been more 
convenient to use a spectrophotometrical assay, which could directly demonstrate 
synthesis instead of hydrolysis. Such a development would have enabled high throughput 
screening of many enzymes with our set of esters, and might have resulted in better 
combinations of enzymes and activating groups than we identified so far. 
 
8.4 Restrictions to large-scale implementation of activating esters  
The objective to explore the scope and limitations of the substrate mimetics strategy, 
which should ultimately have led to a universal approach to couple amino acids to a 
peptide chain or effect fragment couplings using cheap enzymes, appeared to be more 
challenging than expected.  
First of all, we showed that in some situations it is better to use the term activating esters 
instead of substrate mimetics, although both strategies have a similar potential for 
becoming a universal and versatile approach.  
Secondly, for every enzyme the search for suitable activating esters has to be carried out 
separately, as the properties of each enzyme are different. The S/H ratio is enzyme 
dependent and is moreover varying for each amino acid. An intrinsic problem is that 
specificity is the main reason to use an enzyme, but at the same time is also its most 
limiting characteristic. Possibly, the OCam and OTfe esters have the best chances for being 
universal activating esters, since they are relatively small and will therefore fit in many 
active sites. Furthermore, they possess the right electronic properties.  
In the third place, an essential condition for activating esters becoming part of an 
industrial process is to develop an effective system to install the activating ester. At this 
moment all the advantages of enzymatic peptide coupling are lost, because the ester has to 
be synthesised by chemical methods. In this situation, it would be more efficient to 
accomplish the peptide bond directly. Without a doubt, the strategy of substrate mimetics 
and activating esters is only worthwhile, when the ester itself is synthesised in an 
enzymatic process. 
In conclusion, the development of a universal method for chemoenzymatic peptide 
synthesis has appeared troublesome. However, the synthesis of a particular peptide 
product using enzyme-specific activation in my view may still be feasible. In that case, the 
focus is shifted from general difficulties to finding a solution for specific challenges 
occurring in that particular sequence. 
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8.5 Outlook 
In my opinion, the most promising strategy for developing enzyme-specific activation 
procedures would consist of a combination of approaches. Several issues have to be 
tackled, the main two being 1) the still existing hydrolytic capacity of the enzyme, and 2) 
the recognition of a broad range of amino acid substrates. The problem of undesired 
enzymatic hydrolysis resulting in low S/H ratios can be solved by genetic engineering. The 
conversion of the protease subtilisin into subtiligase (S221C and P225A) is a very 
successful example of such an approach.[3] To prevent secondary hydrolysis of peptide 
products containing a specific amino acid residue recognised by the enzyme, another 
approach is required. Ideally, using directed evolution protocols an enzyme is created, 
which is specific for an ‘orthogonal’ amino acid, i.e. a residue not likely to be incorporated 
in any peptide chain. The previously discussed spectrophotometrical assay to demonstrate 
synthesis instead of hydrolysis is essential at this point to enable high throughput 
screening of the clones. For the resulting reprogrammed enzyme, a specifically activating 
group should be developed to achieve more universal substrate acceptance. All in all, a 
challenging task. 
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Summary  
 
This thesis describes a section of the chemoenzymatic peptide synthesis project, which has 
been performed within the framework of the NWO-IBOS programme. The integration of 
Biosynthesis and Organic Synthesis is the central approach to synthesise peptides in a 
sustainable and efficient way. This is important, because peptides make up a growing 
segment of drugs within the pharmaceutical industry, but the development of improved 
production methods lags behind.  
Peptides are composed of amino acids, which can be coupled both in a chemical and 
enzymatic way. An overview of these procedures is provided in Chapter	1. In addition, 
special attention is paid to the substrate mimetics strategy, which was taken as a starting 
point for the research described in this thesis. The substrate mimetics strategy combines 
the advantages of chemical synthesis (almost unlimited choice of amino acids) with the 
benefits of enzymatic synthesis (region- and stereospecific, mild reaction conditions). In 
practice, this is realised by equipping amino acids with an additional universal moiety, the 
so-called mimetic, resulting in recognition by the enzyme. 
 
 
 
Figure 1  Principle of the substrate mimetics strategy 
 
A well-known mimetic from literature is the guanidinophenyl ester (OGp), which, by 
resembling the amino acid arginine, is specifically recognised by the enzyme trypsin 
(Figure 1). Until now, OGp has been mainly applied in small-scale academic research. 
However, to make this concept of substrate mimetics applicable for large-scale industrial 
processes, a simple and cheap replacement of OGp is required. Preferably, it should be 
possible to install the mimetic enzymatically in the amino acid of choice.  
Our quest for an alternative mimetic commenced in a fairly fundamental way by 
investigating whether OGp would prove a suitable mimetic for papain, a cysteine protease 
with a broader specificity than trypsin (Chapter	2). A less specific enzyme may allow more 
variation in the structure of the mimetic without losing activity. As a test substrate Z-Gly-
OGp was synthesised and subjected to a chemoenzymatic reaction with papain in the 
presence of H-Phe-NH2 as acyl acceptor under aqueous conditions (Scheme 1). The 
reaction was followed in time and analysed using HPLC. 
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Scheme 1 Chemoenzymatic synthesis with papain 
 
To our delight, the conversion into the corresponding dipeptide was very efficient, which 
led us to conclude that OGp coupled to Z-Gly-OH is well-recognised by papain. To gain 
insight into the molecular interactions between enzyme and substrate mimetic, a 
modelling study was performed, in which also the remaining natural amino acids were 
involved, as well as a β- and a D-configured amino acid. Surprisingly, this study showed an 
unexpected binding mode: OGp was predicted to bind papain in a different orientation 
than the arginine side chain. This suggests that, in this case, the OGp ester is not actually 
mimicking the natural substrate, but recognition is accomplished in an alternative manner. 
We named this phenomenon enzyme-specific activation. 
Based on these results, we hypothesised that it is not strictly required to have an arginine-
like activating ester, provided that sufficient interactions can be made with the enzyme. In 
Chapter	3 this hypothesis is investigated, using a set of potentially activating moieties 
(Figure 2). The variation was mainly brought about by the presence or absence of a 
positive charge under slightly basic conditions, an aromatic or aliphatic part and the 
possibility to form hydrogen bonds. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Structures of potentially activating moieties 
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Each of these moieties was coupled to Z-Gly-OH, experimentally evaluated with papain, 
and subjected to modelling studies, which showed that OBn and ODmap are the most 
suitable replacements for OGp. Besides Z-Gly-OH, the remaining natural amino acids and a 
β- and a D-configured amino acid can indeed be used to chemoenzymatically synthesise 
dipeptides, albeit in varying yields and with an exception for Z-Pro-OH. The applicability of 
the ODmap and OBn esters was validated in preparative-scale syntheses of two biologically 
active dipeptides. The computational model demonstrated that besides a proper fit in the 
active site, the leaving group ability is also important. This intricate relationship was 
studied further in Chapter	 4 by means of OGp analogues (Figure 3) and the enzyme 
trypsin, using both experimental and computational approaches.  
 
 
 
Figure 3  Structures of OGp analogues 
 
The experimental evaluation presented us with large differences in reaction times in the 
conversion of various Z-Gly-analogues into dipeptides in the presence of H-Phe-NH2 under 
the influence of trypsin. Based on these observations however, it is virtually impossible to 
distinguish between the contribution of affinity for the enzyme (a proper fit) and the 
contribution of the leaving group ability (electronic properties) on the reaction speed. 
Docking and ab	initio calculations, two computational techniques, provided insight into the 
fit of the substrate in the enzyme and the leaving group ability, respectively. Combining all 
data taught us that the electronic properties of the activating moiety are decisive for 
enzymatic activity. However, as a precondition, the activating moiety has to fit in the active 
site, and a nice fit certainly contributes to a higher activity.  
Following this study to determine which properties contribute to a successful activating 
moiety, we investigated the scope of enzyme-specific activation. The previously introduced 
set of potentially activating moieties (Figure 2) was employed to also find a suitable 
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activating group for α-chymotrypsin (Chapter	5). Furthermore, a comparison was made 
with the results obtained with papain. It was observed that OBn and ODmap, activating 
moieties for papain, do not have a specific activating effect on α-chymotrypsin, whereas 
the reverse is true for OGb. The activating potential of the different moieties are indeed 
enzyme dependent. 
A similar study was carried out with the enzyme Alcalase-CLEA, except that we switched to 
an organic solvent (Chapter	6). Under these conditions the best performing moieties are 
the two positively charged phenols OGp and OTmap, which is remarkable for an enzyme 
that prefers large uncharged amino acid residues. Yet, these two moieties happen to be 
good leaving groups, which is in line with the outcome of chapter 4. 
Chapter	7 covers the synthesis of all activating moieties that appear in this thesis. 
In Chapter	8 eventually, my personal view on this piece of research and the results are 
described. A better fundamental understanding of activating esters may be the most 
important result produced. Based on this insight I wonder whether an industrially cost-
effective process for peptide synthesis derived from substrate mimetics or activating 
esters is feasible in the near future. Nevertheless, I am convinced that the scope and 
limitations are extensively mapped out.	
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Samenvatting  
 
Dit proefschrift beschrijft een onderdeel van het chemoenzymatische peptidesynthese 
project dat uitgevoerd is binnen het kader van het NWO-IBOS programma. De Integratie 
van Biosynthese en Organische Synthese staat centraal met als doel peptiden op een 
duurzame en efficiënte wijze te synthetiseren. Dit is belangrijk omdat peptiden een 
groeiend segment vormen binnen de farmaceutische industrie, maar de ontwikkeling van 
verbeterde productiemethoden achterloopt bij de vraag. 
Peptiden zijn opgebouwd uit aminozuren, die zowel chemisch als enzymatisch gekoppeld 
kunnen worden. In hoofdstuk	1 wordt hier verder op ingegaan. Daarnaast is er speciale 
aandacht voor de substrate	mimetics strategie, die als uitgangspunt heeft gediend voor dit 
proefschrift. In de substrate	 mimetics strategie worden de voordelen van chemische 
synthese (nauwelijks gelimiteerde keuze van aminozuren) gecombineerd met de 
voordelen van enzymatische synthese (regio- en stereospecifiek, milde reactiecondities). 
Dit wordt bewerkstelligd door aminozuren toe te rusten met een extra universele groep, 
de zogenaamde mimetic, wat herkenning door een enzym tot gevolg heeft. 
 
 
 
Figuur 1  Principe van de substrate mimetics strategie 
 
Een bekende mimetic uit de literatuur is de guanidinofenyl ester (OGp), die lijkt op het 
aminozuur arginine dat specifiek herkend wordt door het enzym trypsine (Figuur 1). Tot 
nu toe is OGp voornamelijk toegepast in academische studies op kleine schaal. Echter, voor 
een industrieel proces is een versimpelde en goedkope vervanging van OGp nodig, die zo 
mogelijk zelf ook weer enzymatisch kan worden geïnstalleerd. 
Onze zoektocht naar een alternatieve mimetic begon redelijk fundamenteel door te 
onderzoeken of OGp ook een geschikte mimetic zou zijn voor papaïne, een 
cysteïneprotease met een bredere specificiteit dan trypsine (hoofdstuk	2). Een enzym dat 
minder specifiek is laat waarschijnlijk meer variatie toe in de mimetic groep, zonder aan 
activiteit in te boeten. Bij wijze van testsubstraat is Z-Gly-OGp gesynthetiseerd en 
onderworpen aan een chemoenzymatische reactie met papaïne in de aanwezigheid van H-
Phe-NH2 als acylacceptor in een waterige omgeving (Schema 1). De reactie werd gevolgd in 
de tijd en geanalyseerd met behulp van HPLC.  
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Schema 1 Chemoenzymatische synthese met papaïne 
 
Tot onze vreugde verliep de omzetting zeer efficiënt en mag worden geconcludeerd dat 
OGp gekoppeld aan Z-Gly-OH goed herkend wordt door papaïne. Om een beter beeld te 
krijgen van de moleculaire interacties tussen enzym en substrate mimetic is een 
modelleerstudie uitgevoerd, waarin ook de overige natuurlijke aminozuren betrokken zijn, 
evenals een β- en D-aminozuur. Verrassend genoeg resulteerde deze studie in een 
onverwachte bindingswijze van het substraat: OGp lijkt op een andere manier aan papaïne 
te binden dan de zijketen van arginine. Dit suggereert dat OGp in dit geval niet optreedt als 
directe look‐a‐like van arginine, maar op een alternatieve wijze enzymatische herkenning 
tot stand brengt. Dit fenomeen hebben we enzym-specifieke activering genoemd. 
Op basis van het voorgaande, verwachtten we dat een activerende groep voor papaïne niet 
noodzakelijkerwijs op arginine hoeft te lijken, zolang deze maar voldoende specifieke 
interacties kan maken met het enzym. In hoofdstuk	 3 wordt deze hypothese getest, 
uitgaande van een set potentieel activerende groepen (Figuur 2). De variatie zit 
voornamelijk in de aan- of afwezigheid van een positieve lading onder licht basische 
condities, een aromatisch of alifatisch gedeelte en de mogelijkheid om waterstofbruggen te 
vormen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figuur 2  Structuren van potentieel activerende groepen 
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Elk van deze groepen is gekoppeld aan Z-Gly-OH, experimenteel getest met papaïne en 
gemodelleerd, waarna bleek dat OBn en ODmap de beste alternatieven vormen voor OGp.  
Naast Z-Gly-OH kunnen ook de overige natuurlijke aminozuren en een β- en D-aminozuur 
gebruikt worden om chemoenzymatisch dipeptiden mee te synthetiseren, zij het in een 
variërende opbrengst en met uitzondering van Z-Pro-OH. De toepasbaarheid van ODmap 
en OBn is geïllustreerd met de synthese van twee biologisch actieve dipeptiden op 
preparatieve schaal. Uit het computationele werk kwam naar voren dat het belangrijk is 
dat de activerende groep goed past in het enzym, maar ook dat de intrinsieke reactiviteit 
voldoende groot is. 
Dit laatste aspect is uitgebreider onderzocht in hoofdstuk	4	met behulp van OGp analoga 
(Figuur 3) en het enzym trypsine, gebruikmakend van zowel experimentele als 
computationele methoden.	
 
 
Figuur 3  Structuren van OGp analoga 
 
De experimentele evaluatie liet grote verschillen zien in de snelheid waarmee de 
verschillende Z-Gly-analoga onder invloed van trypsine en in aanwezigheid van H-Phe-NH2 
werden omgezet in dipeptiden. Het is echter vrijwel onmogelijk om op basis hiervan 
onderscheid te maken tussen de bijdrage van affiniteit voor het enzym (de pasvorm) en de 
bijdrage van het vertrekkende groep karakter (elektronische eigenschappen) op de 
reactiesnelheid. Docking en ab	initio berekeningen, twee computationele technieken, geven 
meer inzicht in respectievelijk de pasvorm van het substraat in het enzym en het 
vertrekkende groep karakter. Combinatie van alle data leert dat de elektronische 
eigenschappen van de activerende groep een grotere invloed hebben op de enzymatische 
activiteit, mits de activerende groep past in het enzym. Wel geldt dat een betere pasvorm 
resulteert in een hogere enzymatische activiteit. 
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Na deze studie om te bepalen welke eigenschappen tot een succesvolle activerende groep 
leiden, is vervolgens gekeken naar de bredere toepasbaarheid van enzym-specifieke 
activering. De eerder gebruikte set potentieel activerende groepen (Figuur 2) is 
aangewend om ook voor α-chymotrypsine een geschikte groep te vinden (hoofdstuk	5). 
Bovendien is een vergelijking gemaakt met de resultaten met papaïne. Opvallend is dat 
OBn en ODmap, activerende groepen voor papaïne, geen specifiek activerend effect hebben 
op α-chymotrypsine, terwijl het omgekeerde waar is voor OGb. De activerende 
eigenschappen van de groepen zijn dus daadwerkelijk enzym-afhankelijk. 
Een vergelijkbaar onderzoek heeft plaatsgevonden voor het enzym Alcalase-CLEA, met een 
additionele grote verandering, namelijk de overstap naar een organisch oplosmiddel 
(hoofdstuk	 6). In dit geval zijn de best presterende groepen de twee positief geladen 
fenolen OGp en OTmap, wat opmerkelijk is voor een enzym met een voorkeur voor grote 
ongeladen hydrofobe residuen. Het zijn echter wel twee goed vertrekkende groepen, wat 
weer in lijn is met de uitkomsten van hoofdstuk 4. 
Hoofdstuk	 7	 beslaat de synthese van alle	 activerende groepen die voorkomen in dit 
proefschrift. 
In hoofdstuk	 8 ten slotte komen mijn persoonlijke visie op dit onderzoek en de 
uitkomsten ervan aan bod. Een beter fundamenteel inzicht in de werking van substrate	
mimetics is misschien wel het belangrijkste wat dit proefschrift heeft voortgebracht. Op 
basis daarvan vraag ik me af of het op korte termijn tot een industrieel rendabel proces 
voor peptidesynthese gebaseerd op substrate	mimetics of activerende esters zal komen. Ik 
ben er echter van overtuigd dat de aandachtspunten en mogelijke problemen uitgebreid in 
kaart zijn gebracht. 
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Dankwoord 
 
Graag wil ik je bedanken door mijn favoriete gedicht met je te delen: 
 
 
Ik	ben	lekker	stout	
  
Ik	wil	niet	meer,	ik	wil	niet	meer!	
Ik	wil	geen	handjes	geven!	
Ik	wil	niet	zeggen	elke	keer:	
Jawel	mevrouw,	jawel	meneer…	
nee,	nooit	meer	van	m’n	leven!	
Ik	hou	m’n	handen	op	m’n	rug	
en	ik	zeg	lekker	niks	terug!	
	
Ik	wil	geen	vieze	havermout,	
ik	wil	geen	tandjes	poetsen!	
‘k	Wil	lekker	knoeien	met	het	zout,	
ik	wil	niet	aardig	zijn	maar	stout	
en	van	de	leuning	roetsen	
en	schipbreuk	spelen	in	de	teil	
en	ik	wil	spugen	op	het	zeil!	
	
En	heel	hard	stampen	in	een	plas	
en	dan	m’n	tong	uitsteken	
en	morsen	op	m’n	nieuwe	jas	
en	ik	wil	overmorgen	pas	
weer	met	twee	woorden	spreken!		
En	ik	wil	alles	wat	niet	mag,	
De	hele	dag,	de	hele	dag!	
	
En	ik	wil	op	de	kanapee	
met	hele	vuile	schoenen	
en	ik	wil	aldoor	gillen:	Nee!	
En	ik	wil	met	de	melkboer	mee	
en	dan	het	paardje	zoenen.	
En	dat	is	alles	wat	ik	wil	
en	als	ze	kwaad	zijn,	zeg	ik:	Bil!	
	
 
Uit: Annie M.G. Schmidt, Ik	ben	lekker	stout,	1955, Em. Querido’s Uitgeverij Amsterdam
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I would like to thank you by sharing my favourite poem with you: 
 
 
Nice	and	Naughty	
 
I’ve	had	enough!	I’m	not	a	lamb!	
I	don’t	want	to	say	hello!	
I	don’t	want	to	say,	‘Yes,	sir,’	–	‘Yes,	ma’am,’	
or	hear	about	how	big	I	am...	
as	if	I	didn’t	know.	
I’ll	stay	out	in	the	yard	all	day	
until	I’m	sure	they’ve	gone	away!	
	
I	don’t	want	to	eat	that	mushy	rice,	
I	don’t	want	to	brush	my	hair!	
I	don’t	want	to	hear	their	good	advice.	
I	want	to	be	naughty,	not	nice,	
and	lean	back	on	my	chair,	
and	play	pirates	in	the	kitchen	sink,	
and	fi	nger‐paint	with	Indian	ink!	
	
And	when	it	rains	I’ll	go	and	dance	
in	puddles	up	to	my	knees.	
I’ll	poke	my	tongue	out	at	my	aunts,	
’cause	when	I’m	old	I’ll	have	a	chance	
to	say	thank	you	and	please.	
And	I’ll	do	everything	that’s	wrong,	
the	whole	day	long,	the	whole	day	long!	
	
I	want	to	jump	on	the	settee	
and	cover	it	with	grime.	
I	want	to	scream	hysterically,	
and	take	the	dog	to	bed	with	me...	
but	I’ll	say	when	it’s	time.	
That’s	all	the	things	I	plan	to	do.	
If	they	don’t	like	it,	I’ll	say,	‘Poo!’	
	
 
Translated by: David Colmer	 	
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